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Summary 
According to the World Health Organization (WHO), infections acquired in a hospital 
are among the major causes of death. Invasive devices such as catheters or implants are 
associated to these infections. Furthermore, the primary cause of implant-associated 
infections is the formation of a well-defined bacterial network on the surface of medical 
devices, termed biofilm, which is extremely resistant to antibiotics. In this work, two 
different strategies to avoid infections related to medical devices have been adopted by 
combining biomaterials with biologically active molecules: the creation of amorphous 
solid dispersions (ASDs) formed by miscible polymer-drug blends for making drug 
eluting devices, and an antifouling coating which will limit the biofilm formation on 
surfaces. 
In medicine, biodegradable polymers offer great potential for controlled drug delivery 
and wound management (e.g., adhesives, sutures, and surgical meshes), for orthopedic 
devices (screws, pins, and rods), as well as for dental applications (filler after a tooth 
extraction) and tissue engineering, just to name the most important. The use of 
biopolymers is a major advance, since, in addition to being materials prepared to act with 
biological systems, they have a great versatility in terms of mechanical properties and 
biodegradation. The combination of these materials with biologically active molecules 
enables the production of biomedical devices with the ability of preventing infections, 
which can be absorbed by the body after they have served their purpose. The material 
selected for making biomedical devices in this work is the biodegradable poly(-
caprolactone) (PCL). PCL is a semicrystalline polymer widely used in the production of 
biomedical devices, whose degradation can last from several months to years, making it 
suitable for long-term biomedical applications such as implants. 
In the last few years, medical devices have evolved from being a mere support to being 
intelligent devices that help with the healing process. Biomedical engineering is now 
focusing on the production of bioactive implants that assist patient recovery. In the case 
of biodegradable drug eluting devices, the challenge is to design the drug release profile, 
the mechanical properties and the rate of degradation, adapted for each problem. Where, 
when and how much drug is necessary in each case must be clarified for an effective 
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design. Polymeric materials offer a broad range of possibilities and contribute to 
substantially improving the effectiveness of the bioactive molecules, directing them 
towards the objective, as well as reducing the side effects of an overdose. The 
combination of biodegradable polymers with biologically active molecules is clearly 
interesting both clinically and commercially. 
In Chapter 1 of this thesis (Chapter 1. Antimicrobial Poly(ε-caprolactone)/Thymol 
Blends: Phase Behavior, Interactions and Drug Release Kinetics) blends of PCL and 
Thymol, which is an effective antimicrobial, have been prepared by melt-mixing. When 
two polymeric materials are miscible, macroscopic properties of single-phase materials 
are expected for the blend, such as a single glass transition temperature intermediate 
between those of the pure components. In this system, the analysis of the glass transition 
(Tg) did not provide clarifying data and, thus, the melting point (Tm) depression study was 
conducted for both PCL-rich and Thymol-rich blends, adapting the Flory-Huggins theory 
in each case, whereby miscibility in the blend was found. Moreover, the specific 
interactions were analyzed by infrared spectroscopy, and strong hydrogen bonding 
interactions were confirmed between the carbonyl groups of the polymer and the hydroxyl 
group of the Thymol (-C=O···O-H-). 
Finally, the analysis of the release kinetics of Thymol was performed. It was concluded 
that the drug is released by diffusion through the swelled polymeric chains, and that it 
does slowly due to the strong molecular interactions established between the two species. 
Hence, the PCL-Thymol system is suitable for building long-lasting antimicrobial 
devices. 
In Chapter 2 (Chapter 2. Physicochemical Characterization and Drug Release Kinetics 
in Poly(-caprolactone)/Chloramphenicol Blends) mixtures of PCL with the broad-
spectrum antibiotic Chloramphenicol (CAM) were studied. Since it is a drug sparingly 
water-soluble, it can remain undissolved in the gastrointestinal tract when administered 
orally, thus, the body does not absorb it but it is excreted. Hence, the combination of this 
antibiotic with the PCL would allow to keep it in an amorphous form, obtaining a greater 
solubility and bioavailability. In order to determine the miscibility in this system, 
PCL/CAM blends prepared by casting were analyzed by differential scanning calorimetry 
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(analysis of Tg, Tm, as well as interaction parameter ). Then, specific interactions 
between the polymer and the antibiotic were studied using infrared spectroscopy, and 
through the analysis of the spherulitic morphology of the blends by means of atomic force 
microscopy (AFM), it was found that the mobility of the polymer chains during the 
crystallization process is reduced due to the -C=O···H-O- interactions in miscible blends. 
Therefore, the hexagonal structure characteristic of the spherulites of the PCL shows a 
less compact morphology due to the presence of the drug. 
In addition, the conformation of Chloramphenicol was exhaustively studied in the order 
and disordered phases by means of FTIR spectroscopy and molecular modelization 
methods. 
After the physicochemical characterization, the study of the release behavior showed that 
when the entire antibiotic is in an amorphous state, about half of the drug is released in 
the first 10 minutes, followed by a constant release rate. This mechanism responds to an 
ideal drug delivery from biomedical devices, since the initial burst serves to deal with the 
risk of infection during implantation and the subsequent constant release at an effective 
therapeutic concentration, to counteract a possible latent infection. In addition, the 
antibacterial activity of the polymer-drug system was analyzed by agar diffusion test 
against Escherichia Coli (bacteria frequent in implant-associated infections), and the 
results confirmed that Chloramphenicol can be released in a controlled way without 
losing antibacterial activity. 
In Chapter 3 (Chapter 3. Miscibility, Interactions and Drug Release Kinetics 
Investigation in Poly(-caprolactone)/Quercetin Blends), PCL was blended with a 
flavonoid which has antioxidant and anti-inflammatory properties. Despite the beneficial 
properties of Quercetin, the main downside of this molecule is a high crystallinity that 
results in low bioavailability, as well as the easy oxidation in aqueous environments such 
as body fluids. In fact, prior performing the release experiments, the oxygen was removed 
from the medium using a nitrogen recirculation system. Quercetin was blended with PCL, 
to tackle its high crystallinity through the specific interactions created with the functional 
groups of the polymeric chains. Once again, the miscibility was studied using the single 
intermediate glass transition criterion (considering the Tg of the Quercetin two-thirds of 
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its melting temperature), and hydrogen bonds were confirmed by means of infrared 
spectroscopy. 
The novelty of this chapter resides in the comparative study of the release behavior of the 
Quercetin from different supports: micrometric films obtained via casting, nanometric 
films obtained by spin coating, and scaffolds composed of micro and nanofibers 
manufactured by the electrospinning technique. The release of Quercetin from 
nanometric films was tested using a quartz crystal microbalance (QCM) that calculates 
the mass variation by measuring the change in frequency of a quartz crystal resonator 
when disturbed by the loss of a small mass. It was examined the dependence on the 
composition, and in turn on the crystallinity, in the release process. Moreover, it was 
assessed the influence of the pore size in mats obtained by electrospinning: the larger the 
pores, the greater the release. Over again, it is confirmed that when the drug is in an 
amorphous form, there is an initial burst good for responding to the high risk of infection 
during an intervention, followed by a sustained release within the desired therapeutic 
margin, to prevent infections in the implant during the healing phase. 
Biofouling is an undesirable process that results in the accumulation of organisms and 
their by-products on surfaces. In the case of bacteria, this process leads to the formation 
of biofilm, which provides bacteria with superior survival properties upon exposure to 
antibiotics. The formation of biofilm in biomedical devices can generate serious 
infections, especially frequent during the hospital stay. Since within the biofilm bacteria 
are 1,000 times more resistant to antibiotics, it is often necessary to replace the implant. 
Antifouling materials alter the properties of surfaces in order to prevent the accumulation 
of microorganisms on the substrates.  
It is in Chapter 4 of the present thesis (Chapter 4. Antifouling Poly(-caprolactone) 
Surfaces for Medical Devices) where films of PCL are superficially modified with an 
antifouling peptide that prevents the formation of biofilm. The coating is based on a 
biocompatible tripeptide, which designs allows its spontaneous adsorption onto any kind 
of substrate due to a DOPA linker (the main constituent of the glue proteins of mussels), 
as well as the creation of non-sticky surfaces thanks to two fluorinated groups. Hence, 
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surfaces coated with this synthetic peptide would be able to interfere with the biofouling 
process.  
Surfaces of PCL (control) and of PCL modified with the peptide were incubated in 
inoculums of E. coli, and subsequently, the number of colonies adhered in each kind of 
substrate was compared to verify the antifouling activity.  
Taking everything into consideration, this PhD thesis explores different combinations to 
combat infections in medical devices. 
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Resumen 
Casi la mitad de las infecciones nosocomiales (aquellas contraídas durante la 
hospitalización) están asociadas a la utilización de dispositivos biomédicos. Son 
infecciones difíciles de tratar y muchas de ellas, implican la extracción del dispositivo. 
Un factor esencial es la formación de biofilm alrededor del implante, ya que constituye 
una fuerte barrera bacteriana frente a los antibióticos. Para prevenir las infecciones en 
este tipo de dispositivos, en este trabajo se han usado dos estrategias: la formación de 
dispersiones sólidas amorfas (ASDs) constituidas por mezclas polímero-fármaco 
miscibles y con fuertes interacciones intermoleculares, para una liberación controlada del 
fármaco, y la biofuncionalización superficial del implante con un péptido antifouling que 
evite la adhesión de las bacterias que forman el biofilm.  
Los materiales poliméricos han ido desplazando paulatinamente a materiales tan 
tradicionales como los metales o los cerámicos en el campo de la medicina. El uso de 
biopolímeros supone un gran avance, ya que, además de ser materiales preparados para 
actuar con sistemas biológicos, poseen una gran versatilidad en cuanto a propiedades 
mecánicas y de biodegradación. Combinando estos materiales con moléculas 
biológicamente activas, se pueden fabricar dispositivos biomédicos capaces de prevenir 
infecciones, con la ventaja de que pueden degradarse dentro del cuerpo después de 
cumplir con su cometido, lo que supone una mejora en la calidad de vida de los pacientes. 
El material que se ha elegido como candidato para la fabricación de dispositivos 
biomédicos en este trabajo, ha sido el polímero biodegradable poli(-caprolactona) 
(PCL). La PCL es un polímero semicristalino ampliamente usado en la producción de 
dispositivos biomédicos, cuya degradación puede durar desde varios meses hasta años, 
haciéndolo adecuado para aplicaciones biomédicas a largo plazo como implantes. 
En los últimos años, los dispositivos médicos han pasado de ser un mero soporte, a ser 
aparatos inteligentes que ayudan con el proceso de curación. La ingeniería biomédica se 
está enfocando en la fabricación de implantes bioactivos, es decir, con una funcionalidad 
adicional que ayude a la recuperación del paciente. En el caso de los dispositivos 
liberadores de fármacos biodegradables, el reto está en diseñar el perfil de liberación del 
fármaco, las propiedades mecánicas y la velocidad de degradación del dispositivo, para 
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cada problemática. Hay que saber dónde, cuándo y cuánto fármaco es necesario en cada 
caso. En este contexto, los materiales poliméricos ofrecen todo un mundo de posibilidades 
y permiten mejorar sustancialmente la eficacia de los medicamentos, dirigiéndolos hacia 
el objetivo y reduciendo los efectos secundarios que acarrea una dosis excesiva. La 
combinación de los polímeros biodegradables con moléculas biológicamente activas, 
tiene un gran potencial en cuanto a mejorar la efectividad de nuevos fármacos, y ese valor 
añadido que se le aporta a los dispositivos biomédicos es claramente interesante tanto 
clínica como comercialmente. 
En el Capítulo 1 de esta tesis (Chapter 1. Antimicrobial Poly(ε-caprolactone)/Thymol 
Blends: Phase Behavior, Interactions and Drug Release Kinetics) se han mezclado en 
fundido la PCL y el Timol, que es un efectivo antimicrobiano. En términos de 
termodinámica clásica, la miscibilidad se define como el nivel de mezcla molecular que 
da propiedades esperadas para materiales de una fase, como una temperatura de transición 
vítrea única e intermedia a las de las sustancias puras de la mezcla. En este caso, el análisis 
de la transición vítrea (Tg) no aportó datos esclarecedores y, por tanto, se recurrió al 
estudio de la depresión del punto de fusión (Tm), tanto para mezclas ricas en PCL como 
ricas en Timol, adaptando la teoría de Flory-Huggins en cada caso, de donde se pudo 
inferir miscibilidad en la mezcla. Asimismo, se analizaron las interacciones específicas 
mediante espectroscopia infrarroja, hallándose fuertes interacciones de puentes de 
hidrogeno entre los grupos carbonilo del polímero y el hidroxilo del Timol                             
(-C=O···O-H-). 
Una vez comprobada la miscibilidad en el sistema, se estudió la cinética de liberación y 
se concluyó que el Timol se libera por difusión a través de las cadenas polimérica, y que 
lo hace con lentitud debido a las fuertes interacciones moleculares establecidas entre las 
dos especies. De ahí que el sistema PCL-Timol sea un sistema válido para construir 
dispositivos antimicrobianos de larga duración. 
En el Capítulo 2 (Chapter 2. Physicochemical Characterization and Drug Release 
Kinetics in Poly(-caprolactone)/Chloramphenicol Blends) se estudiaron las mezclas de 
PCL con el antibiótico de amplio espectro cloranfenicol (CAM). Se trata de un                            
fármaco poco hidrosoluble que, administrado por vía oral, puede permanecer sin disolver 
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en el tracto gastrointestinal, de manera que no es absorbido por el organismo y termina 
siendo excretado. Así pues, la interacción entre este antibiótico y la PCL nos permitiría 
mantenerlo en estado amorfo, para una mayor solubilidad y biodisponibilidad. Con el fin 
establecer la miscibilidad en este sistema, las mezclas de PCL/CAM obtenidas por 
solvent-casting fueron analizadas por calorimetría diferencial de barrido (análisis de Tg, 
Tm y factor de interacción ). Las interacciones de puentes de hidrógeno existentes entre 
el polímero y el antibiótico fueron estudiadas mediante espectroscopia infrarroja. 
Además, a través del análisis de la morfología esferulítica de las mezclas por medio de 
microscopía de fuerza atómica (AFM) se encontró que, en sistemas miscibles, la 
movilidad de las cadenas poliméricas durante el proceso de cristalización se ve reducida 
debido a las interacciones -C=O···H-O-, de forma que la estructura hexagonal 
característica de las esferulitas de la PCL se hace menos compacta. También se estudió 
de manera exhaustiva el comportamiento conformacional de la molécula de cloranfenicol. 
Tras la caracterización fisicoquímica, el estudio de la cinética de liberación mostró que 
cuando todo el antibiótico se encuentra en estado amorfo, cerca de la mitad del fármaco 
se libera en los primeros 10 minutos, seguido de una liberación constante. Este 
mecanismo responde a un sistema ideal de liberación de fármacos para dispositivos 
biomédicos, ya que la liberación brusca inicial sirve para hacer frente al riesgo de 
infección durante la implantación, y la posterior liberación constante a una concentración 
terapéutica efectiva, para contrarrestar una posible infección latente. Asimismo, la 
actividad antibacteriana del sistema polímero-fármaco fue analizada mediante el método 
de difusión en agar inoculando la bacteria Escherichia Coli (bacteria causante de 
infecciones en implantes médicos), y los resultados confirmaron que el Cloranfenicol 
puede ser liberado de manera controlada sin perder su poder bactericida. 
En el Capítulo 3, (Chapter 3. Miscibility, Interactions and Drug Release Kinetics 
Investigation in Poly(-caprolactone)/Quercetin Blends Blends), se examinaron las 
mezclas de PCL con un flavonoide con propiedades antioxidantes y antiinflamatorias. A 
pesar de las propiedades beneficiosas de la Quercetina, las desventajas de esta molécula 
residen en su fuerte tendencia a autoasociarse, que deriva en una baja biodisponibilidad, 
además de ser una sustancia que se oxida fácilmente. De hecho, para hacer los ensayos 
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de liberación se tuvo que quitar el oxígeno del medio mediante un sistema de 
recirculación de nitrógeno. El objetivo consiste en intentar suprimir la cristalinidad de la 
Quercetina, gracias a las interacciones específicas con los grupos funcionales de las 
cadenas poliméricas. En este caso, se vuelve a estudiar la miscibilidad a través del criterio 
de una transición vítrea intermedia a los componentes puros (suponiendo como Tg de la 
Quercetina 2/3 de su temperatura de fusión), y se confirman los enlaces de hidrógeno por 
medio de espectroscopia infrarroja. 
Lo novedoso de este capítulo es que se hace una comparativa de la liberación desde 
distintos soportes: filmes micrométricos obtenidos vía casting, filmes nanométricos 
obtenidos por spin coating, y scaffolds compuestos por micro y nanofibras fabricados por 
la técnica de electrohilado. La liberación de Quercetina desde los filmes nanómetricos se 
ensayó usando una microbalanza de cristal de cuarzo (QCM) que mide la masa mediante 
los cambios de frecuencia de un cristal de cuarzo piezoeléctrico al ser perturbado por la 
pérdida de una pequeña cantidad de masa. A través de este estudio, se observó la 
dependencia de la composición, y a su vez de la cristalinidad, en el proceso de liberación, 
además de la influencia que tiene el tamaño de poro en los filmes obtenidos por 
electrohilado: a mayores poros, mayor liberación. Una vez más queda demostrado que 
cuando el fármaco está en estado amorfo, se da una liberación brusca inicial capaz de 
responder al elevado riesgo de infección durante la intervención, seguida de una 
liberación sostenida dentro del intervalo terapéutico deseado, para prevenir las 
infecciones microbianas en el implante durante la fase de curación. 
El biofouling se define como la acumulación de microorganismos indeseables, como 
bacterias, hongos, diatomeas, algas, plantas o animales, que se adhieren a las superficies. 
En el caso de bacterias, este proceso deriva en la formación de una red bacteriana llamada 
biofilm resistente a los antibióticos. La formación de biofilm en dispositivos biomédicos 
puede generar graves infecciones, especialmente frecuentes durante la estancia 
hospitalaria. Dado que las bacterias del biofilm pueden ser hasta 1.000 veces más 
resistentes a los antibióticos, la mayoría de las veces se hace necesario sustituir el 
implante. Los materiales antifouling alteran las propiedades de las superficies, para 
prevenir la acumulación de microorganismos sobre los substratos. Es en el Capítulo 4 de 
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la presente tesis (Chapter 4. Antifouling Poly(-caprolactone) Surfaces for Medical 
Devices) cuando se lleva a cabo el recubrimiento de superficies de PCL con un péptido 
antifouling que evita la formación de biofilm. Se trata de un tripéptido biocompatible con 
carácter antifouling, el cual, cuenta en su estructura con un grupo DOPA (principal 
componente del pegamento natural que usan los moluscos para agarrarse a las rocas) que 
le dota de la capacidad de adherirse espontáneamente a las superficies en medio básico, 
y que cuenta también con grupos fluorados que le proporcionan la cualidad antiadherente. 
De esta forma, las superficies recubiertas con este péptido sintético son capaces de hacer 
frente al perjudicial proceso de biofouling.  
Las superficies, tanto de PCL (control) como las de PCL modificadas con péptido, fueron 
incubadas en un medio de cultivo con bacterias de E. coli, y posteriormente, se comparó 
el número de colonias adheridas a las superficies de PCL con las que se habían pegado a 
las de PCL recubiertas con péptido tras la incubación, para verificar su actividad 
antifouling. 
Teniendo en cuenta todo lo expuesto, en esta tesis se investigan diferentes combinaciones 
para combatir infecciones en implantes médicos.  
 26 
 27 
Introduction   
 
 
 
 
 
 
  
 
 
 
 
 
 
 28 
 
 
 
 
 
 
Introduction 
29 
1. Drug Eluting Devices 
Since the beginning of pharmacological therapy, maintaining steady therapeutic drug 
concentration levels in the bloodstream has been a major problem. In the conventional 
systems for administration of drugs, the level of the medicine reaches a maximum and 
then falls to a minimum, so that the application of a new dosage becomes necessary. When 
using oral drug administration, high plasma concentration of drug may lead to toxicity, 
but concentration below the minimum effective may also cause subtherapeutic blood 
levels and drug resistance in some instances.   
Combining the abilities of a medical device with the capability of locally releasing a drug 
in a controlled way is a solution to clinical problems involving complications associated 
with device implantation. In this way, the dose necessary to be administered is lower since 
the drug has to overcome fewer biological barriers (many drugs are inactivated or 
eliminated by the gastrointestinal system, kidney or liver). The improved sustained 
release action of these delivery systems also offers additional advantages, such as better 
patient compliance, as the patient does not need to think about taking medication. Other 
potential benefit of this type of delivery system is the protection of drugs from being too 
rapidly metabolized. This added value to medical devices is clearly interesting both 
clinically and commercially. 
Historically, implantable drug delivery systems started in 1938 in London, with the 
implantation of compressed estrogen pellets subcutaneously to treat a young woman 
afflicted with premature menopause [1]. In the mid-1960s J. Folkman and D.M. Long 
investigated the use of silicone rubber as a method for prolonged systemic drug 
administration, after discovering that the introduction of tubes exposed to anesthesic 
gases in rabbits made them fall asleep [2]. Nowadays, nanotechnology has enabled the 
development of more efficient and precise drug eluting devices able to, prompted by 
external stimuli, perform remotely controlled delivery at different parts of the body. 
The surface of a medical device is crucial for its integration within the body, since it 
constitutes the interfacial barrier between the biological environment and the artificial 
element. The primary cause of implant associated infections is the formation of a well 
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defined bacterial network on the surface of medical devices, termed biofilm, which is 
extremely resistant to antibiotics [3,4]. Micro and nanotechnology techniques have made 
possible to modify the surface by using different strategies: coating with different 
materials such as polymers or inorganic nanoporous coatings which can be loaded with a 
broad range of drugs, as well as modifying the topography to form an antifouling surface 
mimicking the defense mechanisms found in nature, like the skin of the shark [5]. 
The effectiveness of a drug eluting device depends on the way in which the 
pharmaceutical is released, determined by the interaction with the matrix. If the drug is 
released very quickly, the infection may not heal; on the contrary, if the release is delayed, 
the device cannot overcome the microorganism invasion. An ideal drug delivery system 
should exhibit an initial burst, in order to respond to the elevated risk of infection from 
bacteria during surgery or implantation, followed by a sustained release at an effective 
level for inhibiting the occurrence of latent infection. In this regard, research efforts have 
focused on the investigation of amorphous solid dispersions (ASDs) as an strategy to 
deliver bioactive agents with poor aqueous solubility and bioavailability [6]. ASDs have 
to be stable to avoid drug recrystallization and for this purpose the drug should be 
completely miscible with the matrix. Exploiting the metastable  region to increase the 
amount of amorphous drug loaded in the device involves the risk of drug recrystallization 
during the useful life of the device [7]. The release mechanisms found in these miscible 
systems is defined by an initial burst that will prevent infection and kill the 
microorganisms found in the implant area before they settle and create a biofilm where 
antibiotics cannot penetrate, followed by a relatively slow release phase to prevent 
microbial infections at the implant site during healing.  
In most drug eluting devices, the drug is incorporated into a polymeric matrix so that it 
can be released in a controlled way within the therapeutic margin. Polymers for clinical 
applications can be broadly classified into biodegradable and non-biodegradable; in non-
biodegradable polymers, the release is controlled by diffusion or swelling mechanisms, 
while in biodegradable polymers the erosion mechanism is also involved [8]. Table I 
summarizes the most relevant polymers used to produce drug eluting devices. The main 
advantage of using biodegradable materials for making medical devices is that they do 
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not need to be removed after finishing their service, as they are absorbed or excreted by 
the body, hence the tissue surrounding can return to its original state, and a follow-up 
surgery is avoided. In addition, biodegradable polymers can release larger quantities of 
antibiotics, and their degradation and mechanical properties can be tailored for specific 
applications [9,10]. 
Table I. Polymers used for producing drug eluting devices. 
Non-degradable Biodegradable 
Poly(dimethylsiloxane) (Silicone) 
Polyurethanes (PU) 
Polyethylene (PE) 
Poly(methyl methacrylate) (PMMA) 
Poly(tetrafluoroethylene) (PTFE) 
Poly(vinylene fluoride) (PVDF) 
Poly(ethylene-co-vinyl acetate) 
(PEVA) 
Poly(ethylene terephthalate) (PET) 
Poly(lactide) (PLLA, PDLLA) 
Poly(glycolic acid) (PGA) 
Poly(lactide-co-glycolide) (PLGA) 
Poly(ε-caprolactone) (PCL) 
Poly(hydroxybutyrate-co-hydroxyvalerate) 
(PHBV) 
Polyhydroxyalkanoates (PHA) 
Polydioxanone (PDS) 
Polyanhydrides 
Collagen  
Chitosan  
It becomes obvious that many factors need to be considered depending upon each clinical 
context, i.e., design, biomaterial  and drug selection, drug release mechanism, and 
fabrication method. This introduction reviews the most extensively studied controlled 
drug eluting devices, as well as recent developments on the micro/nanotechnology scales, 
and their future challenges. For this purpose we divided medical devices into different 
systems of the body (see Fig. I): orthopedic devices, breathing stents, gastrointestinal and 
urinary systems, devices for cardiovascular diseases, neuronal implants, and wound 
dressings. 
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Figure I. Different systems of the body: (a) skeletal system, (b) 
respiratory system, (c) digestive system, (d) urinary system, (e) 
circulatory system, (f) nervous system, and (g) integumentary 
system. 
2. Orthopedic Drug Eluting Devices 
An orthopedic device is any device that is placed within the body’s skeleton to provide 
stability or to correct problems that currently exist there. This includes orthopedic 
prostheses, orthopedic fixation devices such as interference screws in the ankle, knee, and 
hand areas; rods and pins for fracture fixation, screws and plates for craniomaxillo facial 
repair, bone tissue engineering scaffolds; and, bone cements to anchor artificial joints 
[11]. A common problem with prosthetic and orthopedic appliances is the infection 
during the healing process, which often results in the removal of the orthopedic implant 
and the need for a follow-up operation. Besides, the infection rate after a follow-up 
surgery is higher (5-40 %) than after the first one [12]. An ideal drug delivery system 
should be able to release drugs over a period of several months to years in order to prevent 
“late” infection. Osteomyelitis is the inflammation of the bone caused by an infecting 
organism introduced from trauma, surgery or implant [13-18]. Conventional therapy with 
antibiotics is usually unsuccessful in these cases, because there is a poor antimicrobial 
distribution at the site of infection due to limited blood circulation to infected skeletal 
tissue, and a high systemic dosage of antibiotics can lead to toxic effects [19]. Therefore, 
site-specific targeted drug delivery devices would be a good strategy in osteomyelitis 
treatment [20].  
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Poly(methyl methacrylate) (PMMA) loaded with an antibacterial agent is commonly used 
as a non-biodegradable bone cement to prevent osteomyelitis [21-23]. The antibiotics are 
either premixed by the manufacturer or added by the surgeon in the operating room. Table 
II shows approved drug eluting bone cements based on PMMA. The release of antibiotic 
from PMMA begins with an initial burst, followed by a slow release that continues for 
days to months. Penetration of water in the pore network of the cement, leads to matrix 
dissolution and outward diffusion of solubilized drug via matrix imperfections; however, 
less than 10 % of the drug trapped is released [24-30]. PMMA is not biodegradable, which 
means that with any clinical failure, secondary surgery would be necessary to remove it 
[31-33]. Besides, this bone cement is limited to antibacterial drugs that are able to 
withstand the heat generated by polymerization, and both, the heat and residual MMA 
monomer, can kill healthy bone cells and inactivate the antibiotic [34]. 
Table II. Commercial PMMA bone cements and beads loaded 
with antibiotics. 
Trade name Supplier Matrix Antibiotic Treatment Device 
Simplex® Stryker 
PMMA 
 
 
Tobramycin 
Bone 
infection 
Bone 
cement 
 
Palacos® Zimmer Biomet 
Gentamicin 
sulphate 
CMW® DePuy  
Septopal® 
 
Biomet Bead chains 
The main advantage of using biodegradable polymeric cements and implants over PMMA 
is that they are able to support tissue growt.h and remodeling, and that they are afterwards 
resorbed, being unnecessary a surgical removal [35]. For example, a fractured bone fixed 
with a rigid, non-biodegradable stainless steel implant has a tendency for re-fracture upon 
removal of the implant. The bone does not carry sufficient load during the healing 
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process, because the load is carried by the rigid stainless steel. In contrast, an implant 
prepared from biodegradable polymer can be engineered to degrade at a rate that will 
slowly transfer load to the healing bone [36]. PDLLA, PLLA, PLGA, PEG, PLA-PLGA 
block copolymers and other copolymers are manufactured into biodegradable beads, 
microspheres, melt-extruded cylinders, and antibiotic loaded implant coatings and films 
for orthopedic applications [37].  
One of the main problems with orthopedic implants is device associated infection caused 
by bacterial adhesion on the surface and subsequent biofilm formation. The biofilm is a 
well defined bacterial-network which provides the bacteria with superior survival 
properties against antibiotics. There is a competition between the integration of the 
implant into the surrounding tissue and adhesion of bacteria. If bacterial adhesion occurs 
prior to tissue integration, the implant will be colonized [34]. Therefore, it is critical to 
prevent the formation of biofilms by inhibiting initial bacterial adhesion or killing bacteria 
directly. Creation of antifouling surfaces is a good strategy to prevent implant-associated 
infections [38].  
Current antimicrobial strategies in orthopedic devices have focused on coating-based 
approaches that aim to prevent infection by mitigating biofilm formation on implants. 
Antibiotic coatings are limited by the duration of drug elution and the risk of developing 
drug resistance. To overcome these drawbacks, “smart coatings” are being developed. A 
“smart surface” is designed to be a self-responsive multitask micro-machine that releases 
antimicrobial (and other) substances after stimulation by microbiological (or other) 
signals such as bacteria (see Fig. II). Changes in the pH, temperature, as well as 
mechanical, chemical, and electrical changes in the surroundings of the device, trigger 
the opening of nanocontainers and the release of a specific substance. As a result, a critical 
component of a smart micro-device is a sensor unit sensitive enough to detect the stimuli 
[39]. 
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Figure II. Smart coating of an orthopedic device. 
 
 
Nanotechnology has revolutionized therapeutics, allowing a greater precision of drug 
delivery, especially beneficial in the field of orthopedics. Though conventional implants 
like artificial knee, hip joints, plates etc. are still the most implantable commercially, a 
great amount of research activity has been initiated recently on employing principles of 
nanotechnology to bone tissue engineering [40]. An example of this is the incorporation 
of drug-releasing Tunneling Nanotubes (TNT) layers grown on Ti-based implants via 
anodization, for treating bone related diseases and prevention of post-implantation 
infections. The process of manufacturing is summarized in Figure III. The nanotubular 
structure of the TNT coatings enables drug loading, and promotes the adhesion and 
proliferation of osteoblast cells on the implant surface [8]. 
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Figure III. Use of TNTs for developing drug-releasing implants. 
 
Bone diseases represent a variety of skeletal-related disorders including defects that cause 
major mobility hindrance and mortality to human beings. As no effective treatments are 
available for some of the most common skeleton disorders such as arthritis, osteoarthritis, 
osteosarcoma, and metastatic bone cancer, there is an urgent need to develop new drugs 
and drug delivery systems for safe and efficient clinical treatments. In the development 
of treatments for bone degenerative diseases (osteoarthritis) and bone cancers 
(osteosarcoma), the balance between medication side effects and treatment efficacy is 
always an issue. To address these issues and to increase the efficacy of treatment, a 
targeted delivery using nanotechnology has been widely proposed as a potential strategy. 
The use of nanoparticles (NPs) for the treatment of bone diseases offers advantages like 
carrying the drug to its destination while protecting the drug from being dispersed or 
degraded by body fluids, as well as increasing the solubility of some hydrophobic drugs 
due to the large surface area of the NPs [41]. 
 
Ti Ti 
TNT Anodization 
Drug loading 
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3. Drug eluting Stents for Breathing System 
A stent is a tube-shaped device that can be inserted into a tubular narrowed passageway 
or vessel to unblock it and to hold it open. The first bare metal stents displayed short-term 
functionality, because they became occluded due to malignant ingrowt.h. Immediately 
after stenting, as a result of the mechanical trauma, the endothelial surface triggered an 
inflammatory process which led to platelet adhesion, activation, and aggregation, 
resulting into a fibrin deposition and thrombus formation within the stent [42]. 
Subsequently, proliferating smooth muscle cells formed a neointimal layer within the 
stent lumen. Drug-eluting stents (DES) have demonstrated a very high success in 
preventing in-stent stenosis, since they are able to locally deliver an appropriate 
concentration of an effective agent to stop this process without systemic toxicity.  
Biodegradable polymers that have been used or investigated as a delivery vehicle for 
stents are PCL, PLGA, and PLA. On the other hand, biodurable polymeric materials used 
for this purpose are PU, silicone, PEVA and PTFE. Selection of material depends on 
duration and site of stenting; for example, PLA and PCL have been investigated for 
tracheal stents (see Fig. IVa), as both are suitable for long term applications due to their 
slow degradation rate. Silicone stents block mucociliary clearance, i.e., the mechanism 
that removes mucus and other material from the lungs. On the contrary, biodegradable 
stents cause minimal interference in the mucociliarity function and reduce stent induced 
inflammatory reaction, with the advantage of that they can be loaded with bioactive 
agents to avoid airway stenosis [43]. Bioresorbable external tracheal stents have been 
investigated for solving the problem of limited tracheal growt.h in children; they are used 
for supporting the neonatal trachea until the airway matures, and afterwards, they can be 
totally resorbed with no need of a removal procedure [44-47].  
In cases of sinusitis and nasal polyps where sinus surgery is indicated, there is a long 
period for wound healing after surgical procedure. Sinus stents loaded with anti-
inflammatory compounds could be helpful for post-operative use, due to inability of 
topical application to reach hidden sinus structures, to avoid the side effects of oral steroid 
therapy [48]. Another use for DES is the palliation of emphysema in patients who cannot 
undergo lung transplantation. Emphysema causes shortness of breathing, because of the 
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destruction of the alveoli (small sacs) that promote oxygen exchange between the air and 
the bloodstream. As can be seen in Figure IVb, airway bypass is a technique to create 
passages between pulmonary parenchyma and bronchial airways. The success of this 
technique is limited due to tissue ingrowt.h, since most stents become obstructed within 
a week due to mucus filling or development of tissue layer over the stent ends [49], 
making therefore preferable the use of biodegradable DES. 
 
  
Figure IV. (a) Tracheal stents, and (b) airway bypass stent for 
emphysema treatment. 
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Table III. Commercial drug eluting devices for breathing 
system. 
Trade 
name Supplier Matrix Antibiotic Treatment Device 
Propel® Intersect Ent PLGA 
Mometasone 
furoate (steroid) 
Chronic 
sinusitis 
Sinus stent 
Relieva 
Stratus® Acclarent PMMA 
Triamcinolone 
acetonide 
Catheter with 
micropore reservoir 
Exhale® Broncus Silicone Paclitaxel Emphysema Airways bypass stent 
 
4. Drug Eluting Gastrointestinal Stents 
Gastrointestinal stents are a tool for relieving obstructive malignancies of gastrointestinal 
tract. There are biliar, pancreatic, esophageal, colonic, and duodenal stents, in order to 
face the obstruction caused by cancer where a surgical intervention could be very risky 
[49].  
Boston Scientific has developed the Polyflex® esophageal stent made of silicone for 
esophageal stenosis (see Fig. V). However, the use of bioresorbable materials for this 
kind of stents is currently being explored, and there is no drug eluting gastrointestinal 
device commercially available [50]. 
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Figure V. Esophageal stent for strictures caused by malignant 
tumors. 
 
5. Antimicrobial Urinary Stents 
Catheter-associated urinary tract infection is the most common hospital acquired 
(nosocomial) infection; one out of four hospitalized patients receives an indwelling 
urinary catheter at some point of their stay (see Fig. VIa) [51]. In about 70 % of the long-
term stenting cases, when there are intractable urinary problems such as chronic urinary 
retention or incontinence not treatable by other means, patients require analgesics to 
overcome stent related pain, and also antibacterial agents to avoid biofilm formation 
which often leads to infections [49]. In this regard, surface modification of the stents is a 
suitable strategy to interfere initial adhesion of bacteria and biofilm formation, therefore 
reducing catheter associated urinary tract infections. One simple method is to immerse 
the stent into antimicrobial solution prior to its insertion (see Fig. VIc). However, this 
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method provides short-term protection against infection, and is unlikely to load enough 
drug to allow the prolonged release required to prevent bacterial infection over long 
periods, since the binding is weak and antimicrobial coatings are depleted rapidly by urine 
flow. Alternatively, the polymeric matrix can be also loaded with a miscible (amorphous) 
drug that would be released for longer times. The only clinical drug eluting ureteral stent 
(see Fig. VIIb) found is Triumph® (Boston Scientific) made of an olefinic block 
copolymer loaded with triclosan. 
 
 
 
 
     
                
 
 
 
 
 
Figure VI. (a) Catheterized urinary bladder: the catheter is 
inserted into the bladder through the urethra, and the balloon is 
then inflated with water to prevent the catheter from slipping out 
of the bladder, (b) ureteral stent to treat the obstruction of a stone, 
and (c) impregnation of a urinary stent with antimicrobials. 
 
a b
 
 
 
 Antimicrobial solution 
c 
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6. Cardiovascular Disease Treatment 
According to the World Health Organization (WHO), heart diseases causing arterial 
obstruction are the major cause of death accounting 15 million deaths in 2015 (27 % of 
all the deaths worldwide). Infection of intravascular devices for vascular access and 
vascular prostheses for the replacement or bypass of damaged arteries is a serious event. 
In this context, drug eluting cardiovascular devices have revolutionized the treatment of 
this kind of illnesses. Thus, drug eluting stents for the treatment of coronary artery disease 
have managed to reduce restenosis by 70 % across all patients when compared to bare 
metal stents [52]. DESs have demonstrated to overcome restenosis after implantation by 
releasing anti-inflammatory, immunosuppressive and cytostatic drugs, such as 
tacrolimus, sirolimus, paclitaxel, etc. 
Coronary artery disease is almost synonymous of stent implantation or balloon 
angioplasty to mechanically recover the vessel dimensions, in order to ensure a smooth 
blood flow. Both procedures induce trauma to the vessels and the body responds in the 
form of neointimal hyperplasia and restenosis, with the result of an additional layer in the 
lumen. Anti-proliferative drugs for this kind of intervention may diminish the adverse 
events, though systemically administered have shown disappointing results in preventing 
in-stent restenosis, due to poor drug bioavailability, toxicity and insufficient drug 
concentration at injury sites. Moreover, the loss of control over the drug release may 
postpone the regeneration of endothelium and raise the risk of adverse events. That is the 
reason for using polymeric drug eluting stents.  
Furthermore, coronary stents are temporary implants which perform scaffolding during 
healing period of a vascular injury. Therefore, a biodegradable vascular drug eluting stent 
will be naturally resorbed and metabolized by the body when no longer needed. As there 
is no permanent implant, the coronary artery can return to its native state, avoiding late 
stent thrombosis risk and foreign body reaction. Biodegradable stents can be suitable for 
children with congenital cardiovascular diseases, because no additional surgery is 
required to replace the stent, as the patient grows older. The most representative examples 
of biopolymers used for cardiovascular treatment are self-expanding and shape-memory 
biocomplatible polymers, such as PLLA or PLGA.  
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It is crucial to control the drug release rate from the interface of a coronary stent; for this 
purpose, there are different strategies such as grooving the surface of the stent, using 
nanoscale carriers, or improving coating technology. Nanostructured surfaces in a stent 
enhance endothelial cell growt.h, minimizing late stent thrombosis, particularly relevant 
for cardiovascular stents [51.] By coating stainless steel stents with inorganic nanopores 
via electrochemical anodization of aluminum, cylindrical nanopores can be obtained for 
drug loading (see Fig. VIIa) [11]. Another strategy to obtain a controlled drug release is 
to obtain a microporous surface on the abluminal side of the metallic stents to store the 
drug and then, to cover these reservoirs with a biodegradable polymer layer (PLA) (see 
Fig. VIIb). As the reservoirs are embedded on the outer stent surface, the drugs are 
released directly to the blood vessel wall and not washed away by the blood stream [53]. 
The progress of micro- and nanotechnology have permitted to produce different 
nanotopographies, providing more sites for the drug or polymer to adsorb than would be 
available on flat surfaces. 
In the field of the nanotechnology, another strategy is to coat the stents with polymeric 
nanocarriers bearing anti-restenotic drugs. For example, a catheter balloon coated with 
nanoparticles would release nanocarriers locally when inflated to expand, providing a 
burst release of the drug at the beginning, followed by a slow drug release from the 
polymeric matrix (see Fig. VIIc) [55]. Combining grooves and nanoparticles, the drug 
release behavior can be further tuned and improved [56]. 
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Figure VII. (a) Nanoporous anodic alumina coating for drug-
release, (b) drug loading of the micro-pits of a microporous 
surface followed by a top-coating with a biodegradable 
polymeric layer, and (c) drug eluting balloon. 
 
 
 
a 
c 
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Table IV. Commercial drug eluting coronary stents. 
Trade name Supplier Matrix Drug Treatment 
Cypher® 
Johnson& 
Johnson/Cordis 
PEVA blend with 
PBMA  Sirolimus 
In-stent restenosis 
 
Taxus® Boston Scientific 
Poly(styrene-b-
isobutylene-b-
styrene) (SIBS) 
Paclitaxel 
Absorb® Abbot Vascular PLLA 
 Everolimus Champion® Guidant 
Synergy® Boston Scientific PLGA 
Yukon® Traslumina Microporous stainless steel Rapamycin 
BioFreedom® Biosensors international 
Micro-structured 
abluminal surface 
Biolimus 
A9 High bleeding risk 
 
Electrospinning of some polymers with drugs into ultrafine fibers is another way to 
enhance the coating of a DES. Their high surface to volume ratio can increase drug 
loading, cell attachment and mass transfer properties [54]. 
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7. Neuronal Implants 
Implantation of macro and microdevices into the brain is increasingly used for treatment 
of neurological disorders, including deafness, paralysis, blindness, epilepsy, and 
Parkinson’s disease. Thus, the interest in the properties of the interfaces between neurons 
and external devices to restore or supplement the function of the nervous system lost 
during injury or disease. Since many elements of neurons have nanoscale dimensions, it 
is required a neural interface with nanoscale components; i.e. biocompatible 
nanomaterials that mimic neural tissue characteristics, cause minimal inflammation and 
neuronal cell loss, and are functional for a long period of time [57]. Incorporation of drugs 
and bioactive molecules into electrically active nanomaterials such as carbon nantotubes 
and conducting polymer nanotubes, can improve the biocompatibility of neural 
electrodes, reduce reactive tissue response, and promote neural process outgrowt.h, by a 
controlled release of the drug (see Fig. VIIIa) [58]. Hydrogels loaded with drugs are a 
good choice for coating neural electrodes to decrease the mechanical mismatch between 
stiff electrodes and soft brain tissue, reducing tissue responses at the electrode-tissue 
interface [59]. 
In neural diseases the dose is crucial, because the therapeutic window is generally narrow 
and toxicity results in severe side effects. Systemically, these drugs are required in a 
higher concentration owing to fencing properties of the blood-brain barrier, resulting in 
peripheral side effects. Moreover, most of the neural treatments need long term therapy. 
Hence the relevance of biodegradable polymers as delivery tools in the treatment of neural 
ailments, owing to their ability for sustained release at the focal site in neuronal tissue, 
their versatility of design and release time, as well as their biocompatibility.  
Among brain related diseases, malignant glioma is the most widespread type of brain 
tumor with very low survival rate. Therefore, alternative therapies are urgently needed to 
treat this disease in a more effective way. Malignant gliomas are considered to be most 
nasty to treat, due to inaccessibility, post-surgical recurrence and associated 
complications [60]. To deal with tumor recurrence, there are post-surgical implants of 
anticancer drugs designed to deliver the drug directly into the surgical cavity created after 
the glioma has been surgically excised (Gliadel®) (see Fig. VIIIb). 
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Figure VIII. (a) Controlled release of dexamethasone (an anti-
inflammatory drug) from PLGA nanofibers, coated with 
poly(3,4-ethylenedioxythiophene) (PEDOT) conducting 
polymer. The PEDOT nanotubes were actuated by applying a 
bias voltage of +1V. Expansion and contraction of conducting 
polymer cavities after electrochemical stimulation produced a 
mechanical force creating pressure within the nanotubes, 
resulting in a controlled drug release, and (b) local 
chemotherapeutic agent Gliadel® Wafer. 
Epilepsy is a disease characterized by unpredictable seizures which restrict patients’ daily 
activities. Oral anti-epileptic therapy results in systemic and central nervous system side 
effects, because of a non-localized drug exposure. In this regard, intercranial adenosine 
releasing biomedical implants can be a good alternative. 
b 
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Considering that deep brain tissue penetration is needed for therapeutic efficacy of 
neurological drugs, implants based on nanotechnology are a promising avenue for 
sustained delivery of bioactive agents towards management of lifelong neurodegenerative 
disorders, e.g., nanoparticles of dopamine entrapped in alginate crosslinked scaffolds for 
site specific delivery in Parkinson treatment [62]. A further example are intracranially 
injectable gel-based implants loaded with nanodrugs for treating central nervous system 
diseases [63].  
Biomedical engineering is developing devices that can substitute a motor, sensory or 
cognitive process, damaged as a result of an injury or a disease, named neural prostheses. 
Recently, a new area of nanoprosthetics is emerging with the use of carbon nanomaterials 
(graphene, carbon nanotubes (CNT), and carbon nanofibers (CNF)). Their 
biocompatibility, mechanical stability and high electrical conductivity make these carbon 
nanomaterials good candidates for deep brain stimulation to restore neuronal activity. 
CNTs and CNFs are employed in the form of 3-D polymeric nanoscaffolds for nerve 
tissue regeneration [64], and also nanocoatings based on CNTs and polymers are being 
researched for improving conventional microelectrodes [65]. 
 
Table V. Commercial drug eluting devices for brain disorders. 
Trade 
name Supplier Matrix Drug Treatment Device 
Gliadel® Eisai Polifeprosan 20 Carmustine Tumor ihibition 
Post-glioma 
surgery wafers 
DepoCyt® Sigma-Tau Liposome Cytarabine 
Lymphomatous 
meningitis 
treatment 
Intrathecal 
injection 
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8. Wound Dressing 
A wound is a damaged area of the body, such as a cut or a hole in the skin that includes 
tissue lost, and the regeneration of damaged skin includes complex tissue interactions 
between cells. Furthermore, a wound provides an ideal environment for bacterial growt.h; 
in burns, infection is the major complication after the initial period of shock. A wound 
dressing is a sterile pad or compress applied to a wound to promote healing and protect 
the wound from further harm [34]. It is designed to be in direct contact with the wound, 
while a bandage is most often used to hold a dressing in place (many modern dressings 
are self-adhesive). Aside from the major function of reducing the risk of infection, 
dressings are also important to stop bleeding and start clotting so that the wound can heal. 
There is a big variety of dressings depending on the type, severity and position of the 
wound. To give an example, hydrocolloid dressings are used on draining wounds, 
whereas hydrogels are used to provide hydration to the wound (see Fig.IX). 
 
 
                   
                                         
 
 
 
 
Figure IX. (a) Hydrocolloid wound dressing, and (b) AFAR™ 
hydrogel wound dressing. 
a 
 
 
 
 
b
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Historically, the use of herbal plants has always had benefits in the wound-closure 
process. A new generation of drug eluting wound dressings with antimicrobial effect, 
provides obvious advantages over traditional wound dressings in preventing bacterial 
infection. Additionally, bioresorbable dressings can deal with the painful and risky 
process of changing a temporary dressinng. A good example to illustrate this are the 
antimicrobial PCL/thymol blends, with potential use as biodegradable wound dressings 
accelerating wound healing due to the anti-inflammatory and antibacterial properties of 
thymol [7].  
 
Table VI. Commercial drug eluting wound dressings. 
Trade name Supplier Matrix Drug Treatment Device 
Contreet® Coloplast Polyurethane Foam Silver 
Moderate to 
highly 
exuding 
wounds Pad 
Silvercel® Acelity Nylon fibers Silver Chronic wounds 
Acticoat® Smith&Nephew Polyester Silver Burns Gauze 
Collatamp® Eusa Pharma Collagen Gentamicin 
Surgeries 
with high 
risk of 
infection 
Sponge 
Septocoll® Biomet  Collagen Gentamicin Hemostasis in surgeries Fleece 
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9. Future of Drug Eluting Devices 
Most new chemical entities have poor aqueous solubility and consequently poor oral 
bioavailability, thus, drugs administered orally can remain undissolved in the 
gastrointestinal tract instead of being absorbed by the organism [66]. Moreover, in 
conventional drug release systems as the concentration of the medicine falls down, a new 
dosage is required. The challenge of drug eluting devices is focused on the control of the 
releasing rate to keep the concentration within the therapeutic window, personalized for 
each patient and therapy. This on demand drug delivery requires drug-releasing devices 
that can decide the suitable dosage at convenient time, in other words, intelligent drug 
releasing devices. Microchips Biotech has developed a technology of microchip-based 
implant that can store hundreds of therapeutic doses over months and years, and release 
each dose at precise times. Each implant contains micro-reservoirs etched into a silicon 
wafer (see Fig. X) which store up to 1 mg of drug.  The implant is activated by a wireless 
signal that applies a voltage to the gold foil, which is hermetically sealing the small 
compartments, with resulting electrochemical dissolution of the cover and release of the 
drug on a pre-programmed dosing schedule. In addition, the implant can be built with 
sensors that release drug in response to physiological or metabolic changes in the patient.  
 
 
Figure X. Implants developed by Microchips Biotech, Inc. 
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Over the years, medical devices have changed from mere support to smart appliances 
aiding the healing process. Another groundbreaking advance in the field of biomedical 
engineering is the advent of micro/nanorobots. Medical micro/nanorobots may be capable 
of carrying a bioactive compound accurately to any part of the body (even to regions like 
eyes and nervous system which are otherwise difficult to reach) through external wireless 
steering. Some researchers fabricated artificial flagella to create entirely autonomous 
robots [67]. Furthermore, as our understanding continues to increase of which DNA 
sequences encode for which diseases, we are able to identify which sequences in the same 
individual DNA may be used to predict precise therapeutic regimes for optimum 
treatment of those diseases in each individual. Such “personalized medicine” will place 
demands on the drug delivery scientist to be more biologically precise and accurate with 
our “controlled” delivery systems [68]. 
Many technical and commercial challenges should be tackled to improve the current drug 
eluting device technology, but the tight health care regulations make the future uncertain. 
10. Conclusions 
Drug eluting devices for treating different diseases affecting different functions of the 
human body have been reviewed. In most cases, drug-releasing devices provide greater 
therapeutic efficacy than conventional oral or intravenous formulations, offering 
alternative ways to deliver therapeutics to any part of the body and reducing the side 
effects associated with excessive dosages of highly toxic drugs [69-81].  
This review makes clear that the development of drug delivery devices needs a 
combination of knowledge, involving material scientists, engineers, medical scientists, 
biologists and clinicians. Significant advances will only be made through 
multidisciplinary teams that utilize the latest advances in the biological, chemical, 
physical, and engineering sciences [82-87]. Studies to discover the ideal material, shape, 
size and dosage for a tailored drug eluting medical device are still needed. 
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The surface of medical devices provides an excellent platform fort the formation of 
bacterial colonies or biofilms, producing life-threatening infections across most types of 
implanted devices. This problem could be overcome through the development of novel 
antifouling materials based on nature. 
 
Drug release profiles of bioactive agents, mechanical and physical properties of the 
device, degradation rate and bacterial inhibition must be elucidated in order to achieve 
the desired properties for each application. Pharmaceutical companies and device 
manufactures are actively seeking development opportunities for new drug/device 
combination products based on the existing raw materials and drugs. The future is a drug 
eluting device that “knows” where, when and how much drug is needed for treating a 
specific illness.  
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The main objective of this doctoral thesis is to study biodegradable polymers loaded with 
biologically active molecules for potential applications in biomedicine. Bearing this in 
mind, the materials required to create drug eluting devices must present a stable phase 
behavior that can only be achieved by forming consistent amorphous solid dispersions, 
i.e., miscible blends with strong intermolecular interactions. Moreover, when a drug is 
dispersed in amorphous form within a polymeric matrix its solubility increases and in 
turn, the bioavailability.  
It is known that when two materials are miscible, macroscopic properties of single-phase 
materials are expected for the blend, such a single glass transition temperature 
intermediate between those of the pure components. In this context, they were mixed by 
solvent-casting, on one hand, an amorphous biopolymer (poly(D,L)-lactide, PDLLA), 
and on the other, a semicrystalline one (poly(ε-caprolactone), PCL), with a selection of 
molecules that kill or inhibit the growth of microbes, attending to their pharmacological 
application, solubility and affinity with the biodegradable polymers used in this work (see 
Table 1). At this point, thermal analyses were conducted on a Differential Scanning 
Calorimetry (DSC) in order to study the glass transition temperatures, and therefore, 
predict the miscibility between the two species. Once this preliminary study was 
completed, a few polymer-drug systems were selected for further analysis. In fact, 
miscibility was only investigated in blends with the biodegradable polymer PCL.  
With the aim of inferring the release behavior, as well as the antibacterial efficacy of these 
materials based on the union of a biodegradable polymer with a biologically active 
molecule, physicochemical characterization and drug release studies were performed. For 
this purpose, in this thesis it will be necessary to study the: 
 Miscibility and interactions between the PCL and the drug. 
 Influence of the composition in the miscibility through the analysis of interaction 
parameters, as well as the crystallinity. 
 Release profiles in PBS medium (in-vitro) for different compositions of the blend. 
 Antibacterial activity of the PCL-drug system against E.coli. 
 Biofilm formation of PCL coated with a fluorinated tripeptide with non-sticky 
feature.  
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Table 1. Miscibility prediction of the different polymer-drug 
systems. 
Biologically active molecules 
Poly(-caprolactone) 
PCL 
Poly(DL-lactide) 
PDLLA 
ERYTHROMYCIN   
THIAMPHENICOL   
TETRACYCLINE   
SULFANILAMIDE   
SULFACETAMIDE   
SULFACHLOROPYRIDAZINE   
SULFAMETHAZINE   
TRIMETHOPRIM   
LEVOFLOXACINE   
BRONIDOX   
THYMOL   
CICLOHEXIMIDE   
CHLORAMPHENICOL   
NARINGIN   
QUERCITIN   
MYCOPHENOLIC ACID   
HYGROMYCIN   
TOBRAMYCIN   
RAMOPLANIN   
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Summary 
Blends of poly(ε-caprolactone) (PCL) and thymol  (THY) have been prepared by melt-
mixing to obtain biodegradable materials with antibacterial properties. Miscibility and 
specific interactions have been investigated by means of DSC and FTIR, and the drug 
release kinetics of the PCL/THY blends have been analyzed using UV spectroscopy at 
274 nm. The melting points of PCL and THY have been analyzed using melting point 
depression analysis, and the interaction energy density has been found to vary from B = 
-30 J/cm3 in THY-rich blends to B = 9 J/cm3 in PCL-rich blends. The former value 
indicates a thermodynamically miscible blend, but the latter is close to critical conditions, 
and the dependence of B on composition has been discussed. The study of the carbonyl 
and hydroxyl stretching regions of the FTIR spectra for different compositions of the 
blend reveals strong -C=O···H-O- hydrogen bonding interactions, supporting the 
miscibility of the PCL/THY blends. Finally, the analysis of the release kinetics of THY 
from the PCL/THY blends in phosphate buffered saline (PBS) solution at 37 ºC (pH 7.4) 
shows that diffusion through the swelled polymeric chains is the leading mechanism for 
drug release. 
1.1. Introduction 
The use of biopolymers for biomedical applications makes feasible smart therapies, 
designed for the need of each patient. In most of the conventional drug release systems, 
the level of the pharmaceutical compound reaches a maximum and then falls down, 
requiring another dose of drug. Besides, the concentration of the drug could be above the 
toxicity level, or below the minimum effective concentration, causing periods of toxicity 
and inefficiency. However, if the drug is incorporated into a polymeric matrix, it can be 
released in a controlled way within the therapeutic margins [1]. Furthermore, if it is a 
biodegradable polymer, it can be reabsorbed or excreted by the body. Consequently, 
medical devices loaded with drugs made of biopolymers do not need to be taken off after 
finishing their service. 
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When formulating new drug molecules, low aqueous solubility is a common problem. In 
fact, more than 50 % of new molecules have delivery problems [1,2]. If a poorly water-
soluble drug is orally administered, it can remain undissolved in the gastrointestinal tract 
until excretion, instead of being absorbed by the organism. The formulation of amorphous 
solid dispersions  (ASDs) is a strategy to increase the solubility [3]. Amorphous polymers 
form a network like structure, due to molecular entanglement. When an amorphous drug 
is incorporated into this network, drug molecules can interact with polymer chains by 
weak physical bonds such as hydrogen bonding, Van de Waals force and/or ionic 
interactions. Consequently, there is a reduction of the molecular mobility since polymer 
chains act as crystallization inhibitors preserving the drug in its amorphous form [4,5]. 
The amorphous drug shows enhanced miscibility in any medium (including the 
physiological medium) since molecular miscibility is not constrained by the strong auto-
association interactions commonly encountered in drugs in their crystalline forms. 
ASDs can be formulated both inside the miscible and the metastable regions of the 
polymer/drug phase diagrams, but the miscible region is safer for the long term stability 
of the formulation. For miscibility to occur in a polymer/drug system, the free energy of 
mixing must be negative (ΔGM ≤ 0). According to the classical Flory-Huggins theory ΔGM 
can be calculated from Eq. 1 [6-8]: 
  
oncontributi
enthalpic
n
oncontributi
entropic
lnnlnn
kT
G
polymerdrugpolymerpolymerdrugdrug
M                          (1) 
where n is the number of molecules,  is the volume fraction, χ is the Flory-Huggins 
interaction parameter, k is the Boltzmann constant, and T is the absolute temperature. The 
quantity χkT represents the difference in energy of a "solvent" molecule  (i.e., the drug) 
immersed in the pure polymer (pol ≈ 1) compared with one surrounded by molecules of 
its own kind, i.e., in the pure solvent [6]. Similarly, χkT can also be defined inverting the 
roles of solvent and polymer, where a different χkT value would indicate the dependence 
of χ on composition (instead of being a constant parameter). In a polymer-drug system 
the entropic contribution to the free energy of mixing of the blend is negative (favorable 
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to miscibility) but small [6-8]. As a result, the enthalpic contribution (ndrugpolymer) 
determines the miscibility of the system in most cases. In this way, a negative interaction 
parameter (χ < 0) implies favorable interactions between the two species, yielding 
miscible systems, whereas a positive χ entails stronger cohesive interactions in the pure 
components than in the blend. According to the Flory-Huggins theory, the miscibility 
limit is given by the critical value of the interaction parameter (χc ~ 0.5, for typical blends 
of high molecular weight polymers with low molecular weight species) [6-8]. In systems 
with slightly unfavorable interactions (those in which 0 < χ < χc), miscibility is driven by 
the small but favorable entropic contribution. 
Poly(-caprolactone) (PCL) is a semicrystalline polyester widely used in biomedical 
applications. Its degradation can last from several months to years, depending on the 
molecular weight, crystallinity and degradation conditions, making it suitable for long-
term biomedical applications [9]. Thymol (THY) is a major component of thyme oil, an 
essential oil with antimicrobial properties. For example, it has antimicrobial activity 
against natural spoilage bacteria and food borne pathogens such as Salmonella 
typhimurium, Escherichia coli, Listeria monocytogenes, Bacillus cereus, and 
Staphylococcus aureus [10]. The chemical structures of the studied species support the 
possibility of hydrogen bonding between hydroxyl groups of thymol and carbonyl groups 
of PCL (see Fig. 1.1). Thymol can act as proton donor that forms hydrogen bonds with 
proton acceptor PCL [11,12].              
 
                              
      
 
            Poly ε-caprolactone)                                            Thymol 
Figure 1.1. Schematic illustration of the chemical structures of 
PCL and Thymol. 
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The aim of this work is to study the miscibility and interactions between PCL and thymol, 
as well as to investigate the release mechanisms of the drug from the polymeric matrix. 
In a system composed of a swellable polymer, such as PCL, loaded with a drug, the 
release of the drug dispersed within the polymer matrix will be controlled by diffusion, 
swelling and erosion [13]. Miscibility of the PCL/THY blends has been studied using 
Differential Scanning Calorimetry (DSC), and the polymer-drug interaction parameter 
has been obtained through melting point depression analysis. Specific interactions in the 
PCL/THY system have been analyzed using Fourier Transform Infrared (FTIR) 
spectroscopy. Finally, the release kinetics of thymol from the PCL matrix has been 
investigated by means of Ultraviolet-Visible (UV-Vis) absorption spectroscopy. 
1.2. Experimental Section 
1.2.1. Starting Materials  
Polycaprolactone (PURASORB® PC12 trade name) with an average molecular weight 
(Mw) of 1.3·105 g·mol-1 and Mw/Mn = 1.76 (as determined by GPC) was kindly supplied 
by Purac Biochem (The Netherlands). Thymol (purity ≥ 99.5 %) and phosphate buffered 
saline 0.1 M (pH 7.4) were obtained from Sigma-Aldrich (Spain). 
1.2.2. Blend Preparation  
Melt mixed blends (total sample amount 1 g) were prepared by melting together PCL and 
THY into small closed vessels to avoid the volatilization of the drug, immersed into a 
heated and stirred paraffin bath at 65 ºC during 24 h. Mechanical mixing was not 
employed because at this temperature THY is liquid and acts as an organic solvent. 
Afterwards, blends were allowed to cool for 24 h before measurements. 
1.2.3. Differential Scanning Calorimetry (DSC)  
Thermal analyses were conducted on a Modulated DSC Q200 from TA Instruments. 
Samples ranging from 5 to 10 mg were placed in aluminum pans, sealed, and scanned 
under a nitrogen atmosphere. 
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1.2.4. Melting Point Depression 
The melting point depression of THY has been investigated in THY-rich blends 
containing 0-20 wt.% PCL. Samples were heated in the DSC with a scan rate of 1 ºC/min 
to obtain the melting temperature of the THY crystals. 
The melting point depression of PCL has been investigated in PCL-rich blends containing 
0-20 wt.% THY. Samples were first heated at 70 ºC for 3 min. to assure complete melting 
of the PCL crystals, and were then cooled at 10 ºC/min to the desired crystallization 
temperatures (Tc) and allowed to crystallize isothermally for 60 min. in the DSC furnace. 
Then, they were heated with a scan rate of 5 ºC/min to measure the melting temperature 
(Tm) of the PCL crystals. For a given composition, crystallizations were assumed 
complete if the melting endotherm deviated less than 10% from the maximum value, 
obtained usually for certain intermediate Tc. 
Finally, no weight loss was observed during the thermal treatments (the DSC crucibles 
were weighed again after the calorimetric scans), indicating no significant THY 
evaporation. 
1.2.5. Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra of the blends were recorded on a Nicolet AVATAR 370 Fourier transform 
infrared spectrophotometer. Spectra were taken with a resolution of 2 cm-1 and were 
averaged over 64 scans in the range of 400-4000 cm-1. Chloroform solutions containing 
0.7 wt.% of blends were cast on KBr pellets by evaporation of the solvent at room 
temperature. The absorbance of the samples was within the range where the Lambert-
Beer law is obeyed. To assure CHCl3 removal without significant evaporation of THY, 
the presence of the former was followed in situ within the FTIR bench using the 
chloroform bands located at about 670 and 760 cm-1. In most cases, these bands were 
undetectable after a few hours.  
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1.2.6. In Vitro Drug Release Kinetics (UV-Vis) 
UV–Vis absorption spectra were recorded over wavelengths ranging from 190 to 500 nm 
using a Perkin Elmer Lambda 265 UV-Visible spectrophotometer. A calibration curve 
was obtained using THY solutions (in the 10 - 100 ppm range) in 0.1 M phosphate 
buffered saline (PBS) medium (pH 7.4). Absorbance values were measured at a 
wavelength of 274 nm (λmax for THY) using a quartz cuvette. 
Square samples (2 mm thick and 1 cm side length; approx. weight 145 mg) of the 
PCL/THY 70/30 blends obtained by melt mixing, were immersed in 100 mL of 0.1 M 
PBS solution at 37 ºC. At fixed time intervals, 2 mL of the solution were taken and 
replaced with fresh PBS at 37 ºC. Drug concentration in solution was determined by UV 
spectroscopy at a wavelength of 274 nm. 
The kinetics of THY release from the square plates was determined by finding the best 
fit of the curves (% release against time) to different kinetic models [14-16]: 
1. Zero order kinetics. This model holds in swelling-controlled drug release systems. 
Release process is controlled by relaxation of polymeric chains and the release rate of 
drug is constant and independent of its concentration (Eq. 2). 
 Ct/C∞ = k0t                                                                  (2) 
2. First order kinetics. Drug release rate depends on its concentration (Eq. 3). 
   ln (1- Ct/C∞) = -k1t                                                            (3) 
3. Higuchi model [32]. Release is controlled by Fickian diffusion (Eq. 4). 
Ct/C∞ = kht1/2                                                      (4) 
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4. Korsmeyer-Peppas model. Fickian diffusional release Eq.(4) and non-Fickian 
relaxational release  Eq.(2) are the limits of this model. When both mechanisms contribute 
additively to the release, the overall behavior can be approximated to Eq. 5: 
 
Ct/C∞ = ktn                                                           (5) 
where 0.5 < n < 1. The actual exponent also depends on the geometry of the releasing 
device. In addition, the case II transport contribution to the release also includes polymer 
disentanglement and erosion in this model. Finally, the exponent n should be determined 
using only the portion of the release curve where Ct/C∞ < 0.6. 
5. Peppas-Sahlin model. This approach couples the effects of Fickian diffusion (kItm) and 
chain relaxation (kII2m) by means of Eq. 6: 
Ct/C∞ = kItm + kIIt2m                                                 (6) 
In all these models, Ct is the cumulative amount of drug released at time t, C∞ represents 
the starting amount of drug, n and m are release exponents; and k, k0, k1, kh, kI and kII are 
constants. 
1.3. Results and Discussion 
1.3.1. DSC Analysis 
Miscibility of polymer-drug systems can be studied trough the depression of the melting 
point (Tm). Morphologically, in miscible blends, the amorphous drug enters into the 
interlamellar region of the semicrystalline polymer, hence lamellae become thinner and 
Tm decreases [17]. Thermodynamically, the chemical potential of the amorphous phase 
decreases when a miscible drug is added, due to both entropic and enthalpic effects [6-8], 
whereas the chemical potential of the crystalline part does not vary. As a consequence, 
the equilibrium between the crystalline and the amorphous part of the polymer is 
established at lower temperatures. For a system lacking attractive specific interactions, 
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the reduction in chemical potential is related to the stabilization of the system associated 
to the entropy of mixing [6-8]. Using basic thermodynamics, since the change in free 
energy at the melting point equals zero (G = 0), the equation G = H - TmS = 0 can 
be solved to Tm = H/S. In the case of a blend, the entropic contribution is larger (it is 
the sum of the entropy of melting plus the entropy of mixing), and consequently the 
melting temperature decreases relative to that of the pure polymer. 
Figure 1.2 shows the first DSC traces (20 ºC/min) obtained for the pure components and 
for different PCL/THY blends. Pure PCL is a semicrystalline polymer displaying a glass 
transition temperature located at about -60 ºC and a melting endotherm at about 65 ºC. In 
turn, pure THY only shows a melting endotherm located at about 55 ºC. The absence of 
a glass transition temperature jump can be attributed to the lack of amorphous fraction at 
the temperatures expected for this transition, since the crystallization of this drug at 
sufficiently low temperatures is hard to avoid. The addition of THY to PCL shifts the 
melting temperature of PCL to lower temperatures, and when the THY content reaches 
40 wt.%, the melting peak of PCL is no longer observed. Both the drop in melting 
temperature and the suppression of the melting peak suggest the miscibility of the system. 
Nevertheless, the most widely accepted criterion to establish the miscibility of 
polymer/drug systems is based on the behavior of the glass transition temperature [18-
21]. Miscible blends should show a single glass transition temperature located at 
intermediate temperatures between those of the pure components. If the drug does not 
show as a glass transition temperature jump (as in the case of THY), the Tg of the blends 
should shift from the location corresponding to the pure polymer to the vitrification 
temperature of the drug, that can be estimated using the empirical Beaman-Boyer rule: 
Tg/Tm = 2/3 [18]. Unfortunately, the Tg estimated for THY according to this rule is about 
-55 ºC, very close to that of PCL, and hence, no significative Tg-shift can be expected for 
the PCL/THY system regardless of its phase behavior. As can be seen in Figure 1.2., all 
the blends investigated in this paper show single Tgs located in a narrow temperature 
range (about -55 ºC), and the DSC results are not conclusive regarding the miscibility of 
the system. However, other evidences obtained in this work and discussed throughout this 
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paper indicate that the glass transition temperature jumps observed in Figure 1.2. should 
be attributed to single miscible phases rather than to PCL-rich phases. 
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Figure 1.2. First scan DSC curves for PCL, thymol and 
PCL/THY blends. 
1.3.2. Melting Point Depression Analysis. 
Melting Point of Thymol. 
The depression of the equilibrium melting point can be analyzed using the Flory-Huggins 
theory [6]. The general expression for blends of two polymeric species is:  
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where Tme0 and Tme are, respectively, the equilibrium melting points of the pure 
crystallizable component and of its blends, the subscripts 1 and 2 refer to the amorphous 
and crystallizable components respectively, R is the universal gas constant, ΔHu is the 
heat of fusion per mole of crystalline repeat units, Vu is the molar volume of the repeating 
unit, m is the degree of polymerization,  is the volume fraction, and χ12 is the polymer-
polymer interaction parameter. 
To apply Eq. (7) to the analysis of the melting point depression of THY (component 2), 
the molar volume of the lattice sites can be taken as the molar volume of liquid THY (V2 
= 158 cm3/mol, according to the density of liquid THY at room temperature, ρ = 0.95 
g/cm3) [22], and consequently, m2 =1. In addition, the same volume can be adopted as 
the molar volume of the polymeric repeat unit (V2 = V1u) so that 1/m1 ≈ 0 (since m1 = 
Vpol/V1u is large). Therefore, Eq. (7) simplifies to Eq. (8): 
 
 2112
2
0
mm
ln
H
R
T
1
T
1  
                                  (8) 
 
The first two terms in the right hand side of Eq. (8) represent the entropic contribution to 
ΔTm, and the third term the enthalpic contribution. Applying the Taylor series expansion, 
ln2 = ln (1-1) = -1- 12/2 - 13/3.... and assuming dilute conditions (i.e. neglecting cubic 
and higher order terms), the bracketed term in Eq. 8 simplifies to (-1/2 + χ)12. Thus, both 
entropic and enthalpic factors contribute to the melting point depression in the whole 
composition range (none of them can be neglected even in diluted conditions). 
Substituting typical numbers in Eq. 8, it is easy to show that the entropic term only 
accounts for a small depression (usually about 1-2 ºC) [23]. 
The melting point of THY has been measured at low heating rates (1 ºC/min) for the pure 
component and for different PCL/THY blends (see Table 1.1). The average melting point 
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of pure Thymol is Tmº(THY) = 49.6 ºC, and the addition of 20 wt.% PCL decreases the 
melting point by about 4 ºC, suggesting the miscibility of the system. Using the melting 
temperature of pure THY and its melting enthalpy (ΔHTHY = 116 J/g) [24], the data in 
Table 1.1 have been analyzed according to Eq. (8) yielding the plot in Figure 1.3. As can 
be seen (Fig. 1.3), the experimental data fit a line passing close to the origin, suggesting 
that the interaction parameter is almost independent of concentration [23]. The negative 
value obtained for χ (-1.8) confirms a thermodynamically miscible blend. Alternatively, 
the interaction energy density, B can be calculated at the melting temperature of THY 
according to Eq. (9): 
RT
BV r
                                                                (9) 
where Vr is a reference volume (in this case, Vr = V2 = 158 cm3/mol), yielding B = - 30 
J/cm3. 
 
Table 1.1. Melting temperature of THY in blends with PCL. 
Thymol wt.. %
Tmmix (ºC) 
Sample 1 Sample 2 Sample 3
100 
95.1 
90.5 
85.5 
80.3 
49.7 
49.1 
49.1 
48.2 
45.5 
49.4 
49.3 
49.1 
47.9 
46.3 
49.6 
49.4 
49.3 
48.3 
46.1 
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Figure 1.3. Analysis of the melting temperature of THY 
according to Eq. (8) for the PCL/THY system. The slope of the 
plot gives the interaction parameter = -1.8. 
Melting Point of PCL 
The depression of the equilibrium melting point of PCL can be analyzed again using the 
Flory-Huggins theory (Eq. 7). Following the same conventions as before, the subscripts 
1 and 2 are assigned to the amorphous and crystallizable components respectively. In 
addition, the molar volume of the amorphous component (THY) is adopted as the molar 
volume of the lattice cells, yielding Eq. 10: 
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The first and second terms in the right hand side of Eq. (10) represent, respectively, the 
entropic and enthalpic contributions to ΔTm. As can be seen, the depression occurring in 
diluted conditions upon addition of a low molecular weight substance to a polymeric 
material is now governed by the entropic term. The enthalpic term only gains importance 
at higher concentrations. The larger relevance of the entropic term in this case (compared 
to Eq. 8) can be attributed to the larger entropy increase occurring when small molecules 
are added to big molecules. This can be rationalized from a statistical point of view 
considering that, if a polymeric chain of length n is replaced by n solvent molecules in a 
lattice, the system gains the combinatorial entropy corresponding to those n small 
molecules. In the opposite case, however, if n solvent molecules were replaced by a single 
polymer chain, the system would only gain the combinatorial entropy corresponding to 
the new chain (actually associated to the locations available for its center of mass) [6,25]. 
In the classical literature dealing with polymer-diluent systems it is preferred to rewrite 
Eq. 10 in terms of the interaction energy density, B, as follows (Eq. 11) [6,26-29]: 
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A plot of the left side of Eq. 11 as a function of /Tme allows calculating ΔH2u from the 
intercept and B from the slope and the intercept. Eq. 11 requires, however, the 
determination of the equilibrium melting points, which is not a straightforward task in 
polymers, since their melting points decrease by both thermodynamic and morphological 
reasons [6,30]. The reference method to determine Tme is based on the Gibbs-Thomson 
(G–T) equation, which shows that plotting Tm vs lc-1 (where lc is the lamellar thickness) 
should result in straight line termed "melting line" [31,32]. Extrapolation of the melting 
line to lc-1 = 0 eliminates the morphological effects rendering Tme. The G–T method is 
based on a correct thermodynamic relationship, but its application is not simple because 
requires the measurement of lamellar thicknesses by SAXS. An alternative method to 
Chapter 1. Antimicrobial Poly(ε-caprolactone)/Thymol Blends: Phase Behavior, Interactions 
and Drug Release Kinetics 
84 
obtain Tme is the Hoffman-Weeks (H–W) plot, which is actually based on the G–T 
equation and the surface nucleation theory [31]. In this procedure, samples are 
crystallized at different crystallization temperatures (Tc) and the corresponding melting 
temperatures (Tm) are subsequently measured. The plot of these points is assumed to 
follow a straight line, and Tme is obtained from the intersection of this line with the Tm = 
Tc line. Recent investigations [31] have shown that the H–W method underestimates the 
equilibrium melting temperature of polymers. Nevertheless, because of its 
straightforward nature, the H–W extrapolation is by far the most widely used method in 
research papers dealing with polymer miscibility [21] and is therefore adopted in this 
work. 
Figure 1.4. shows the melting peaks recorded for a PCL/THY 90/10 blend isothermally 
crystallized at different temperatures. As can be seen, a single crystallization peak can be 
observed for the samples crystallized at higher temperatures, but the melting endotherm 
splits progressively in two peaks with the decrease in crystallization temperature. A 
similar behavior was also reported for blends of PCL with Poly(vinylphenol) [11]. Double 
melting peak behavior is usually attributed to melting, recrystallization and subsequent 
remelting during the DSC scan [11,20]. Nowadays the occurrence of recrystallization or 
reordering processes during heating scans is widely accepted for both pure polymers and 
polymer blends. In cases were two melting components can be observed, the lower 
temperature contribution (LTm) has been attributed to the initial crystals existing in the 
sample, while the higher melting point (HTm), which is almost independent of the 
isothermal crystallization temperature, has been attributed to the crystals formed during 
the recrystallization process occurring after melting of the initial crystals[20]. 
Consequently, the LTm melting points (obtained from the samples crystallized at lower 
temperatures) are recommended to perform the H-W extrapolations [20]. 
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Figure 1.4. Melting endotherms obtained by DSC (5 ºC/min) for 
the PCL/THY 90/10 system crystallized at (●) 33, (○) 30, (▲) 
27, (∆) 24, (■) 21 and () 18 ºC. LTm stands for Lower melting 
temperature and HTm stands for Higher melting temperature (see 
text). 
Unfortunately, the two peaks are strongly overlapped making impossible the H-W 
extrapolation based on LTm. Even though the addition of THY seems to improve peak 
splitting, the two components are hardly distinguishable in pure PCL. The only alternative 
to perform reliable and consistent H-W extrapolations in this system is therefore using 
the melting peaks recorded for the samples crystallized at the highest temperatures, since 
they should be less affected by possible recrystallization processes occurring during the 
heating step. We have hence constrained the experimental data only to the four melting 
points obtained for the samples crystallized at the higher crystallization temperatures, 
covering a Tc range of only 9 ºC. Figure 1.5 shows the H-W extrapolations and Table 1.2 
lists the Tme data obtained from the extrapolations. As can be seen in Table 1.2, the 
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addition of 20 wt.% THY to PCL depresses the melting temperature of PCL by about 6 
ºC, which is a relatively small depression compared to other polymer-diluent systems 
[6,25-29]. 
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Figure 1.5. Hoffman-Weeks extrapolations for (•) PCL, (●) 
PCL/THY 95/5, (■) PCL/THY 90/10 and (▲) PCL/THY 80/20. 
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Table 1.2. Equilibrium melting points (Tme) obtained from the 
H-W extrapolations in Fig. 1.5. 
System Tme (ºC)
PCL 60.6 
PCL/THY 95/5 58.7 
PCL/THY 90/10 57.4 
PCL/THY 80/20 54.1 
Figure 1.6 shows the plot of (1/Tm - 1/Tmº)/1 as a function of 1/Tm. The intercept leads 
to ΔH2u = 163 J/g, which is located within the values accepted in the literature, ranging 
from 136 J/g to 167 J/g [33-35]. The slope leads to a positive value for the interaction 
energy density B ≈ 9 J/cm3, indicating that autoassociation interactions are stronger than 
the interassociation contacts. In addition, the critical interaction energy density (Bcrit) can 
be calculated from [7]: 
2
2w
2
1w
1
crit MM2
RTB 


                                                 (12) 
 
resulting in Bcrit ≈ 9 J/cm3. Hence, the miscibility of the PCL-rich PCL/THY blends is 
close to critical conditions. 
In summary, the interaction energy density in the PCL/THY system shows a strong 
dependence on composition, varying from about -30 J/cm3 in THY-rich blends (indicating 
strong favorable interactions) to about 9 J/cm3 in PCL-rich blends (indicating moderately 
unfavorable interactions). The dependence on composition resembles qualitatively that 
observed for blends of different polyesters with poly(vinyl phenol) (PVPh) [19, 36-38], 
although the interaction parameters obtained here for the PCL/THY system are shifted 
upward (to more positive values). Since THY is crystalline while PVPh is amorphous, 
the less favorable interaction parameters obtained for the blends with THY can be 
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attributed to the higher autoassociation expected in pure crystalline THY compared to 
pure amorphous PVPh. In general, the stronger autoassociation of THY (compared to 
PVPh) is expected to hinder its miscibility with polyesters. 
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8
0,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
(1
/T
m
e -
 1
/T
0 m
e)/
 1 
(x
10
3 )
1/Tme (x103)
 
Figure 1.6. Analysis of the equilibrium melting temperature of 
PCL according to Eq. (11) for the PCL/THY system. 
1.3.3. FTIR Analysis 
Specific interactions present in PCL/THY blends can be investigated by infrared 
spectroscopy. The chemical structures of the studied species support the possibility of 
hydrogen bonding between the hydroxyl groups of thymol and the carbonyl groups of 
PCL [11,12]. 
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Figure 1.7. Carbonyl stretching region for pure PCL and 
PCL/THY blends of different composition. 
Fig. 1.7 shows the carbonyl stretching region of PCL and PCL/THY blends of different 
compositions. The spectrum of pure PCL shows a peak at 1725 cm-1 attributable to the 
PCL crystals and a shoulder at 1735 cm-1 representing the amorphous phase [11]. The 
80/20 composition shows again similar bands to those of pure PCL, but accompanied by 
a new contribution located at lower wavenumbers, attributable to hydrogen bonded C=O 
groups in PCL [39]. When 40 wt.% thymol is added to the blend, the band corresponding 
to crystalline PCL is not observed, and the spectrum only shows two bands located at 
about 1735 and 1710 cm-1, attributable respectively to free and hydrogen bonded C=O 
groups in PCL [39]. Further addition of Thymol results in an increase of the relative 
intensity of the band located at 1710 cm-1 relative to the band located at 1735 cm-1. 
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Figure 1.8. Hydroxyl stretching region for pure Thymol and 
PCL/THY blends of different compositions. 
Fig. 1.8. displays the hydroxyl stretching region of PCL and PCL/THY blends. The 
spectrum of pure thymol shows a broad band centered at 3465 cm-1 attributable to a wide 
distribution of self-associated hydroxyl groups [40,41], as well as a shoulder at about 
3525 cm-1. This component has been attribute in the classical literature to free OH groups 
[40], however, according to recent investigations, it indeed corresponds to hydroxyl 
groups interacting with aromatic rings (OH···π interactions) [41-43]. Actually, free OH 
stretching band has been claimed to occur at about 3600 cm-1 [41-43], but is undetectable 
in the spectrum of pure THY. The PCL/THY 20/80 blend shows a peak located at about 
3440 cm-1, characteristic of hydroxyl groups associated with carbonyl groups of PCL (-
C=O···H-O-) [11,39]. Consequently, the shoulder is weaker, indicating a decrease in the 
fraction of non-bonded hydroxyl groups. When the amount of thymol reaches 60 wt.%, 
the spectrum is governed by the sharp peak at 3440 cm-1, while the shoulder at higher 
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wavenumbers is no longer discerned, indicating that -C=O···H-O- interactions increase 
at the expense of hydroxyl-hydroxyl autoassociation and of OH···π interactions. 
Finally, it is interesting to perform a quantitative study of the degree of interassociation 
and its dependence with composition. For this purpose, a least-squares curve-fitting 
analysis has been applied to the carbonyl stretching bands. The two bands corresponding 
to the contributions of free and associated carbonyls fit well to a Gaussian function. Table 
1.3 lists the calculated results. The free carbonyl fraction, fF, has been determined from 
[44]: 
 
aAA
Af
AF
F
F                                                             (13) 
 
where AF and AA are the areas (absorbances) under the peaks corresponding to the free 
and associated carbonyl groups respectively, and a is the ratio of the molar absorption 
coefficients (a = εA/εF). A value of 1.5 has been taken for this ratio according to preceding 
studies [44]. Figure 1.9 shows the dependence of the interassociation with composition. 
As can be seen fF increases smoothly with the addition of thymol. The calculated data 
suggest that the interassociation degree reaches a limiting value in THY-rich 
compositions, a limitation that is mainly attributed to intramolecular screening [45]. 
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Table 1.3. Curve fitting results for the PCL/THY system. 
PCL/THY 
wt.% 
free C=O band  HB C=O band 
fF 
ῡ (cm-1) FWHH Area  ῡ (cm-1) FWHH Area 
60/40 1735.6 17.2 48.3  1710.7 25.0 51.7 0.58 
40/60 1736.0 16.5 38.6  1710.6 25.6 61.4 0.49 
20/80 1737.9 16.0 11.9  1709.4 25.8 88.1 0.17 
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0,0
0,2
0,4
0,6
0,8
1,0
f F
mole fraction THY
 
Figure 1.9. Dependence of the fraction of free C=O groups with 
composition. 
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1.3.4. In Vitro Drug Release 
Figure 1.10. shows the in vitro release profile of THY from a PCL/THY 70/30 sample in 
10 days (240 hours). In the first 2 hours no drug release is detected, but then THY release 
begins and 7 wt.% THY is released after 24 h. The highest release rate is achieved during 
the first day. Thereafter release rate slows down, and a sustained release of THY is 
observed during the following days. After a week (168 h), a 23 wt.% of drug is released. 
Afterwards, the release rate slows down and throughout the last days of the study just an 
additional 2 wt.% drug is released. Only a 25 wt.% of the THY contained into the 
polymeric matrix is released in 10 days. Stability of PCL is not affected after that period, 
since the in vitro degradation rate of PCL is KMw = 0.001 days-1 [46]. Thus, the rest of 
the drug will not be quantitatively released until the beginning of bulk erosion. 
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Figure 1.10. Drug release profile for a PCL/THY 70/30 sample 
(1 cm2 x 2 mm) obtained by melt mixing and immersed into 100 
mL of PBS at 37 ºC during 10 days. 
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The observed profile indicates that the first step is the penetration of the buffered solution 
into the matrix, leading to its swelling and, as a result, the free volume of the polymer 
increases. Temperature in the solution is 37 ºC which is above glass transition of the 
polymer (Tg PCL = -60 º C), hence chains have a certain degree of mobility when they are 
immersed in the solution. The polymeric network becomes wider, and the amorphous 
THY dissolved in the polymer matrix diffuses throughout it to reach the outer solution. 
Thymol is only sparingly soluble in water (solubility is about 0.9 g/l) [47], and in our 
experimental setup, the concentration of THY in the outer solution should come close to 
0.1 g/L after 7 days. Thus, considering the much larger solubility of THY in the polymeric 
matrix compared to the aqueous phase, the concentration plateau observed after a week 
is probably dictated by the partition coefficient of THY between the organic and the 
aqueous phases [48]. Entrapped remaining thymol should be released after the 
degradation of the polymer in several months. 
Release data has been fitted to different kinetic equations used to study the mechanism of 
drug release. Results are shown in Table 1.4. The release exponent obtained from 
Korrmeyer-Peppas model is n = 0.931 (0.5 < n < 1) which indicates anomalous drug 
transport consisting on a combination of Fickian diffusion and polymer relaxation. The 
best fit has been obtained using the Peppas-Sahlin mathematical model. As can be seen 
in Table 1.4, the value obtained for kI in the Peppas-Sahlin model is significantly bigger 
than kII, therefore Fickian diffusion prevails over relaxation of polymeric chains. 
 
Table 1.4. Fitting of the release data to the mathematical models 
for drug release kinetics. R2 is the correlation coefficient, n is the 
release exponent, and kI and kII indicate the contribution to 
Fickian and relaxation mechanisms respectively. 
Zero order First order Higuchi Korsmeyer-
Peppas 
Peppas-Sahlin 
R2 = 0.8951 R2 = 0.9153 R2 = 0.9858 R2 = 0.9492 R2 = 0.9904 
   n = 0.931 kI = 2.5x10-3 kII = -0.006x10-3 
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1.4. Conclusions 
Miscibility and interactions have been investigated in the PCL/THY system. The analysis 
of the glass transition temperature by DSC is not conclusive regarding the miscibility 
behavior of the blends, but the melting points of both PCL and THY shift to lower 
temperatures when blended, indicating the miscibility of the system. According to the 
melting point depression analysis, the interaction energy density varies from B = -30 
J/cm3 in THY-rich blends to B = 9 J/cm3 in PCL-rich blends. The dependence on 
composition can be rationalized considering that in the latter case a larger energy cost can 
be expected for the extraction of a THY molecule (compared to a PCL repeat unit) from 
the pure component, penalizing therefore the energy balance associated to the process of 
moving it to the diluted blend. Moreover, even though the chemical structure of THY is 
similar to that of Poly(vinylphenol) (PVPh), the interaction parameters obtained for THY 
are higher (more positive), probably due to a larger autoassociation degree in the 
crystalline molecule than in the amorphous polymer. 
The specific interactions have been analyzed using FTIR spectroscopy. The analysis of 
the C=O stretching band of PCL and of the O-H stretching band of THY indicate strong 
-C=O···H-O- interactions. The location observed for the interassociated O-H stretching 
band (3440 cm-1) indicates hydrogen bonds of similar strength to those reported for blends 
of PCL with other phenolic compounds [12]. The in vitro drug release studies indicate 
that, during the first stage, THY release from PCL is governed by diffusion through the 
swelled polymeric matrix. In our experimental setup, about 23 wt.% of the drug was 
released into the PBS solution during the first 7 days. Afterwards, THY reached 
equilibrium conditions between the organic and aqueous phases, according to its partition 
coefficient. In a physiological environment, however, such equilibrium conditions can be 
hardly expected since THY is metabolized by the organism and its concentration should 
be small, and consequently, its release should continue without reaching an asymptotic 
stage. Overall, THY is slowly released and can be used to build antimicrobial devices of 
long lasting action.  
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Summary 
The conformational behavior of chloramphenicol (CAM) in the solid, liquid and vapor 
phases is established here by means of FTIR spectroscopy and modern QM methods, 
combined with reported experimental results. In the crystalline phase, the IR analysis 
discards the conformer proposed by Acharya et al. (Acta Cryst., 1979, B35:1360-1363) 
and supports the one proposed by Chatterjee et al. (J. Cryst. Mol. Struct., 1979, 9:295-
304), characterised by an intramolecular O-H•••O hydrogen bond in which the primary 
hydroxyl group acts as hydrogen bond donor. The conformational behavior of CAM in 
the liquid and gas phases has been analyzed using QM calculations. The Onsager self-
consistent reaction field (SCRF) model has been used for the geometry optimizations in 
solution. Releasing the CAM molecules from the intermolecular interactions occurring in 
the crystalline phase results in the reversal of the intramolecular O-H•••O hydrogen bond 
so that the secondary hydroxyl group acts as hydrogen bond donor. In addition, the 
dichloroacetamide group folds back further over the phenyl ring to form an intramolecular 
C-Cl•••π halogen bond. Two different halogen bonds are actually observed (each one with 
a different chlorine atom) resulting in two different stable conformers, that can be 
detected by FTIR spectroscopy due to the conformational sensitivity of the C=O group to 
the conformation of the dichloroacetyl group. Finally, the stability of the conformers with 
the polarity of the medium is also discussed.  
2.1.1. Introduction 
Chloramphenicol (CAM) is a broad-spectrum antibiotic isolated originally from 
Streptomyces venezuelae in 1947 [1, 2]. Its structure was soon elucidated, and it became 
the first antibiotic to be synthesized by chemical means [1, 2]. CAM acts essentially as a 
bacteriostatic agent, inhibiting bacterial synthesis by binding to the 50S subunit of 70S 
ribosomes [1]. A wide range of microorganisms can be effectively treated by CAM; for 
example, it is useful in the treatment of staphylococcal brain abscesses, meningitis caused 
by Enterococcus faecium or ocular infections caused by a number of bacteria including 
Staphylococcus aureus, Streptococcus pneumoniae and Escherichia coli [1, 2, 3]. CAM 
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is currently included in List of Essential Medicines (EML) published by the World Health 
Organization (WHO) [4]. 
CAM contains different reactive groups that have been exploited to obtain derivatives 
(more than 500 compounds have been reported) and to explore structure-activity 
relationships [1, 2]. The molecule of CAM (Figure 2.1.1) can be divided in three parts: 
(I) a p-nitrobenzene moiety, (II) a dichloroacetyl moiety and (III) a 2-amino-propanediol 
moiety [1, 2]. The aromatic part (I) permits considerable variation, resulting in 
compounds whose bacterial activity is modified rather than suppressed. The acyl side 
chain (II) is essential for in vivo bacterial growt.h inhibition, where bulkier groups usually 
reduce antibacterial activity, but is less constraining for in vitro protein synthesis 
inhibition [2]. Therefore, it was concluded that the acyl side chain is important for the 
penetration of the antibiotic in the bacterial cell [1, 2]. Finally, the propanediol moiety 
(III) contains two asymmetric Carbons, and among the four possible stereoisomers, only 
the D-threo configuration (the one occurring on CAM) presents high antibacterial 
activity. This stereospecificity suggests that the conformation plays a crucial role on 
antibacterial activity. 
 
 
Figure 2.1.1. Chemical structure of CAM. 
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The conformational analysis of CAM is therefore of great interest both from the 
fundamental and applied points of view. For example, the binding of CAM to the 
Escherichia coli 70 S ribosome has been investigated by NMR spectroscopy [5], 
suggesting that it binds in its receptor site in essentially the same conformation that exists 
free in solution. The recognition is most likely of the classic lock and key type, with the 
ribosomal site being essentially an open gate for the fitting of the drug [5]. The geometry 
of the binding site has been recently reexamined using solid state crystallographic 
analyses [6]. One of the goals of these works is the comparison of the geometry of the 
ligand in the binding site with its free geometry in solution or with its geometry in the 
crystals [7]. According to Nicklaus, flexible ligands usually undergo substantial 
deformations upon binding to receptors [8]. 
The conformational behavior of pure CAM has been investigated in a number of papers 
(Dunitz, 1952; Chatterjee, Dattagupta, Saha, Saenger, & Müller, 1979; Acharya, Gowda, 
& Post, The Structure of Chloramphenicol, 1979; Jardetzky, 1963; Mitscher, Kautz, & 
Lapidus, 1969; Bustard, Egan, & Perun, 1973; Höltje & Kier, 1974; Fitzhugh, 1991). 
However, a number of contradictory results have been published, and currently there is 
no consensus on the actual conformation of CAM. For example, Chatterjee [10] 
investigated the crystalline structure of CAM using XRD, and proposed a conformer 
containing an intramolecular O-H···O hydrogen bond in which the primary hydroxyl 
group acts as hydrogen bond donor and the secondary one as acceptor. The same year, 
Acharya (Acharya, Gowda, & Post, The Structure of Chloramphenicol, 1979) reported a 
crystalline conformer in which the intramolecular hydrogen bond is established in the 
opposite direction (the secondary hydrogen bond acts as donor and the primary one as 
acceptor). None of these structures has been discarded, and both are considered in the 
current literature [17, 18, 19, 20, 21, 22]. 
The situation in solution is even worst. Using NMR spectroscopy, Jardetzky [12] 
concluded the presence of a unique CAM conformer in solvents of different polarity 
ranging from acetone to water. The predominant conformer contained an intramolecular 
O-H···O hydrogen bond in which the secondary hydroxyl acts as hydrogen bond donor. 
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However, using NMR spectroscopy and molecular modeling calculations Bustard [14] 
and Höltje [15] concluded the existence of a second conformer devoid of intramolecular 
hydrogen bonding. Hahn claimed a definitive study in view of these contradictory reports 
[1]. To mess things up, Fitzhugh [16] obtained the high dilution FTIR spectrum of CAM 
in CDCl3 and suggested the coexistence of two intramolecularly hydrogen bonded 
conformers, in which the hydroxyl groups act alternatively as donors and acceptors. These 
conformational studies were performed some decades ago, and are therefore based mainly 
on experimental techniques. Bustard [14] also used a very simple molecular force field 
and Höltje [15] used an old semi empirical QM method (CNDO/2). To our knowledge, 
no conformational analysis has been reported using modern ab initio QM methods. 
This paper revisits the conformational of CAM in the crystalline phase, in the melt, in 
free molecules in solution and in the gas phase. FTIR spectroscopy is used to discriminate 
between the two crystalline structures currently accepted (Chatterjee, Dattagupta, Saha, 
Saenger, & Müller, 1979; Acharya, Gowda, & Post, The Structure of Chloramphenicol, 
1979). The conformational behavior of free CAM molecules in solution and in the gas 
phase is analyzed using ab initio QM calculations. The Onsager self-consistent reaction 
field (SCRF) model is used for the geometry optimizations in solution. These analyses 
provide clear results regarding the conformational behavior of CAM and establish the 
correct intramolecular hydrogen bonding pattern in each case. Finally, the stability of the 
conformers with the polarity of the medium is also discussed. 
2.1.2. Experimental Section 
2.1.2.1. Starting Materials  
Chloramphenicol (purity ≥ 98 %) and acetonitrile were supplied by Aldrich Chemical 
Corp. (Spain) and were used as received. 
2.1.2.2. Differential Scanning Calorimetry (DSC)  
Thermal analyses were conducted on a Modulated DSC Q200 from TA Instruments. All 
the scans were carried out in hermetic aluminum pans under nitrogen atmosphere with 
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sample weights between 5 and 10 mg. Two consecutive scans were performed from -80 
ºC to 180 ºC with a scan rate of 20 ºC/min. 
2.1.2.3. Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra were recorded on a Nicolet AVATAR 370 Fourier transform infrared 
spectrophotometer. Spectra were taken with a resolution of 2 cm-1 and were averaged 
over 64 scans in the 4000-450 cm-1 range. Pure CAM FTIR samples were prepared by 
grinding CAM with KBr and pressing. The absorbance of the samples was within the 
range where the Lambert-Beer law is obeyed. A controlled high temperature transmission 
cell mounted in the spectrometer was used to obtain the spectra of molten samples. 
Second derivative spectra were smoothed using the Norris-Williams Gap Derivatives [23] 
using maximum gap sizes and segment lengths of 5 points and 5 cm-1 respectively in the 
derivative transformations. 
Spectra in solution was recorded from 1 wt.% CAM solutions in acetonitrile using a 
variable path length cell equipped with IR grade Silicon windows (2 mm thick). To reduce 
interference fringes, the background was collected with the cell introduced in the FTIR 
bench. The spectrum of the solvent was then recorded. Finally, the spectrum of CAM in 
solution was obtained by substraction of the solvent spectrum in the appropriate spectral 
region. 
2.1.2.4. Conformational Analysis 
Ab initio calculations were performed using the Firefly QC package [24], which is 
partially based on the GAMESS (US) [25] source code. Geometry optimizations were 
carried out using the hybrid DFT method B3LYP-D3/DZP, consisting on the B3LYP 
functional [26, 27] extended with the D3 version of Grimme’s dispersion correction [28]. 
The DZP basis function is based on the DZ basis function of Dunning [29] plus one set 
of polarization functions with the exponents recommended by Dunning for correlated 
calculations: H(p) 0.935; C(d) 0.550; N(d) 0.817; O(d) 1.185; Cl(d) 0.600 [30, 31]. 
Vibrational mode analyses were carried out at the B3LYP-D3/def2-TZVP(-f) (-f means 
without f polarization functions) [32]. Final geometries of improved accuracy for the 
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stable conformers were also calculated using the Møller-Plesset perturbation theory, at 
the MP2/def2-TZVP(-f) level of theory. 
2.1.3. Results and Discussion 
2.1.3.1. DSC Analysis 
Figure 2.1.2 shows the first and second DSC traces obtained for pure CAM. As can be 
seen, CAM is a crystalline solid melting at about 151 ºC. Cooling in the DSC at about      
-20 ºC/min results in a supercooled liquid with a glass transition temperature located at 
about 32 ºC. Considering this thermal behavior, supercooled CAM at room temperature 
is in the glassy state and is expected to crystallize quite slowly. 
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Figure 2.1.2. First scan DSC traces for PCL, CAM and PCL/CAM blends. 
2.1.3.2. FTIR Analysis of Crystalline CAM 
The hydrogen bonding pattern and consequently the infrared spectrum of crystalline 
CAM depend on the molecular conformation and on the crystalline packing. The 
crystalline structure of CAM was first investigated by Dunitz [9], although the atomic 
coordinates were reported only later by Chatterjee [10] and Acharya (Acharya, Gowda, 
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& Post, The Structure of Chloramphenicol, 1979). According to Chatterjee, CAM 
crystallizes in the orthorhombic space group C2221, with a = 17.495 Å, b = 7.321 Å, c = 
22.130 Å, and Z = 8 [10], adopting a conformation in which the dichloroacetamide moiety 
is folded back over the phenyl ring. Following the usual practice, both authors (Chatterjee, 
Dattagupta, Saha, Saenger, & Müller, 1979; Acharya, Gowda, & Post, The Structure of 
Chloramphenicol, 1979) determined the location of the heavy atoms by means of the X-
Ray diffraction data, but the location of the hydrogen atoms was guessed from the 
molecular structure. However, since the location of the hydroxyl hydrogens is particularly 
difficult to assess, they proposed different orientations for the OH groups, resulting in 
two different conformers with different association patterns in the crystalline structure 
(Fig. 2.1.3). Both conformers present an intramolecular O-H···O-H hydrogen bond, but 
in the conformer proposed by Chatterjee the primary hydroxyl acts as donor (Fig. 2.1.3a) 
[10] while in the conformer proposed by Acharya the primary hydroxyl acts as acceptor 
(Fig. 2.1.3b) (Acharya, Gowda, & Post, The Structure of Chloramphenicol, 1979). 
Regarding the intermolecular association in the crystalline structure, both models present 
an intermolecular –N-H····O-H hydrogen bond (to primary OH, Fig. 2.1.3c and 2.1.3d) 
(Chatterjee, Dattagupta, Saha, Saenger, & Müller, 1979; Acharya, Gowda, & Post, The 
Structure of Chloramphenicol, 1979). However, the model of Chatterjee presents an 
intermolecular –O-H····O=C hydrogen bond in which the secondary OH acts as donor 
(Fig. 2.1.3c) [10] while the model of Acharya presents an intermolecular –O-H····Cl 
hydrogen bond in which the primary OH acts as donor (Fig. 2.1.3d) [11]. Both structures 
have received similar attention in the literature, and none has been discarded yet [17, 18, 
19, 20, 21, 22]. 
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Figure 2.1.3. Conformers proposed by a) Chatterjee and b) 
Acharya, and molecular models showing the hydrogen bonding 
patterns in the resulting crystalline structures, c) Chatterjee and 
d) Acharya. 
Figure 2.1.4 shows the X-H stretching region for pure crystalline CAM at room 
temperature, which can be used to discriminate the correct crystalline structure. As can 
be seen, pure crystalline CAM shows three bands located at about 3476, 3345 and 3262 
cm-1. In the solid or liquid phases, hydrogen bonded secondary amides generally exhibit 
a strong band at about 3270 cm-1 and a weak band at about 3100 cm-1 for the overtone of 
the Amide II band [33]. Hence, the band at 3262 cm-1 can be attributed to N-H stretching. 
This assignment is supported by the Raman spectrum of CAM in the X-H stretching 
region, where only a single band at about 3620 cm-1 [17] has been resolved (the OH bands 
only display weak broad Raman peaks since they are poor scattered [34]). Therefore, the 
bands located at 3476 and 3345 cm-1 can be attributed to the two OH groups present in 
CAM. The band at 3345 cm-1 is strongly red shifted (free OH stretching occurs in the 
d 
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3650-3600 cm-1 range [33]) and is only attributable to hydroxyl stretching in 
cooperatively hydrogen bonded O-H···O-H systems. The band at 3476 cm-1 can be 
attributed to O-H···O=C interactions (usually in the range 3600-3450 cm-1 [33]) assuming 
the model of Chatterjee [10], but is too red shifted to be attributable to the weak O-H···Cl 
interactions proposed by Acharya (Acharya, Gowda, & Post, The Structure of 
Chloramphenicol, 1979). 
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Figure 2.1.4.  Hydroxyl stretching region for pure crystalline 
CAM (A), and molten CAM at 160 ºC (B). 
The analysis of the hydrogen bonding cooperativity in the models of Chatterjee and 
Acharya gives additional support to the former structure. In the model of Chatterjee [10], 
the interacting groups form linear N-H···O-H···O-H···O=C chains (see Fig. 2.1.3c). 
Nonetheless, in the model of Acharya (Acharya, Gowda, & Post, The Structure of 
Chloramphenicol, 1979) the interacting groups form bifurcated (N-H)(O-H)>O-H···Cl-
C structures (see Fig. 2.1.3d). Recently, Ohno et al. have proposed a simple method to 
analyze the degree of cooperativity (or the strength of hydrogen bonding) in O-H···O-H 
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hydrogen bonded chains [35]. Each O-H···O-H couple is considered a donor-acceptor 
(DA) group, and the interactions established by D or A with surrounding molecules are 
assumed to strengthen or weaken the hydrogen bonding interaction between D and A. 
The number of protons accepted by D is termed aD (in the 0-2 range), the number of 
protons accepted by A is aA (0-1), and the number of protons donated by A is dA (0-1). 
The hydrogen bonding structure adopted by the DA couple with its surroundings is then 
characterized by the aDDAdAaA string, and the strength of the DA hydrogen bond is 
classified according to the cooperativity indicator MOH = aD + dA - aA, proportional to the 
hydrogen bonding energy [35]. Application of this procedure to the O-H···O-H 
interaction in the crystalline structure proposed by Chatterjee results in the 1DA10 string 
and MOH = 2, but in the Acharya case the string is 0DA11 and the indicator is MOH = 0. 
This analysis indicates strong cooperativity in the structure of Chatterjee, but no 
cooperativity in the structure of Acharya. For the Structure of Acharya, the 
intramolecularly hydrogen bonded OH stretching mode should be located above             
3500  cm-1, as in other non-cooperative intramolecularly hydrogen bonded 1,3 diols [36, 
37]. For the structure of Chatterjee, cooperativity should be similar to that occurring in 
tetrols [38, 39], in which the cooperativity indicator is also MOH = 2. These compounds 
contain four OH groups in 1,3 relative positions arranged along a linear chain, and have 
been investigated as model systems for the vibrational spectroscopy of naturally 
occurring hydrogen bonding networks. In the liquid phase the all-syn tetrol shows a very 
broad OH-stretching band peaking at 3388 cm-1 [38], location comparable to the band at 
3345 cm-1 observed in crystalline CAM, particularly considering the different states of 
aggregation (liquid vs. crystalline). In summary, the two OH stretching bands observed 
in crystalline CAM can be feasibly assigned assuming the conformation assumed by 
Chatterjee, but neither of them is compatible with the atomic coordinates provided for the 
OH groups by Acharya.  
2.1.3.3. FTIR Analysis of Molten CAM and Free CAM in Solution 
Figure 2.1.4 also shows the O-H stretching band of molten CAM at 160 ºC. In the melt, 
only a broad envelope can be observed for the OH stretching band, indicating molecular 
Chapter 2. Physicochemical Characterization and Drug Release Kinetics in                          
Poly(-caprolactone)/Chloramphenicol Blends                                                           Chapter 2.1. 
118 
disorder and a broad range of interaction strengths. The N-H stretching band shifts to 
higher wavenumbers (3400 cm-1), indicating the rupture of the N-H···O-H interactions 
occurring in the crystalline phase, but remains below the typical range for free N-H groups 
(3460-3440 cm-1 [33]), suggesting the occurrence of weak interactions in the amorphous 
phase such as contacts with the aromatic rings. 
The Amide I stretching region of CAM is shown in Figure 2.1.5. Pure crystalline CAM 
displays a narrow peak at about 1687 cm-1. Upon melting the peak shows an unexpectedly 
large broadening (its half height width reaches about 40 cm-1), and maintains its location 
instead of shifting to higher wavenumbers as expected. Moreover, after quenching to 
room temperature the peak red shifts to about 1679 cm-1, at even lower wavenumbers 
than the initial crystalline C=O band. These changes suggest the formation upon melting 
of a new conformer located at lower wavenumbers, since the O-H•••O=C interactions in 
the amorphous phase can hardly be stronger than in the crystalline phase. Second 
derivative spectroscopy of quenched CAM at room temperature reveals two components 
located at about 1690 and 1675 cm-1, where the lower wavenumber band can be attributed 
to the new conformer formed upon melting. 
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Figure 2.1.5. Carbonyl stretching region of CAM and second 
derivatives (’’) of: a) crystalline CAM at 40 ºC, b) molten CAM 
at 160 ºC, c) supercooled CAM at 40 ºC, d) CAM in acetonitrile 
solution (1 wt.%), and e) computed spectrum of CAM in 
acetonitrile solution at the B3LYP-D3/def2-TZVP(-f) level of 
theory (scaling factor 0.9834). 
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Figure 2.1.5 also displays the spectrum of CAM in dilute acetonitrile (ACN) solution (1 
wt.%). As can be seen, the C=O stretching band of CAM in dilute solution shows two 
components located at about 1697 and 1710 cm-1. The occurrence of other split bands in 
this spectrum supports the presence of different conformers over Fermi resonance as the 
origin of the splitting. The most probable explanation for the conformational sensitivity 
of the C=O group is some conformational isomerism involving the electronegative 
(chlorine) atoms present in the alpha carbon relative to the C=O group [40, 18]. Most 
studies dealing with these effects have focused however on CO-CH2-X structures (where 
X is an electronegative atom such as F, O, N, Cl, Br, S, I) [41, 42, 43, 44]. The presence 
of a single electronegative atom in the alpha Carbon is known to modify the typical 
threefold rotational isomerism around the CO-Cα bond (anti, gauche±) to a twofold one 
(anti, syn) [18, 41, 42], and shift the location of the C=O stretching band [45]. 
2.1.3.4. Ab Initio Quantum Mechanical Calculations 
Assuming that the amide bond prefers the anti conformation, CAM contains seven 
potential rotatable bonds (see scheme 2.1.6). The first four dihedrals determine to a large 
extent the overall shape of the molecule, while the remaining three have a minor effect. 
From the analysis of the coupling constants obtained in different solvents by NMR 
spectroscopy, Jardetzky [12] proposed the existence of a single predominant conformer 
stabilized by an intramolecular HB. Bustard [14] combined NMR spectroscopy and a 
molecular mechanics approach to analyze the conformational preferences of CAM and 
proposed two dominant conformers in solution, one of them unable to establish 
intramolecular HB since ϕ3 = 180º. Höltje [15] arrived later at essentially the same 
geometries using semiempirical QM calculations (see table 2.1.1 for conformational 
details). These results [14, 15] conflict with the presence of intramolecular HBs reported 
by other authors using NMR [12] and FTIR [16], and with the prevalence of a single 
conformer reported by Jardetzky [12], making a definitive study necessary [1]. 
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Figure 2.1.6. The seven rotatable bonds in chloramphenicol. 
 
Table 2.1.1. Dihedrals proposed by Höltje for the two most 
stable conformers of CAM in solution, and dihedrals 
corresponding to the crystalline conformers proposed by 
Chatterjee and Acharya. 
Dihedral Reference atoms Conf. 1 Conf. 2 Chatterjee Acharya 
ϕ1 CaCaCC 90 90 91 95 
ϕ2 CaCCN -60 -60 -55 -58 
ϕ3 CCCO 180 60 72 70 
ϕ4 HCNH 180 180 -162 175 
ϕ5 OCCH 60 60 -171 -162 
ϕ6 CaCOH -60 180 -18 146 
ϕ7 CCOH -60 30 -42 -124 
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Hence, the conformational behavior of CAM in solution has been revisited here. The task 
has been simplified reconsidering exclusively a few reliable results reported so far. The 
minimum of ϕ1 is known to be at about 90º [46, 47]. Bustard [14] concluded using NMR 
spectroscopy that ϕ4 adopts the anti conformation. In addition, ϕ5 is known to adopt both 
the anti and syn conformations in condensed phases (though it prefers exclusively the syn 
conformation in vacuum) [18]. Hence, ϕ1 = 90º, ϕ4 = 180º and ϕ5 = 0º, 180º have been 
assumed here. Regarding ϕ2, ϕ3, ϕ6 and ϕ7 the anti and gauche± rotamers have been 
considered. Therefore, 162 molecular models have been built and optimized at the 
B3LYP-D3/DZP level of theory. To account for the solvent effects, the Kirkwood-
Onsager self-consistent reaction field (SCRF) method has been applied in the 
optimizations [48, 49, 50]. This model locates the dipole moment of the solute in the 
center of a spherical cavity, and calculates the interaction energy between the dipole 
moment and the surrounding solvent, characterized by its dielectric constant. In case of 
nearly spherical molecules, the cavity radius can be determined from the molar volume 
of the molecule, resulting in R = 4.4 Å according to the density of amorphous CAM (1.47 
g/cm3 [51]). In case of more elongated molecules, it is preferred to take the cavity radius 
as the half-length of the long-molecular axis without van-der-waals radii [52], leading to 
R = 4.6 Å according to the V-shaped conformations in table 4. Both values are rather 
close, suggesting that CAM should work correctly regarding the cavity shape criterion. 
Another limitation of this model is the lack of higher order multipoles to properly describe 
the electrostatic potential of the solute [50]. Anyway, this model is very cheap from a 
computational point of view and has been widely applied with substantial success. In the 
special case of roundish molecules with large dipole moments, the SCRF model is 
considered to include sufficient physics to be meaningful [50]. In this paper, the radius 
has been set to R = 4.4 Å and the dielectric constant of acetonitrile to 37.5. 
Table 2.1.2 shows the dihedral angles for the 6 conformers of lower energy obtained in 
this conformational analysis. According to the computed electronic energies, dilute CAM 
solutions in acetonitrile should contain mainly conformers I and II in similar amounts 
(see Figure 2.1.7 for geometries). These two conformers adopt similar geometries (they 
only differ in the orientation of the dichloromethyl group, determined by ϕ5) and show 
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similar energies. Our results discard the prevalence of conformer 1 (the non-
autoassociated one of Bustard and Höltje, see table 2.1.1); in fact, the energy of the first 
conformer with ϕ3 = 180º (conformer V in table 2.1.5) is about 32 kJ/mol larger than that 
of conformer I. In addition, conformer 2 of Höltje is not a true minimum since 
optimization of this geometry results in a final structure with ϕ7 ≈ 180º (corresponding to 
conformer I). Similarly to conformers I and II, the remaining conformers also follow a 
pairwise arrangement, in the sense that in spite of differing in ϕ5, show similar energies 
and geometries. Conformers I-IV present an intramolecular hydrogen bond, while this 
interaction is not possible in conformers V and VI since ϕ3 adopts the anti conformation. 
Optimizations have also lead to a Chaterjee-like conformer (not listed in table 2) with ΔE 
~ 35 kJ/mol, making evident the importance of the strong cooperative intermolecular 
interactions in the crystalline structure (the computed ΔE corresponds actually to 
acetonitrile medium, but should be of about the same order of magnitude for the 
electrostatic interactions with the crystalline environment). 
Table 2.1.2. Dihedral angles and electronic energies for the first 
six conformers of CAM in acetonitrile solution optimized at the 
B3LYP-D3/DZP level of theory. 
Dihedral I II III IV V VI 
ϕ1 (CaCaCC) 103 106 117 101 101 101 
ϕ2 (CaCCN) -64 -68 -48 -56 -60 -64 
ϕ3 (CCCO) 63 63 -36 -36 -175 180 
ϕ4 (HCNH) 154 153 167 168 155 144 
ϕ5 (OCCH) 42 154 38 112 44 159 
ϕ6 (CaCOH) 165 168 -164 -161 -160 -158 
ϕ7 (CCOH) 176 176 -169 -171 180 178 
E (kJ/mol) 0 0.4 17.0 20.7 31.8 32.2 
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Figure 2.1.7. Equilibrium geometries for conformers I (left) and 
II (right) in acetonitrile at the B3LYP-D3/DZP level of theory. 
Considering that conformers I and II share the major part of the geometry (they only 
differ in the rotation of the dichloromethyl group), the results of this conformational 
analysis are compatible with the work of Jardetzky [12] (who concluded the existence of 
a single predominant conformer stabilized by an intramolecular HB). However, our 
analysis is not compatible with the Bailey method used by Bustard [14] to analyze the 
relative prevalence of ϕ3(CCCO). In fact, the Bailey method is known to be based on 
questionable assumptions [53, 54] and has been seldom used in the literature. 
Thus, only conformers I and II must be considered to explain the spectral properties of 
CAM in solution. The vibrational analysis of CAM in acetonitrile solution has been 
carried out using the Kirkwood-Onsager SCRF method at the B3LYP1-D3/def2-TZVP(-
f) level of theory. The locations computed for the C=O stretching bands of conformers I 
and II are 1725 and 1740 cm-1 respectively. The computed values are larger than the 
experimental ones (1697 and 1710 cm-1) due mainly to the neglect of anharmonicity 
effects, but most importantly the computed shift (Δν = 15 cm-1) is in good agreement with 
the experimental one (Δν = 13 cm-1), supporting the rotation of the dichloromethyl group 
as the actual source for the conformational sensitivity of the C=O stretching band (see 
Fig. 2.1.5). In addition, it is worth to notice that the blue shift relative to the location of 
aliphatic secondary amides (absorbing at about 1691 cm-1 [55, 45]) is larger for conformer 
II (ϕ5(HCCO) in anti conformation) because the chlorine atoms are closer to the C=O 
group and the electronic interaction between these moieties is stronger. 
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Conformers I and II have also been optimized in vacuum in order to extend the analysis 
of the conformational behavior to different media. Since in vacuum the dichloroacetamide 
group prefers exclusively the syn conformation [18], a single conformer was a priori 
expected in this medium. However, minimizations lead again to two different conformers, 
according to the absence of negative frequencies in the vibrational analysis at the B3LYP-
D3/def2-TZVP(-f) level. In addition, conformer I prevails almost completely over 
conformer II in vacuum since ΔE ≈ 12 kJ/mol. Table 2.1.3 summarizes the most relevant 
results obtained for conformers I and II in vacuum and in acetonitrile at the higher levels 
of theory used in this investigation.  
Table 2.1.3. Optimized geometries for conformers I and II in 
vacuum and acetonitrile at the MP2/def2-TZVP(-f) level of 
theory. Dipole moments and electronic energies have been 
obtained from single point computations at the MP2/def2-
TZVPP level. Free energies and relative populations (NI/N) also 
consider the harmonic vibrational analysis at the B3LYP-
D3/def2-TZVP(-f) level of theory. 
 Vacuum Acetonitrile 
Dihedral I II I II 
ϕ1 (CaCaCC) 96 98 98 101 
ϕ2 (CaCCN) -61 -60 -62 -64 
ϕ3 (CCCO) 62 61 65 66 
ϕ4 (HCNH) -178 -173 152 151 
ϕ5 (OCCH) -28 -153 51 160 
ϕ6 (CaCOH) 167 168 164 166 
ϕ7 (CCOH) 174 175 176 177 
μ (D) 9.4 10.4 19.5 21.0 
ΔE (kJ/mol) 0 12.5 0 0.9 
ΔGº (kJ/mol) 0 14.0 0 0 
NI/N 0.996 0.004 0.5 0.5 
 
In order to rationalize the conformational behavior around ϕ5, the relaxed potential energy 
surfaces (PES) have been scanned both in vacuum and in acetonitrile solution (see Figure 
2.1.8). In addition, since the stable conformers in both media (see Figure 2.1.7) show 
chlorine atoms close to the aromatic ring, their geometries have been scrutinized for the 
occurrence of intramolecular C-Cl···π interactions. These contacts, termed halogen 
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bonds, are widespread among pharmaceutical compounds since about 40% drugs 
currently on the market or in clinical trials are halogenated [56]. However, they have been 
usually overlooked because their importance in, for example, crystals and biological 
systems, has been only recently established [57, 58]. The halogen bond is a highly 
directional and specific non-covalent interaction, analogous to the hydrogen bond. It is 
formed between a halogen and a proximal halogen-bond acceptor (such as O, N, S, and 
aromatic ring) [56, 58]. Figure 2.1.8 also displays the distance between the Cl atoms and 
the closest aromatic π-bonds for the conformers of CAM in vacuum. As can be seen, the 
minimum distances occur at about 50º (dCl-π = 3.86 Å) and 150º (dCl-π = 3.88 Å), 
suggesting the formation of two C-Cl···π halogen bonds. The observed distances are in 
good agreement with those reported for the complexes formed between wild-type 
enzymes and chlorobenzyl cyanide [56], and support the occurrence of intramolecular C-
Cl···π interactions in CAM. The halogen bond occurring at about 50º seems responsible 
for the asymmetry of the PES surface in vacuum, which is skewed to positive dihedrals. 
The halogen bond occurring at about 150º seems responsible for the unexpected minimum 
occurring at about 150º in vacuum, corresponding to conformer II. 
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Figure 2.1 8. Relaxed PES scans around ϕ5 (HCCO dihedral) of 
CAM in vacuum (■) and in acetonitrile solution (▲) together 
with the distances between the two chlorine atoms and the 
aromatic ring for the structures obtained in vacuum (● & ♦). 
Computations at the B3LYP-D3/def2-TZVP(-f) level of theory. 
 
Figure 2.1.8 also displays the PES surface computed in acetonitrile solution. In this case, 
conformer II is strongly stabilized, and its energy becomes similar to that of conformer 
I. This strong stabilization can be accounted for using the classical Onsager model, which 
attributes the stabilization of polar conformers in solution to favorable electrostatic 
interactions with the solvent [49, 59]. According to this model, the difference in the free 
energy of solvation between two conformers of the same size is given by equation 1: 
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where NA is the Avogadro number, ε0 is the permittivity of vacuum, εr is the relative 
permittivity and μ is the dipole moment. The stabilizing contribution arising from 
electrostatic interactions with the solvent depends on the stabilizing character of the 
medium, given by the Onsager term, (εr - 1)/(2εr + 1), and on the difference of the square 
of the dipole moments. In vacuum, the anti conformer does not suffer any electrostatic 
stabilizing effect from the solvent because the Onsager term is zero, and the 
dichloroacetamide moiety prefers the syn conformation. However, in acetonitrile 
solution, the more polar anti conformer (see table 2.1.3) is strongly stabilized by the 
solvent up to the point where the energies of the syn and the anti conformers become 
similar. It must be noticed that the classical Eq. 1 does not account for the distortion of 
the wave function occurring when the conformer is introduced in the polar medium 
(which originates the increase in dipole moment observed in table 2.1.3), and does not 
therefore account for the corresponding variations of electronic energy. It is therefore a 
less accurate approach to the problem than the SCRF method used in this paper [50], and 
is introduced here only for a qualitative discussion of the results. 
In summary, the PES scans in Figure 2.1.8 indicate that both the anti and the syn 
conformers are stable conformers regardless of the medium. In media of high polarity, 
both are present in similar amounts, but in solvents of lower dielectric constant, conformer 
I is expected to dominate over conformer II. This situation is actually observed in molten 
CAM, though in this case the hydrogen bonding ability of the conformers could also affect 
the conformational equilibrium. 
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2.1.4. Conclusions 
The conformational behavior of CAM has been has been revisited in order to enlighten 
the contradictory results reported so far. The analysis of the X-H stretching region 
indicates that CAM crystallizes in the conformation proposed by Chatterjee [10], and not 
in the conformation proposed by Acharya (Acharya, Gowda, & Post, The Structure of 
Chloramphenicol, 1979). The OH stretching band observed at 3345 cm-1 is particularly 
meaningful to discriminate the correct conformer, since it is only attributable to the 
cooperative O-H···O-H interactions occurring in the structure proposed by Chatterjee. In 
this crystalline structure, the primary hydroxyl group acts as hydrogen bond donor and 
the secondary hydroxyl group acts as acceptor. Halogen bonding is not observed in the 
crystalline phase (dCl-π ~ 4.4 Å). 
Upon breaking the crystalline structure, the hydroxyl groups of CAM turn over so that 
the secondary hydroxyl group acts as hydrogen bond donor and the primary one acts as 
acceptor in the dominant conformers. This change allows the molecule to fold back 
further to form an intramolecular C-Cl···π halogen bond, resulting in two different 
conformers depending on the Chlorine atom participating in the halogen bond. In media 
of low dielectric constant (vacuum or solvents of low polarity), the ϕ5 dihedral (HCCO) 
prefers the syn conformation, and conformer I is the only dominant conformer. Solvents 
of increased polarity tend to stabilize conformer II, in which the ϕ5 dihedral (HCCO) 
adopts the anti conformation and the halogen bond is established by the second chlorine 
atom. Conformer II presents a larger dipole moment, and thus, more favorable 
electrostatic interactions with polar media. The two conformers can be easily 
distinguished experimentally by means of infrared spectroscopy taking advantage of the 
conformational sensitivity of the C=O stretching band (the syn rotamer absorbs at lower 
wavenumbers). In acetonitrile solution both conformers present similar stabilities. In 
vacuum only conformer I should be detected. In media of intermediate polarity (such as 
molten CAM) intermediate situations can be expected. 
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Summary 
Poly(ε-caprolactone) (PCL) has been blended with Chloramphenicol (CAM), a well-
known bacteriostatic antibiotic, in order to obtain new biomaterials with antibacterial 
properties. The resulting samples have been thoroughly characterized regarding both their 
physicochemical behavior and antimicrobial efficacy by means of very diverse 
techniques. Hence, PCL/CAM blend miscibility has been analyzed by Differential 
Scanning Calorimetry (DSC) using the single intermediate criterion. In turn, the 
interaction parameter has been obtained from the analysis of the melting point depression 
in both PCL rich and CAM rich blends. Fourier-Transform Infra-Red (FTIR) 
spectroscopy and X-Ray Diffraction (XRD) analysis have been used -in the pure 
components and in the blends- to analyze both the specific interactions and the 
crystallization behavior, respectively. The morphology of PCL/CAM blends obtained by 
spin-coating has been also studied by means of Atomic Force Microscopy (AFM). 
Finally, drug release kinetics of different PCL/CAM systems as well as their antibacterial 
efficacy against Escherichia Coli have been investigated, indicating that CAM can be 
released from the PCL/CAM blends in a controlled way while keeping intact the 
antibacterial efficiency. 
2.2.1. Introduction 
A controlled drug-delivery device is that able to deliver the drug at the desired release 
rate and duration, thus maintaining the drug level in the body within the therapeutic 
window (see Fig. 2.2.1). Upon intake, drug molecules must be dissolved in aqueous-based 
gastrointestinal fluids in a sufficient quantity as to reach their whatsoever therapeutic 
effect. Nevertheless, most drugs are in crystalline form, which implies auto-association 
interactions and low water solubility [1]. A successful strategy to improve the solubility 
of poorly soluble drugs is to dispense the drug in the form of amorphous solid dispersions 
(ASDs).   
The dispersion of a drug into a polymeric matrix enables the establishment of strong 
specific interactions with its functional groups. Thus, the chemical potential of the drug 
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in the amorphous phase is reduced, and as a result, its crystallization can be hindered. In 
other words, miscibility between the two components should favor the formation of 
ASDs, preventing the crystallization of the drug, and as a result, enhancing its solubility 
[2]. The drug release mechanism from a polymer depends on parameters such as the 
nature of the polymer, matrix geometry, drug-related properties, initial drug loading, and 
drug–matrix interactions. If, in addition, a medical device is made of a biodegradable 
polymer, it does not have to be removed after finishing its task. Furthermore, in a 
biopolymer-drug system the control of the degradation rate of the biopolymer enables the 
control of the drug release from the matrix. Consequently, biopolymer-drug systems are 
appropriate for drug delivery applications. 
 
  
 
 
 
 
Figure 2.2.1. A comparison of conventional drug delivery profile 
vs. a controlled drug release profile. 
In this regard, Poly(-caprolactone) (PCL) is one of the most promising biodegradable 
polymers and is already widely used in biomedical applications. PCL is suitable for long-
term biomedical applications since its degradation can last from several months to years 
[3]. In turn, Chloramphenicol (CAM) is a broad-spectrum bacteriostatic antibiotic, which 
diffuses through the bacterial cell and binds to 50S ribosomal subunit. Such interaction 
induces inhibition of the bacterial protein synthesis as well as the blocking of bacterial 
cell proliferation. A wide range of microorganisms can be effectively treated by CAM; 
for example, it is useful in the treatment of staphylococcal brain abscesses due to an 
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excellent blood-barrier penetration or meningitis caused by Enterococcus faecium. Its 
employment has also been shown to be effective in treating ocular infections caused by a 
number of bacteria including Staphylococcus aureus, Streptococcus pneumoniae and 
Escherichia coli [4]. As main disadvantage CAM shows low aqueous solubility. 
Considering the respective chemical structures of the two species under study (see Fig. 
2.2.2), hydrogen bonding can be expected to be formed between the hydroxyl groups of 
CAM and the carbonyl groups of PCL. In this paper, the miscibility of the PCL/CAM 
blends is analyzed using the criterion of the single intermediate glass transition 
temperature (Tg), while the strength of the resulting intermolecular interactions is 
evaluated from the interaction parameter. FTIR spectroscopy is then used to analyze the 
specific interactions responsible for the miscibility of the blends. Moreover, 
morphological changes in the blends are discussed in terms of PCL/CAM intermolecular 
interactions through the analysis of the spherulitic growt.h by means of AFM. The 
suitability of the blends for biomedical applications has been analyzed by investigating 
the release kinetics of CAM in PBS solution at 37 ºC, as well as by analyzing the 
antibacterial efficacy of the PCL/CAM blends against Escherichia Coli conducting the 
agar diffusion test. E. Coli is a gram-negative etiologic agent associated with biofilm 
formation on implants and susceptible to chloramphenicol treatment. The results obtained 
by these techniques show that CAM can be released in a controlled way from the 
PCL/CAM blends. 
 
                                    
                    Poly(ε-caprolactone)                                                  Chloramphenicol 
Figure 2.2.2. Chemical structures of PCL and CAM. 
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2.2.2. Experimental Section 
2.2.2.1. Starting Materials  
Poly(ε-caprolactone) (PURASORB® PC12 trade name) with an average molecular 
weight (Mw) of 1.3·105 g mol-1 and Mw/Mn = 1.76 (as determined by GPC) was obtained 
from Purac Biochem (The Netherlands). Chloramphenicol (purity ≥ 98 %) and Phosphate 
Buffered Saline (PBS) solution 1 M (pH 7.4) were supplied by Aldrich Chemical Corp. 
(Spain). Escherichia coli (ATCC 1655) was purchased from ATCC (Virginia, USA). 
2.2.2.2 Blend Preparation  
Films were prepared by casting from tetrahydrofuran (THF) solutions at room 
temperature. Films 100 m thick were prepared by casting from 2.7 wt.% solutions into 
60 mm diameter Petri dishes, and films 800 nm thick were obtained by spin-coating onto 
glass substrates from 10 mg/mL solutions using a spin-coater (Schaefer Tech) operating 
at 1000 rpm for 60 s.  
2.2.2.3. Differential Scanning Calorimetry (DSC)  
Thermal analyses were conducted on a Modulated DSC Q200 from TA Instruments. All 
the scans were carried out in hermetic aluminum pans under nitrogen atmosphere with 
sample weights between 5 and 10 mg. In order to study the glass transition temperatures, 
two consecutive scans were performed from -80 ºC to 180 ºC with a scan rate of 20 
ºC/min, ensuring complete melting of the sample. Glass transition temperatures (Tg) were 
measured in the second scan as the midpoint of the specific heat increment.  
2.2.2.4. Melting Point Depression   
The melting point depression of CAM was investigated from CAM-rich blends 
containing 100-70 wt.% CAM. Samples were heated in the DSC with a scan rate of 1 
ºC/min to obtain the melting temperature of the CAM crystals. No weight loss was 
observed during the thermal treatments. 
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The melting point depression of PCL was analyzed from PCL/CAM blends containing 
100-80 wt.% PCL. Samples were first heated at 180 ºC for 3 min to assure complete 
melting of the PCL and CAM crystals, and then cooled at 10 ºC/min to the desired 
crystallization temperatures (Tc) allowing to crystallize isothermally for 60 min. Then, 
they were heated to 180ºC to obtain the melting points with a scan rate of 10 ºC/min. 
2.2.2.5. Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra were recorded on a Nicolet AVATAR 370 Fourier transform infrared 
spectrophotometer. Spectra were taken with a resolution of 2 cm-1 and were averaged 
over 64 scans in the 4000-450 cm-1 range.  Tetrahydrofuran solutions (1.1 wt.%) were 
cast on KBr pellets by evaporation of the solvent at room temperature. Traces of 
tetrahydrofuran were removed placing the films into a heated vacuum oven for 24 h. The 
absorbance of the samples was within the range where the Lambert-Beer law is obeyed. 
A controlled high temperature transmission cell mounted in the spectrometer was used to 
obtain the spectra of molten samples. Second derivative spectra were smoothed using the 
Norris-Williams Gap Derivatives [5] using maximum gap sizes and segment lengths of 5 
points and 5 cm-1 respectively in the derivative transformations. 
2.2.2.6. X-ray Diffraction (XRD) 
X-ray powder diffraction patterns were collected by using a Philips X’pert PRO automatic 
diffractometer operating at 40 kV and 40 mA, in theta-theta configuration, secondary 
monochromator with Cu-K radiation (λ = 1.5418 Å) and a PIXcel solid state detector 
(active length in 2θ 3.347º). Data were collected from 5 to 50° 2θ (step size 0.026 and 
time per step = 700 s) at room temperature. A fixed divergence and antiscattering slit 
giving a constant volume of sample illumination was used. 
2.2.2.7. Atomic Force Spectroscopy (AFM) 
An AFM instrument Nanowizard I (JPK Instruments, Germany) was operated in air, using 
contact imaging mode at constant loading forces and rates. Cantilevers were calibrated 
before each experiment by means of the thermal tune method [6]. Silicon-nitride probes 
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(DNP-10, Bruker, USA) with a nominal spring constant of 0.12 N/m were used in the 
experiments. All images were processed using the JPK data analysis software. 
2.2.2.8. In Vitro Release Studies and Release Kinetics (UV-Vis) 
UV–Vis absorption spectra were recorded over wavelengths ranging from 190 to 500 nm 
using a Perkin Elmer Lambda 265 UV-Visible spectrophotometer. Before performing the 
drug release experiments, a calibration curve was obtained measuring the absorbance at 
a wavelength of 278 nm for solutions of chloramphenicol in 0.1 M PBS (pH 7.4) with 
concentrations ranging from 10 to 100 ppm. Square samples of PCL/CAM films of 1 cm2 
with a thickness of 100 m obtained by solvent casting were immersed in 100 mL of 0.1 
M PBS buffer at 37 ºC. At fixed time intervals, samples of 2 mL were taken and replaced 
with fresh PBS at 37 ºC. Drug concentration in solution was determined by UV 
spectroscopy using the calibration curve. 
The release kinetics of chloramphenicol were examined considering three mathematical 
models [7, 8, 9]: 
1. Zero order: Ct/C∞ = k0t                                                                                             (1) 
2. First order: ln (1- Ct/C∞) = -k1t                                                                                (2) 
3. Higuchi: Ct/C∞ = kht1/2                                                                                             (3)                              
Ct is the cumulative amount of drug released at time t, C∞ represents the starting amount 
of drug; and k0, k1 and kh are constants. 
2.2.2.9. Agar Diffusion Test (E. coli) 
Square samples (1 cm2) of PCL/CAM 50/50 and 80/20 blends obtained by solvent casting 
were tested for antibacterial activity. The films were placed in 3 mL PBS buffer at 37 ºC 
and 5 μl of the solution were taken at fixed intervals (30 min, 3 h and 24 h), and poured 
over Luria-Bertani (LB) agar plates containing E.Coli. As positive control, drops of pure 
chloramphenicol (1 mg/mL) were placed in the same manner on the plates. A negative 
control was also examined in the form of PCL film, in order to demonstrate that the PCL 
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does not have antibacterial traits. Radius of inhibition zones were measured to evaluate 
the antibacterial efficacy. 
2.2.3. Results and Discussion 
2.2.3.1. PCL/CAM Blend Characterization 
DSC Analysis of Thermal Transitions and Miscibility 
When two polymeric materials are miscible, macroscopic properties of single-phase 
materials are expected for the blend, such as a single glass transition temperature 
intermediate between those of the pure components [10, 11, 12]. This intermediate Tg 
usually obeys the Fox equation [13]: 
                                                             (4) 
where w1 and w2 are the weight fractions of components 1 and 2 respectively, Tg1 and Tg2 
are the glass transition temperatures of the pure components, and Tgb is the glass transition 
temperature of the blend (values in Kelvin).  
Figure 2.2.3a shows the first DSC traces obtained for the pure components and for 
different PCL/CAM blends. It can be observed that PCL is a semicrystalline polymer 
melting at about 65 ºC, while CAM is a crystalline solid melting at about 151 ºC. In 
addition, all the PCL/CAM blends display the two melting endotherms corresponding to 
the pure components of the blend. Furthermore, Figure 2.2.3b shows the second scan DSC 
curves recorded after cooling from the melt (cooling rate ~20 ºC/min) for PCL, CAM and 
their blends. As can be seen, fast cooled CAM results in a super cooled liquid which 
shows the glass transition temperature at about 32 ºC. The glass transition temperature of 
PCL is located at about -60 ºC. Below the Tg of CAM, molecular mobility is frozen, 
nucleation points are no longer formed and crystallization of the drug is inhibited [14]. 
Supercooling also enhances the glass transition temperature jumps observed in the second 
scan for the PCL/CAM blends, which show single Tgs intermediate between those of the 
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pure components in the whole composition range. Consequently, the two components are 
completely miscible in the amorphous phase. As shown in Table 2.2.1, the observed Tgs 
are close to the values predicted by the Fox equation (Eq. 4). 
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Figure 2.2.3. DSC traces for PCL, CAM and PCL/CAM blends. 
(a) First scan, and (b) second scan traces. 
(a) 
(b) 
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Table 2.2.1. Thermal properties of PCL/CAM blends in the 
second scan. 
PCL/CAM Tg experimental ºC 
Tg (calculated, Fox) 
ºC 
Tm PCL 
ºC 
∆Hm PCL 
J/g 
PCL -60 - 57.2 66.4 
80/20 -36 -46 52.3 58.1 
60/40 -32 -31 45.7 35.0 
50/50 -21 -22 41.5 9.1 
40/60 -7 -13 - - 
20/80 6 8 - - 
CAM 32 - - - 
Melting Point Depression Analysis 
The free energy of mixing of a polymer-drug binary system is described by the Flory-
Huggins solution theory [15, 16]: 
         polymerdrugpolymerpolymerdrugdrugM nnnkT
G  lnln                                           (5) 
 
where n is the number of molecules,  is the volume fraction, χ is the Flory-Huggins 
interaction parameter, k is the Boltzmann constant, and T is the absolute temperature. 
Since the entropic contribution corresponding to the polymer can be neglected in Eq. (5), 
GM depends on the entropic contribution corresponding to the drug (always negative and 
favorable to miscibility), as well as on the enthalpic contribution (ndrugpolymer). The latter 
is also beneficial to miscibility when  indicating favorable interactions between the 
blend components.  
Thermodynamically, the change in free energy at the melting point is zero                           
(G = H - TmS = 0), hence Tm = H/S, and since the entropy change in a miscible 
blend (entropy of melting plus entropy of mixing) is larger than in the pure component, 
the melting temperature decreases [15, 17]. The depression of the equilibrium melting 
point can be analyzed using Flory’s relationship [16]: 
entropic enthalpic 
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where Tme0 and Tme are, respectively, the equilibrium melting points of the pure 
crystallizable component and of its blends, the subscripts 1 and 2 refer to the amorphous 
and crystallizable components respectively, R is the universal gas constant, ΔHu is the 
heat of fusion per mole of crystalline repeat units, Vu is the molar volume of the repeating 
unit, m is the degree of polymerization,  is the volume fraction, and χ12 is the polymer-
polymer interaction parameter.  
To apply Eq. (6) to the analysis of the melting point depression of CAM (component 2), 
the molar volume of liquid CAM (V2 = 220 cm3/mol [18]) is taken as the molar volume 
of the lattice sites, and consequently m2 =1. In addition, the same volume can be adopted 
as the molar volume of the polymeric repeat unit (V2 = V1u) so that 1/m1 ≈ 0 (since m1 = 
V1/V1u is large). Therefore, Eq. (6) simplifies to Eq. (7): 
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                                    (7) 
The melting point of CAM has been measured at low heating rates (1 ºC/min) for the pure 
component and for different PCL/CAM blends (see Table 2.2.2). The average melting 
point of pure Chloramphenicol is Tmº(CAM) = 150.8 ºC, and the addition of 30 wt.% PCL 
decreases the melting point by about 6 ºC. Using the average melting enthalpy of pure 
CAM (ΔHCAM = 119 J/g), the data in Table 2.2.2 have been analyzed according to Eq. (7) 
yielding the plot in Figure 2.2.4a. The negative value obtained for χ (-0.2) confirms a 
thermodynamically miscible blend. Alternatively, the interaction energy density, B can 
be calculated at the melting temperature of CAM according to Eq. (8): 
                                       RT
BV r
                                                                  (8) 
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where Vr is a reference volume (in this case, Vr = V2 = 220 cm3/mol), yielding B = - 3 
J/cm3. 
Table 2.2.2. Melting temperature of CAM in CAM-rich 
PCL/CAM blends. 
CAM wt.% Tm (ºC) Sample 1 Sample 2 Sample 3 
100 
90 
80 
70 
150.8 
149.3 
147.9 
145.5 
150.8 
149.3 
147.4 
145.2 
150.8 
149.3 
147.6 
145.3 
When equation 6 is applied to the melting point depression of a polymer (m2 >> 1) in a 
polymer-drug system, the molar volume of the amorphous drug is usually adopted as the 
molar volume of the lattice cells (m1 = 1), leading to: 
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Nevertheless, in case of polymers, morphological effects such as lamellae thinning due 
to the penetration of the amorphous blend partner in the interlamellar region also 
contribute to the observed melting point depression, and must be accounted for [19]. The 
usual correction is the Hoffman-Weeks (H-W) method, which allows the determination 
of the equilibrium melting temperature of PCL in the pure polymer and in the blends [20] 
(see experimental). This method assumes a linear relation between the crystallization (Tc) 
and melting temperatures (Tm), and Tme is obtained from the intersection of this line with 
the Tm = Tc line. Figure 2.2.5 displays the H-W plots to obtain the equilibrium melting 
temperatures for pure PCL (Tme0) and blended PCL (Tme), which are summarized in Table 
2.2.3. The decrease in the equilibrium melting temperatures suggests the miscibility of 
the system. 
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Figure 2.2.4. (a) Analysis of the melting temperature of CAM 
according to Eq. (7) in the presence of PCL. The slope of the plot 
gives the interaction parameter = -0.2. (b) Plot used to calculate 
the interaction parameter for the PCL/CAM system according to 
Eq. (9). The slope of the plot gives the interaction parameter χ = 
-3.4. 
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Figure 2.2.5. Hoffman-Weeks extrapolations for (■) PCL, (●) 
PCL/CAM 90/10, (▲) PCL/CAM 85/15, and (♦) PCL/CAM 
80/20. 
 
Table 2.2.3. Equilibrium melting temperatures (Tme) obtained 
from the H-W extrapolations. 
 
 
 
 
 
 
System Tme (ºC) 
PCL 
PCL/CAM 90/10 
PCL/CAM 85/15 
PCL/CAM 80/20 
64.7 
62.0 
60.4 
58.0 
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Figure 2.2.4b shows the analysis of the equilibrium melting temperatures according to the 
Flory-Huggins equation (Eq. 9). The parameters used in the calculations are V1 = 220 
cm3/mol (CAM) [20], V2u = 105 cm3/mol and H2u = 140 J/g (PCL) [21]. From the slope 
the value obtained for the interaction parameter is χ = -3.4. The negative value obtained 
for  confirms a thermodynamically miscible blend. 
FTIR Analysis of PCL/CAM Blends 
Figure 2.2.6 shows the X-H stretching region for molten CAM and PCL/CAM blends of 
different composition at 160 ºC. As discussed in the previous section, pure CAM presents 
a peak at about 3400 cm-1 attributable to the N-H stretching mode of secondary amides 
participating in weak contacts [22]. The O-H stretching band is the broad envelope from 
about 3200 to 3650 cm-1, indicating a broad range of interaction strengths resulting from 
the adoption of the distorted hydrogen bonding geometries allowing interactions with the 
disordered amorphous environment. In pure CAM, the maximum of the OH stretching 
band overlaps with the N-H stretching band, and occurs somewhere about 3450 cm-1. 
Upon the addition of PCL to CAM, the OH stretching band shifts to higher wavenumbers, 
up to about 3500 cm-1 in the PCL rich blends. The shift to higher wavenumbers is typical 
of systems in which the stronger OH···OH interactions are replaced by weaker C=O···O-
H interactions, and suggests the establishment of intermolecular C=O···H-O interactions 
at the expense of the O-H···O-H autoassociation. Notice that the PCL/CAM 40/60 blend 
contains approximately equimolecular amounts of PCL repeat units and CAM molecules, 
and therefore contains approximately equimolecular amounts of C=O and OH groups. 
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Figure 2.2.6. X-H stretching region for the PCL/CAM system at 
160 ºC. 
Figure 2.2.7 shows the carbonyl stretching region of the pure components and their blends 
in the melt (at 160 ºC). Molten PCL shows a peak at 1735 cm-1 attributable to free C=O 
groups in the amorphous phase and molten CAM shows a broad peak located at about 
1688 cm-1 attributable to C=O groups hydrogen bonded to the hydroxyl groups present in 
pure CAM. As can be observed, blending increases the relative intensity at wavenumbers 
located between those of the pure components, suggesting the occurrence of new bands. 
However, the substantial overlap between the bands corresponding to the pure 
components makes difficult the identification of new bands in this spectral region. In 
order to improve spectral resolution, Norris second derivatives have been obtained for 
CAM and for the PCL/CAM 40/60 blend in both molten (160 ºC) and supercooled 
samples (40 ºC) (see Fig. 2.2.7b). The second derivative of supercooled CAM shows two 
components located at about 1690 and 1675 cm-1, attributable to the two main conformers 
occurring in molten CAM which only differ in the orientation of the terminal 
dichloromethyl group. At 160 ºC, the second derivative spectrum of the PCL/CAM blend 
shows a new intermediate band located between those corresponding to free C=O groups 
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of PCL and the hydrogen bonded C=O groups of CAM, that can be attributed to C=O 
groups of PCL, hydrogen bonded to hydroxyl groups of CAM. After quenching to room 
temperature, the locations obtained for the two PCL bands using second derivative 
spectroscopy are respectively 1735 and 1709 cm-1. The red shift obtained for the hydrogen 
bonded C=O groups of PCL is therefore 24 cm-1. The analysis of the C=O stretching band 
confirms the occurrence of C=O···H-O hydrogen bonding between PCL and CAM. 
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Figure 2.2.7. (a) Carbonyl stretching region for the PCL and 
PCL/CAM blends at 160 ºC. (b) Spectra and Norris second 
derivatives for CAM and for the PCL/CAM 40/60 blend in both 
molten (160 ºC) and supercooled samples (40 ºC). 
 
(a) 
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Crystallization Behavior Based on the X-ray Diffraction Analysis 
The XRD patterns of PCL, CAM and their blends are shown in Figure 2.2.8. CAM 
exhibits a characteristic peak at 2 = 13º, as well as several strong peaks at 16º, 18º, 19º 
and 20º. As the polymer content in the blend increases, the intensity of the crystalline 
peaks decreases while their width increases. The width of X-ray diffraction peaks is 
related to the size of the crystallites, and peak widening is usually a consequence of 
smaller, more imperfect crystals [23]. The PCL/CAM 90/10 blend still shows tiny CAM 
peaks, while in the PCL/CAM 95/5 blend crystallization of CAM is completely 
suppressed. Hence, completely amorphous CAM (as required in amorphous solid 
dispersions, ASDs) can only be obtained when the CAM content is below 10 wt.%. 
 
 
Figure 2.2.8. XRD patterns of: (a) pure PCL, (b) PCL/CAM 
95/5, (c) PCL/CAM 90/10, (d) PCL/CAM 85/15, (e) PCL/CAM 
80/20, and (f) pure CAM. 
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AFM Analysis 
AFM topographic images of thin films (800 nm) of pure PCL, show the characteristic 
spherulitic morphology of semicrystalline polymers (Figure 2.2.9a). In the melt, PCL and 
CAM form a single phase, however, crystallization of PCL upon cooling creates a CAM 
enriched amorphous phase that is displaced by the growing crystalline phase to the 
interlamellar region and to the spherulitic grain boundaries [24]. As the CAM content in 
the blend increases, spherulitic boundaries become less defined, and the crystalline phase 
shows a looser, less compact morphology. The PCL/CAM 40/60 blend (Figure 2.2.9d) is 
a clear example of this behavior. In the PCL/CAM 20/80 blend (Figure 2.2.9e) 
crystallization of PCL is completely suppressed. Finally, Figure 2.2.9f shows the 
morphology observed in an immiscible PCL/drug blend (with erythromycin), 
characterized by straight interspherulitic boundaries similar to those observed in pure 
PCL samples.   
       
Figure 2.2.9. AFM topographic images: (a) pure PCL; (b) 
PCL/CAM 80/20, (c) PCL/CAM 60/40, (d) PCL/CAM 40/60, (e) 
PCL/CAM 20/80, and (f) PCL/Erythromycin 50/50 
(immiscible). Films thicknesses were about 800 nm. 
b a c 
d e f 
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2.2.3.2. Drug Release Behavior 
Figure 2.2.10 shows the in vitro drug release experiments performed for PCL/CAM 
40/60, 80/20 and 95/5 blends for 7 hours (since the whole antibiotic was released within 
that time). Considering the release profiles of chloramphenicol coupled with the XRD 
results, two different release behaviors can be distinguished: one for PCL/CAM 40/60 
and 80/20 blends, where part of the antibiotic is crystalline; and another one for 
PCL/CAM 95/5 blend, where the drug is in amorphous form. In the latter case, there is 
an initial burst in which 39 wt.% of the drug is released during the first 10 minutes, 
whereas for the other two compositions only 5 wt.% is released in the same period of 
time. 
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Figure 2.2.10. Drug release profile of PCL/CAM 40/60, 80/20 
and 95/5 samples of 1 cm2 with a thickness of 100 m obtained 
by solvent casting, immersed into 100 mL of PBS (pH 7.4) at 37 
ºC for 7 hours. 
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The release process starts with the penetration of the buffered solution into the polymeric 
matrix leading to its swelling. Consequently, the free volume of the polymeric chains 
increases and the polymeric network becomes looser, leading to the diffusion of the 
amorphous chloramphenicol through the PCL matrix into the outer solution [25]. The 
release data has been fitted to different kinetic equations used to study the mechanism of 
drug release. Regression coefficients are shown in Table 4. PCL/CAM 95/5 system 
follows a first order kinetics, thus, the release depends on drug concentration. There is an 
initial burst, because the drug is in amorphous form and then, it is released in a controlled 
way. Therefore, it can be a good choice in applications where it is necessary to attain 
rapidly the effective therapeutic concentration and to maintain it for some hours. 
On the other hand, the release from PCL/CAM 80/20 and 40/60 systems fits to zero order 
kinetics, where the release occurs at a constant rate, independent of the drug concentration 
used to prepare the blend. In the zero order kinetics, the CAM crystallites act as drug 
reservoirs that, after the initial burst, maintain the concentration of amorphous drug 
dissolved in the polymeric matrix in nearly steady conditions. This release mechanism is 
useful for sustained drug delivery systems. 
 
Table 2.2.4. Fitting of the release data to the mathematical 
models for drug release kinetics. R2 is the correlation coefficient. 
PCL/CAM Zero order First order Higuchi 
95/5 R2 = 0.804 R2 = 0.976 R2 = 0.931 
80/20 R2 = 0.972 R2 = 0.797 R2 = 0.961 
40/60 R2 = 0.982 R2 = 0.87 R2 = 0.971 
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2.2.3.3. Bacterial inhibition assay 
The agar diffusion test was carried out on PCL/CAM 80/20 and 50/50 blends, which are 
characterized by a constant release rate according to the preceding section. Inhibition 
zones were observed when the released solutions containing CAM were placed on plates 
with a layer of E. Coli (see Fig. 2.2.11 and Table 2.2.5). PCL was used as negative control, 
and inhibition zones could not be detected from its leachates (Fig. 2.2.11a). A CAM 
solution of concentration 1 mg/mL (the solubility of CAM in water at 25 ºC is 2.5 mg/mL 
[26]) was used as positive control, resulting in inhibition zones of average radius of 0.8 
cm (Fig. 2.2.11b). In case of the PCL/CAM blends, the concentration of CAM in the 
leachate at different times was calculated from the kinetic models obtained in the 
preceding section. In all cases, the entire drug was released from the polymer after 24 h, 
as confirmed also by ATR spectroscopy of the final films. After 24 h, the concentration 
of CAM in the leachate was 0.7 mg/mL for the PCL/CAM 80/20 sample, and 1.1 mg/mL 
for the PCL/CAM 50/50 blend. Overall, the inhibition radii are proportional to the 
concentration of CAM in the solutions, indicating that CAM can be released in a 
controlled way from its blends with PCL, without losing antibacterial activity. Moreover, 
it is also known that amorphous forms possess a higher apparent solubility in comparison 
to their crystalline counterparts [27,28], and blending with PCL could be an interesting 
strategy to obtain therapeutical concentrations above the solubility limit of the drug. 
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Figure 2.2.11. Images of inhibition zones created after pouring 
on LB agar plates with E. Coli 5 l drops of the leachates 
obtained from (a) PCL after 24 h, (b) chloramphenicol solution 
of 1 mg/mL, (c) PCL/CAM 80/20 after 30 min, (d) PCL/CAM 
50/50 after 30 min, (e) PCL/CAM 80/20 after 3 h, (f) PCL/CAM 
50/50 after 3 h, (g) PCL/CAM 80/20 after 24 h, and (h) 
PCL/CAM 50/50 after 24 h. 
 
Table 2.2.5. Average radius of the inhibition zones measured 
after fixed intervals, and the amount of drug released at each 
time. 
Radius (cm) 30 min 3 h 24 h 
CAM 0.8 0.8 0.8 
PCL/CAM 80/20 0.4 0.5 0.8 
PCL/CAM 50/50 0.5 1 1.3 
% Drug released 20 % 60 % 100 % 
 
PCL  80/20  80/20  80/20 
 CAM  50/50  50/50  50/50 
t = 3 h t = 24 h t = 30 min t = 24 h 
a 
b 
g 
d 
e c 
h f 
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2.2.4. Conclusions 
Miscibility has been confirmed in the PCL/CAM system according to the intermediate 
glass transition temperature criterion. The analysis of the melting point depressions using 
the expression of Flory indicates negative interaction parameters for both PCL-rich and 
CAM-rich blends. 
The analysis by FTIR spectroscopy of the PCL/CAM blends shows new bands in the C=O 
stretching region attributable to C=O···H-O interactions between the carbonyl groups of 
PCL and the hydroxyl groups of CAM. In addition, the OH stretching band of molten 
CAM is observed to shift to higher wavenumbers. These changes suggest the formation 
of new C=O···H-O interactions between PCL and CAM, mainly at the expense of the O-
H···O-H interactions present in pure CAM, since reducing the number of hydroxyl-
hydroxyl interactions reduces their degree of cooperativity and shifts the band to higher 
wavenumbers. 
The analysis of the spherulitic morphology of the blends by AFM shows that the addition 
of CAM to PCL results in less defined spherulites, showing a laxer morphology, 
characteristic of miscible blends. The XRD analysis shows that the maximum CAM 
content in the blend to achieve an amorphous solid dispersion is about 10 wt.% CAM. 
Release kinetic analyses show that CAM can be completely released from the PCL/CAM 
films in about 7 hours in aqueous media. First order kinetics are observed for the samples 
containing CAM in amorphous form, and zero order kinetics for samples containing 
crystalline CAM. Finally, the agar diffusion test against E. Coli (a gram-negative bacteria 
associated with biofilm formation on medical devices) shows that CAM can be released 
in a controlled way from its blends with PCL without losing antibacterial activity. 
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Summary 
Miscibility and specific interactions between poly(-caprolactone) (PCL) and Quercetin 
(Q) are investigated for the purpose of obtaining a miscible polymer/drug system to cope 
with the high crystallinity and low bioavailability of the flavonoid. PCL/Q blends were 
prepared using different methods for the fabrication of various drug release platforms: 
solvent casting for micrometric films, spin coating for nanometric films, and 
electrospinning for mats composed of micro and nanofibers. The miscibility and 
interactions were analyzed by means of DSC, ATR-FTIR and AFM. A single 
intermediate glass transition temperature (Tg) confirms the miscibility in PCL-rich 
blends. Through the study of carbonyl and hydroxyl stretching regions of the infrared 
spectra for PCL/Q blends, hydrogen bonding interactions have been found                            
(-C=O···H-O-). Then, morphologies of thin films obtained by spin coating have been 
studied through atomic force microscopy, in order to analyze how specific interactions, 
as well as the spinning speed affect the shape of PCL crystals. Finally, drug release 
kinetics for different PCL/Q systems have been studied in PBS buffer solution at 37 ºC 
under inert atmosphere in order to displace oxygen and to avoid the oxidation of 
quercetin. In contrast to the micrometric PCL/Q films, where part of the quercetin remains 
within the polymeric matrix, in films 1,000 times thinner the whole drug is released by 
diffusion, and the release mechanism is different depending on the composition, and 
hence, on the interactions established. When comparing the drug release from films to 
scaffolds with the same composition and thickness, the difference is originated by the 
pore size: larger pores contribute to the release, due to the superficial area to volume 
relationship. The PCL/Q system is found to allow the design of versatile drug eluting 
devices.  
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3.1. Introduction 
Onions, tea, strawberries, apples, grapes, parsley, and many spices are just a few natural 
foods rich in flavonoids. Flavonoids are a group of polyphenolic compounds synthesized 
by plants, which have inhibitory activity against organisms that cause plant diseases. They 
have recently gained interest, owing to their potential health benefits arising from their 
antioxidant activity. It has been studied that the functional hydroxyl groups found in 
flavonoids have the ability to scavenge free radicals, as well as to induce human protective 
enzyme systems. Numerous investigations have suggested protective effects of 
flavonoids against many infectious and degenerative illnesses such as cardiovascular 
diseases, and other age-related disorders [1]. 
Quercetin (Q) is a flavonoid present in fruits and vegetables, and it was selected due to 
its anti-oxidant and anti-inflammatory properties. As a drawback, it easily oxidizes in 
aqueous aerobic environments such as body fluids, and it is poorly absorbed in the 
gastrointestinal tract [2]. Quercetin is especially crystalline, meaning that the energy 
needed to break the intermolecular interactions within its natural crystalline network is 
high enough that water will not effectively dissolve it. Furthermore, the bioavailability of 
quercetin through oral dose has been reported to be around 2% [3]. 
A good strategy to overcome shortcomings associated with the quercetin (poor solubility, 
physiochemical instability, reduced bioavailability and short half-life) is the formulation 
of amorphous solid dispersions (ASDs). In ASDs, polymer chains act as crystallization 
inhibitor preserving the drug in amorphous form. Although the amorphous form is 
actually less stable than the crystalline one, it can be stabilized to some extent by weak 
physical interactions with the polymeric matrix (see Fig. 3.1). Drugs in the amorphous 
state have a better solubility in aqueous environment, and can subsequently be absorbed 
by the body in sufficient quantity to have therapeutic effect [4]. Polyesters are a good 
choice to formulate ASDs with hydroxyl-bearing drugs because they possess ester groups 
that are able to establish C=O···O-H hydrogen bonding interactions with the drug and 
stabilize it in the amorphous form [5]. Poly(-caprolactone) (PCL) is one of the most 
promising biodegradable polyesters which is widely used for biomedical applications. Its 
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degradation can last from several months to years, which make it suitable for long-term 
biomedical applications [6]. 
 
 
 
 
 
 
 
 
 
Figure 3.1. Amorphous solid dispersion (ASD). 
Miscible polymer-flavonoid systems where interactions are formed between the two 
species would allow the formation of ASDs, preventing the crystallization of the 
flavonoid [7]. Considering the chemical structures of the two species under study (see 
Fig. 3.2), hydrogen bonding between the hydroxyl groups of quercetin and the carbonyl 
groups of PCL can be expected, and those interactions should overcome the strong 
autoassociation interactions occurring between the quercetin molecules in the crystalline 
phase. Thus, throughout this chapter, miscibility and interactions of PCL/Q blends, as 
well as release kinetics of quercetin from different polymeric platforms will be 
investigated. The combination of the unique properties of antioxidant quercetin molecules 
with the versatility of a biopolymer such as the PCL, can lead to a sustained activity of 
the flavonoid against several diseases from medical devices with different designs.  
Polymer Drug 
Solvent-casting
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 The miscibility of the PCL/Q blends was studied through the criterion of the single 
intermediate glass transition temperature (Tg), and the specific interactions between the 
two species were established using ATR-FTIR spectroscopy. It should be noted that the 
quercetin is unstable when exposed to UV-irradiation, electrochemical oxidation, enzyme 
catalyzed oxidation, but also to atmospheric or aqueous oxygen. The oxidative 
degradation reduces the pharmacological efficiency of this antioxidant and makes 
analytical determination more difficult [8]. Since the quercetin is a molecule that oxidizes 
rapidly in aqueous aerobic environments, we removed the oxygen of the PBS buffer 
solution used to investigate the release mechanism of this flavonoid by recirculating 
nitrogen.  
Then, quartz crystal microbalance with dissipation monitoring (QCM-D) was used to 
study the release in thin films (~ 200 nm) through the analysis of the increase in the 
frequency related to the mass loss, as well as to compare the release behavior with films 
1,000 times thicker studied by means of UV-Vis spectroscopy. Moreover, just like 
Vashisth et al. [9] reported using PLGA-PCL nanofibers, we were also able to encapsulate 
quercetin in PCL fibers to study the effect of the 3D structure on the release. For this aim, 
three different platforms with 10% quercetin content were evaluated by means of UV-Vis 
absorption spectroscopy: a film and two electrospun mats, one of them formed by 
nanofibers and the other composed by a heterogeneous distribution of micro- and 
nanofibers. The results obtained by these techniques show that different platforms can be 
obtained for a controlled release of the quercetin from the PCL/Q blends suitable for 
different applications. 
                                               
                     Poly(-caprolactone)                                                       Quercetin 
Figure 3.2. Chemical structures of PCL and Quercetin. 
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3.2. Experimental Section 
3.2.1. Starting Materials  
Polycaprolactone (PURASORB® PC12 trade name) with an average molecular weight 
(Mw) of 1.3·105 g mol-1 and Mw/Mn = 1.76 (as determined by GPC) was obtained from 
Purac Biochem (The Netherlands). Quercetin (purity ≥ 95 %), formic acid, and phosphate 
buffered saline (PBS) 1 M, pH 7.4, were supplied by Aldrich Chemical Corp. (Spain). 
Tetrahydrofuran (THF) and 2.2.2-trifluoroethanol (TFE) were purchased from Labkem.  
3.2.2. Blend Preparation 
Films   
Films 200 m thick were prepared by casting from 2 wt.% tetrahydrofuran (THF) 
solutions at room temperature into 40 mm diameter dishes. Nanometric films were 
obtained by spin coating onto glass substrates from 10 mg/mL solutions using a spin-
coater (Schaefer Tech) operating at 1000 rpm for films 800 nm thick, and at 3600 rpm 
onto QCM sensors for 200 nm thick films. With the intention of making a correlation 
between film thickness and spinning speed, drops of PCL solution were deposited during 
60 s on the glass substrates after setting the spin coating machine to a specific speed: 500, 
1000, 2000 and 3600 rpm. Then, the thickness of the films obtained at different speeds 
was assessed removing part of the material with acetone and quantifying the step by 
means of AFM (see Fig. 3.3a). The correlation between film thickness and spinning 
speed, as well as the spherulitic morphology for thin films of different dimensions, are 
shown in the Figure 3.3b. 
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Figure 3.3. (a) Step used to measure the thickness of the films 
obtained by spin coating. (b) Correlation between film thickness 
and spinning speed from 10 mg/mL PCL solutions, and AFM 
images of PCL thin films of different thicknesses. 
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Scaffolds 
For the production of the porous scaffolds, PCL/Q (10 % of quercetin) solutions were 
prepared using 2.2.2-trifluoroethanol (TFE) and a mixture of TFE and formic acid (FA), 
added to increase the conductivity. In the first case, 4.0 g of PCL and 0.444 g of quercetin 
were mixed in 15 mL of TFE. In the other solution, 4.5 g of PCL and 0.5 g of quercetin 
were dissolved in 11 mL of TFE and 4 mL of FA. The mixtures were subsequently 
vortexed to ensure proper mixing. Afterwards, electrospinning was performed at room 
temperature (21±2ºC) with controlled humidity (~ 40 %) in a Nanospinner Ne-200 
(Inovenso) system. The tunable high-voltage power supply was connected to the tip of 
the needle (positive lead) and attached to the collector (negative lead) with an alligator 
clip. The needle-to-collector distance was 20 cm and the polymer solutions were ejected 
using a syringe pump at an adjusted flow rate. Polymer mats were spun directly onto a 
plate-shaped collector for 1 hour to achieve rectangular samples with a thickness of 
approximately 125 μm. Steady conditions were achieved at a flow rate of 0.5 mL/h and 
17.5 Kv of voltage for the TFE solution, while a flow rate of 1.0 mL/h and 19.9 Kv of 
voltage were used when formic acid was added. 
3.2.3. Field Emission Scanning Electron Microscopy (FE-SEM) 
The electrospun mats were examined by means of Field Emission Scanning Electron 
Microscopy (FE-SEM). The PCL-Quercetin scaffolds were sputter-coated with a thin 
layer of gold (~ 15 nm) in an Emitech K550X and observed in a Hitachi SEM (Hitachi S-
4800N). The voltage used was 10.0 kV and the working distance was 7.0-9.0 mm with a 
magnification of 1000x, 5000x and 20000x. In order to assess the average diameter, over 
100 individual fibers were measured by Image J software using SEM images from at least 
five different sections of each sample.  
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3.2.5. Differential Scanning Calorimetry (DSC)  
Thermal analyses were conducted on a Modulated DSC Q200 from TA Instruments. All 
scans were carried out in hermetic aluminum pans under a nitrogen atmosphere for sample 
weights between 5 and 10 mg. For the purpose of studying glass transition temperatures, 
two consecutive scans were performed from -80 ºC to 340 ºC with a scan rate of 20 
ºC/min, ensuring complete melting of the sample. Firstly, it was performed an isotherm 
at a temperature of 110 ºC during 30 min to eliminate the water contained in the quercetin. 
Glass transition temperatures (Tg) were measured in the second scan as midpoint of the 
specific heat increment.  
3.2.6. Attenuated Total Reflection Fourier Transform Infrared Spectroscopy (ATR-
FTIR) 
ATR-FTIR spectra of the PCL/Q films were recorded on a Nicolet AVATAR 370 Fourier 
transform infrared spectrophotometer with a PIKE MIRacle ATR accessory containing 
diamond crystal. Spectra were taken with a resolution of 4 cm-1 and were averaged over 
32 scans in the 4000-525 cm-1 range.  
3.2.7. Atomic Force Spectroscopy (AFM) 
An AFM instrument Nanowizard I (JPK Instruments, Germany) was operated in air, using 
contact imaging mode at constant loading forces and rates. Cantilevers were calibrated 
before each experiment by means of thermal tune method (Hutter and Bechhoefer, 1993). 
Silicon-nitride probes (DNP-10, Bruker, USA) with a nominal spring constant of 0.12 
N/m were used in the experiments. All images were processed by JPK data analysis 
software. 
3.2.8. In Vitro Release Studies and Release Kinetics 
Release kinetics of quercetin was examined from different types of platforms: 
micrometric films obtained by solvent-casting, nanometric films obtained by spin coating, 
and scaffolds obtained by electrospinning. The release behaviour was studied considering 
four mathematical models [10, 11, 12]: 
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4. Zero order: Ct/C∞ = k0t                                                                                             (1) 
5. First order: ln (1- Ct/C∞) = -k1t                                                                                (2) 
6. Higuchi: Ct/C∞ = kht1/2                                                                                                   (3) 
7. Korsmeyer-Peppas: : Ct/C∞ = ktn                                                                             (4) 
Ct is the cumulative amount of drug released at time t, C∞ represents the starting amount 
of drug, n is the release exponent; and k0, k1, kh and k are constants. 
Micrometric Films (UV-Vis) 
UV–Vis absorption spectra were recorded over wavelengths ranging from 190 to 500 nm 
using a Perkin Elmer Lambda 265 UV-Visible spectrophotometer. In advance of the drug 
release experiments, two standard curves with known concentrations of quercetin were 
built. On the one hand, quercetin dissolved in tetrahydrofuran with a λmax at 370 nm was 
used to measure the initial and the final content of quercetin encapsulated in the PCL 
fibers. On the other hand, a second calibration curve was prepared measuring the 
absorbance of the quercetin in PBS buffer solution under nitrogen atmosphere at the 375 
nm wavelength. Drug release experiments were carried out at concentrations lower than 
25 ppm because at higher concentrations the flavonoid was partially insoluble [13]. 
Then, 1 cm2 square PCL/Q films 200 m thick obtained by solvent casting, as well as 
scaffolds 125 m thick, were immersed in 100 mL of 0.1 M nitrogen-treated PBS at 37 
ºC (pH 7.4). As explained before, with the aim of avoiding the oxidation of the quercetin, 
the oxygen of the PBS was previously removed through nitrogen recirculation. At fixed 
time intervals, samples of 2 mL were taken and replaced with fresh nitrogen-treated PBS 
at 37 ºC. Quercetin concentration in solution was determined by UV spectroscopy at a 
wavelength of 375 nm (attributed to the B-ring catechol structure), using the 
corresponding calibration curve. 
 Nanometric films (QCM-D) 
Even though being UV-Vis spectroscopy the general way to monitor the release 
mechanism, here, quartz crystal microbalance with dissipation monitoring (QCM-D) 
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experiments were performed in a Q-Sense E4 instrument (Q-Sense, Biolin Scientific AB) 
to measure the quercetin release from the nanometric films due to its high sensitivity, 
durability and linear response to the amount of mass adsorbed on electrodes [14]. Prior 
to their use in the experiments, QSX303 Silicon coated quartz sensors (Q-Sense, Biolin 
Scientific AB) were sonicated in ethanol for 20 min, dried under N2 stream, and treated 
with UV/Ozone for 30 min. Then, the sensors were spin coated pouring a single drop of 
PCL/Q solution of 10 mg/mL before mounted into the QCM-D chamber. Experiments 
were performed at 37 °C and the volume of nitrogen-treated PBS contained in each 
chamber was 300 L. Real time variations of frequency (∆f) and dissipation (∆D) 
parameters were observed at several overtones (n = 3, 5, 7,. . .,13) throughout the QCM-
D experiment. Each point of ∆D/∆f plot represents a dissipation and frequency data at a 
certain time, which provides a more detailed view on the viscoelastic evolution of films 
per mass unit (∆m) change. Hence, we used the Sauerbrey equation (m = -kf) for 
correlating changes in the oscillation frequency of a quartz crystal with the mass deposited 
on it. The analysis of the mass loss during the experiment enables the study of quercetin 
release kinetics from PCL nanometric films. As the polymer did not degrade during the 
experiment, the mass loss is only attributable to the release of quercetin. 
3.3. Results and discussion 
3.3.1. DSC Analysis 
Miscible polymer-drug systems show a single glass transition temperature (Tg) 
intermediate between those of the pure components [15, 16, 17] that usually follow the 
Fox equation [18]: 
                                                                           (6) 
where w1 and w2 are the weight fractions of components 1 and 2 respectively, Tg1 and Tg2 
are glass transitions of pure components, and Tgb is the glass transition of the blend 
(temperatures in Kelvin).  
1
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As can be seen in Figure 3.4, pure PCL is a semicrystalline polymer displaying a glass 
transition temperature located at about -60 ºC and a melting endotherm at about 65 ºC. In 
contrast, quercetin is a crystalline flavonoid with a melting endotherm located at about 
327 ºC. Figure 3.4a shows first DSC traces obtained for the pure components and for 
different PCL/Q blends. It was observed that the addition of 20 wt.% of quercetin lowers 
the melting temperature of PCL by 10 ºC, suggesting miscibility. However, due to the 
strong autoassociation of the flavonoid, Quercetin is able to crystallize at compositions 
above 40 wt.%. It can form crystals, as reflected by the two melting endotherms 
corresponding to the pure components of the blends (see Fig. 3.4a).  
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Figure 3.4. (a) First and (b) second scan DSC curves for PCL, 
Quercetin and PCL/Q blends. 
 
Since Quercetin does not show a glass transition temperature jump, it can be estimated 
using the empirical Beaman-Boyer rule Tg/Tm = 2/3 at about 127 ºC [19]. Consequently, 
for miscibility to occur, Tg of the blends should shift from the location corresponding to 
the pure polymer (-60 ºC) to the approximate vitrification temperature of the quercetin 
(127 ºC) as the content of the flavonoid increases. Traces taken after cooling from the 
melt (Fig. 3.4b) show how the glass transition temperature shifts. Nonetheless, with the 
addition of more than 40 wt.% flavonoid, crystalline quercetin is formed and the Tg of 
the blend stops its continuous increase (see Tab. 3.1).  
 
(b) 
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Table 3.1. Thermal properties of PCL/Q blends in the second scan. 
PCL/Q Tg experimental 
ºC 
Tg (calculated, 
Fox) 
ºC 
Tm PCL 
ºC 
∆HmPCL 
J/g 
Tm Q 
ºC 
∆Hm Q 
J/g 
PCL -60 - 57.2 66.4 - - 
80/20 -43.8 -38 47.4 41.7 - - 
60/40 -34.9 -10.9 46.7 8.1 - - 
40/60 9.9 23.1 - - 265.7 16.6 
20/80 -0.5 67.4 - - 303.3 70.3 
Q - 127.3 - - 315.7 128.4 
3.3.3. ATR-FTIR Analysis 
Specific interactions present in PCL/Q blends can be investigated by infrared 
spectroscopy. The chemical structures of the studied species support the possibility of 
hydrogen bonding between the hydroxyl groups of quercetin and the carbonyl groups of 
PCL [20]. Prior to performing the spectra of the PCL/Q samples with the ATR-FTIR, 
they were melted at a temperature of 330 ºC for 5 min, and subsequently allowed to cool 
to room temperature. 
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Figure 3.5. Carbonyl stretching region for pure PCL, Quercetin 
and PCL/Q blends of different compositions. 
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Fig. 3.5 shows the carbonyl stretching region of PCL, quercetin and PCL/Q blends of 
different compositions. The spectrum of pure PCL shows a peak at 1721 cm-1 representing 
the crystalline part and a slight shoulder at 1735 cm-1 attributable to the amorphous part 
[21]. Upon blending with quercetin, a new band appears at 1700 cm-1 in the intermediate 
compositions attributable to hydrogen bonded C=O groups in PCL, whereas the band at 
1730 cm-1 corresponds to amorphous self-associated PCL [22,23]. Pure quercetin has a 
peak at 1655 cm-1 corresponding to the valence vibration band of the carbonyl group in 
the flavones, influenced by the formation of intramolecular hydrogen bond [24]. That 
band shifts slightly to 1650 cm-1 in the intermediate compositions, indicating that the 
carbonyl group remains hydrogen bonded in the amorphous phase [25].  
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Figure 3.6. Hydroxyl stretching region for pure Quercetin and 
PCL/Q blends of different compositions. 
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Figure 3.6 shows the ATR-FTIR spectra of the hydroxyl stretching region for the PCL/Q 
blends. The spectrum of pure Quercetin shows a complex, broad band with at least two 
discernable components located at about 3280 and 3350 cm-1. These locations can be 
attributed to the O-H stretching of hydroxyl groups participating in cooperative hydrogen 
bonds of different strength. The strength of a cooperative hydrogen bond depends on its 
hydrogen bonding environment in the hydrogen bonding chains/network formed in the 
crystalline structure, which is different for the different hydroxyl groups depending on 
the crystalline structure. Upon addition of PCL, the band at 3280 cm-1 loses intensity and 
only a broad band located at about 3350 cm-1 can be observed in the PCL rich blends. 
Hence, the spectral changes in the OH region confirm the role of the hydrogen bonding 
interactions, suggesting that the strongest cooperative interactions occurring in pure 
crystalline Quercetin are replaced by weaker (but still cooperative) hydrogen bonding 
interactions in the blends. The shift of the OH stretching band to higher wavenumbers is 
typical when O-H··O-H interactions are replaced by -C=O···H-O- ones [26]. The latter 
act as terminal groups that disrupt the O-H···O-H···O-H cooperative chains, reducing 
hence the cooperativity of the hydrogen bonding interactions. 
 3.3.4. AFM Analysis 
The images of PCL/Q blends shown in Figure 3.7 reveal the influence of intermolecular 
interactions in the chain organizing process of a semicrystalline polymer. In a miscible 
polymer-drug system, the mobility of polymer chains during the crystal formation is 
hindered due to the weak physical bonds developed between the two species, originating 
a decrease in the growt.h rate of crystals. In other words, there is no enough time for the 
arrangement of the polymeric chains, due to a lower chain mobility [27, 28]. In AFM 
topographic images of PCL thin films (800 nm), it is observed the characteristic 
spherulitic morphology of semicrystalline polymers (Figure 3.7a). However, as the 
flavonoid content in the blend increases, spherulitic boundaries become round and the 
crystalline phase shows a less compact morphology (Fig. 3.7b and 3.7c).  
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Figure 3.7. AFM topographic images: (a) PCL, (b) PCL/Q 80/20, 
and (c) PCL/Q 60/40. Films thicknesses were about 800 nm. 
3.3.5. Drug Release Behavior 
Effect of the Film Thickness on the Quercetin Release 
In vitro release experiments were performed for 200 m and 200 nm thick PCL/Q 80/20 
and 60/40 films, since the lack of a melting point in the DSC thermogram (see Fig. 3.4) 
suggests that the quercetin is in amorphous form, and as a result, ready to release from 
the PCL. As mentioned in other chapters, the first step of the release is the penetration of 
the buffered solution into the polymeric matrix, leading to its swelling. As a result, the 
polymeric network becomes wider, and the amorphous quercetin dissolved in the polymer 
matrix diffuses throughout it to reach the outer solution [29]. In the case of the 
micrometric films, the experiment was carried out for 6 h, considering that no more 
quercetin is released after that time. As can be seen in Figure 3.8a, the 70 wt..% of 
flavonoid is released from the PCL/Q 80/20 blend after 2.5 hours, whereas only the 20 
wt..% from the 60/40 blend at the end of the experiment.  
Then, the kinetic studies of nanometric PCL/Q 80/20 and 60/40 samples (200 nm) were 
investigated by QCM-D measurements, until no changes in the frequency were detected 
and the whole quercetin was released (30 h). In order to ensure the steadiness in the signal, 
the experiment was performed during 3 days. Quercetin release profiles from PCL/Q 
blends are shown in Figure 3.8b. As can be seen, the release behavior is completely 
different depending on thickness and composition. While in the PCL 80/20 nanometric 
blend took 25 h to release 70 wt.% Quercetin, in the micrometric counterpart the same 
b ca 
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percentage was released in only 1.5 h. On the contrary, 35 wt.% Quercetin was released 
in 2 hours from the nanometric 60/40 blend, while only 20 wt.% was released from the 
micrometric system after that same time.  
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Figure 3.8. (a) Drug release profile of PCL/Q 80/20 and 60/40 
samples with a thickness of 200m obtained by solvent casting, 
immersed into 100 mL of nitrogen-treated PBS (pH 7.4) at 37ºC 
during 6 hours. (b) Drug release profile of PCL/Q 80/20 and 
60/40 samples with a volume of PBS of 300 L at 37 ºC during 
30 hours. 
(a) 
(b) 
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Release data obtained from the films at different scales has been fitted to kinetic equations 
to study the mechanism of flavonoid release, and regression coefficients are shown in 
Table 3.2.  
 
Table 3.2. Fitting of the release data to the mathematical models 
for drug release kinetics. R2 is the correlation coefficient. 
Film thickness PCL/Q Zero order First order Higuchi Korsmeyer-Peppas 
200 m 
80/20 R2 = 0.759 R2 = 0.845 R2 = 0.887 R2 = 0.946 
60/40 R2 = 0.669 R2 = 0.688 R2 = 0.822 R2 = 0.897 
200 nm 
80/20 R2 = 0.995 R2 = 0.987 R2 = 0.992 R2 = 0.888 
40/60 R2 = 0.888 R2 = 0.991 R2 = 0.979 R2 = 0.970 
 
In accordance with the results obtained, PCL/Q blends with a thickness of 200 m follow 
the Korsmeyer-Peppas kinetic model, and the release is governed by a Fickian diffusion 
mechanism. In contrast, the release model in nanometric films differs depending on the 
composition. The release from PCL/Q 80/20 blend fits to zero order kinetics, where it 
occurs at a constant rate and is controlled the by the relaxation of polymeric chains. Zero 
order or constant rate release of drug is desirable in order to minimize swings in drug 
concentration in the blood, allowing a stable effect. Thus, this release mechanism is useful 
for sustained drug delivery systems. Conversely, PCL/Q 60/40 nanometric system 
follows a first order kinetic model. Hence, there is an initial burst (the 50 % is released 
within the first 4 hours), because the drug is in amorphous form since the beginning and 
then, the quercetin is released in a controlled way. Therefore, it can be a good choice in 
applications where it is necessary to attain rapidly the effective therapeutic concentration, 
and then a maintained dose of the desired drug is required.  
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Effect of the 3D Structure on the Quercetin Release 
Apart from building scaffolds for tissue engineering, drug delivery is one of the most 
promising applications of electrospun fibers due to their large specific surface area, 
resulting in high loading capacity. Other appealing features for electrospinning in this 
field include high encapsulation efficiency, the possibility of simultaneous delivery of 
diverse therapies, ease of operation, as well as cost-effectiveness [30-32]. From the first 
study made by Kenawi et al. using nanofibers as drug delivery systems [33], different 
controlled drug release profiles, such as immediate, smooth, pulsatile, delayed, and 
biphasic releases, have been successfully developed [34, 35]. 
In this section, the burst release of quercetin was studied in three different PCL platforms 
with similar thickness (~ 125 μm) having a flavonoid content of ~ 10 % by weight: a film 
and two mats made by electrospinning. It is well known that the structural properties 
(surface area to volume ratio and porosity, along with the thickness) of the release 
platform, affect the release behavior of the drug [36]. Therefore, tunable release profiles 
can be achieved by altering the 3D physical morphology of the polyester-quercetin 
composites.  
 
Figure 3.9. Quercetin release profiles of PCL/Q 90/10 samples 
of different structures with a thickness of 125 m, immersed into 
100 mL of nitrogen treated-PBS at 37 ºC for 8 h. 
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During the period of study (8 hours) poly(ε-caprolactone) did not degrade [37] and thus, 
the measured drug can only be attributed to quercetin diffused from both the matrix and 
the porous structures. As shown in Figure 3.9, different release profiles were obtained 
depending on the type of platform, concluding that the release rate of quercetin decreased 
with the size of the pores (Micro-nanofibers mat > Nanofibers mat > Film). This means 
that bigger pores implies faster release, which could be explained by the greater 
interactions between the eluting medium and the material. The non-porous film displayed 
lower water uptake capacity and in the first 2 hours, the release only reached a 16.8% 
with a final percentage of 23.1 % at the end of the study. The film surface lost its 
crystalline structure during the time submerged in PBS buffer solution and, thanks to the 
drug diffusion as well as the erosion caused by the surrounding medium, some micropores 
started to appear (see Figure 3.10). In contrast, the electrospun scaffolds maintained its 
fibrous structure throughout the entire experiment. Although both systems had similar 
porosities (~ 75%), the scale of their pores affected the ability of water to penetrate, as 
well as the release. 
 
Figure 3.10. FE-SEM images of PCL/Q 90/10 film (a) before, 
and (b) after 8 hours of in vitro quercetin release. 
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Figure 3.11. FE-SEM images of PCL/Q 90/10 nanofibers 
scaffold (a) before, and (b) after 8 hours of in vitro quercetin 
release. 
The nanofibers mat, fabricated using a TFE-FA solvent mix, presented a fiber average 
diameter of 193 nm and after 8 hours of release, in which 25.8 % of quercetin was 
released, showed slight symptoms of deterioration (see Figure 3.11b).  After 2 hours of 
experiment, while the nanofibers mat showed an accumulated quercetin content in the 
media of 22.2 %, the heterogeneous mico-nano scaffold had already release the 24.5%. 
The latter structure, as can be seen in Figure 3.12a, exhibited initially three types of fiber 
morphologies leading to higher pore sizes: nanofibers of around 200 nm of diameter, 
microfibers of ~ 1 μm diameter and some fibers of large dimensions (4 μm of diameter) 
which had dilatations of almost 10 μm. These balloon-like fibers might be attributed to 
encapsulated microparticles that did not dissolve in TFE (formic acid in addition to 
increase the conductivity reducing the nanofiber diameter, also enhanced the solubility of 
quercetin). Nevertheless, at the end of the study, these arrangements almost disappeared 
and only the nanofibers along with some microfibers remained (see Figure 11b). At that 
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moment, a 36.3% of quercetin was released, the maximum peak registered during the 
entire study. 
 
Figure 3.12. FE-SEM images of PCL/Q 90/10 micro-nanofibers 
scaffold (a) before, and (b) after 8 hours of in vitro quercetin 
release. 
3.4. Conclusions 
Miscibility has been confirmed in the PCL/Q system through a glass transition 
temperature intermediate between those of the pure components. Nevertheless, when the 
composition of quercetin in the blend exceeds 40 wt.%, crystallization cannot be 
suppressed, and the ASD turns to a biphasic system. In the PCL/Q blends, -C=O···H-O- 
specific interactions were found by means of ATR-FTIR, supported by the analysis of the 
spherulitic morphology by AFM. 
In vitro drug release experiments showed that in PCL/Q 80/20 system quercetin is 
released by diffusion from micrometric film faster than from its nanometric version. On 
the contrary, for PCL/Q 60/40 blend, the release is faster from nanometric films. It should 
be mentioned that the crystallinity of the PCL changes depending on the film thickness: 
when it is a thin film on a substrate the molecular mobility is restricted, the growt.h of 
crystals is slower with less nuclei density, and therefore, crystals grow to bigger size (see 
Figure 3.3b as an illustration of how the crystals are bigger as the film is thinner). The 
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crystallinity of the nanometric PCL/Q 80/20 system is high enough to block the release 
of the quercetin, delaying the release for 5 hours. Conversely, in nanometric PCL/Q 60/40 
sample, the specific interactions between the two species allow the quercetin to be in 
amorphous form, thus, there is an initial burst where around the 35 % of the drug is release 
in the first couple of hours.  
Through the analysis of drug release mechanism observed for PCL/Q system in the form 
of film or fiber mat, it was concluded that not only the thickness influences the release, 
but also the size of the pores. Therefore, there is a greater release in mats composed by 
micro-nanofibers caused by larger pores when comparing to the release from films with 
the same composition and thickness. Depending on the application, as well as on the 
release rate needed, it can be chosen between micro- or nanometric films, or scaffolds. 
Over the last few years, scientists have turned to various flavonoids to explain some of 
the health benefits of a diet rich in fruits and vegetables. However, flavonoids have a very 
low bioavailability due to its minimum absorption when ingested. That being said, the 
mixture of quercetin with a biopolymer increases quercetin stability, leading to a 
sustained activity of the flavonoid. Taking everything into consideration, it is clear that 
these compounds coming from food deserve further research considering their 
capabilities of curing diseases. 
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Summary 
The insertion of a medical device into the organism supports the growt.h of an aggregate 
of bacteria on its surface termed biofilm, with the ability to resist antimicrobial treatments. 
Thus, implant-associated infections cannot be treated in an effective way with antibiotics, 
and in the majority of cases, the only way to get rid of the infection is to remove the 
implant. This event poses a public health problem, being crucial to find new strategies to 
face this serious issue. The first stage in the biofilm formation is the adhesion of some 
biomolecules contained in bacterial cells to the surface of the medical device. 
Consequently, a good approach is to prevent that adhesion with a coating that avoids 
bacterial attachment on surfaces, i.e., an antifouling coating. In this work, that coating is 
based on a fluorinated tripeptide with non-sticky feature whose adsorption is enabled by 
a DOPA linker. The surface selected is the poly(ε-caprolactone) (PCL), since this 
biopolymer is suitable for making biodegradable medical devices 
4.1. Introduction 
Invasive medical devices are widely used for diagnostic and therapeutic purposes in most 
medical specialties. Infectious risk is one of the most frequent complications related to 
the use of medical devices such as orthopedic or cardiac prostheses, and vascular or 
urinary catheters [1]. Bacteria colonize the surface of the foreign material forming a well-
defined network called biofilm, which is extremely resistant to antibiotics [2]. Hence, the 
replacement of the contaminated device is often the only way to treat the infection. It is a 
proven fact that medical device-related infections are a public health concern and an 
economic burden.  
Biofilm formation is an important strategy of bacteria to survive in adverse environmental 
conditions. This process consists of different stages: reversible attachment, irreversible 
attachment, microcolony formation, maturation and dispersion [1]. Therefore, when a 
medical device is contaminated with bacteria, the microorganisms must adhere to the 
implant enough time so that the settlement is irreversible to form the biofilm [3]. Once 
adhered, microorganisms duplicate and develop as microcolonies over the entire surface. 
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That being said, a promising strategy for avoiding infections on implants is the 
development of antifouling surfaces that prevent the initial bacterial adhesion [4].  
The aim of this work is to combine the versatility of an elastomeric biodegradable 
material with a new antifouling coating that will reduce the attachment of bacteria on the 
surface. The main advantage of using biodegradable medical devices is that they do not 
need to be removed after finishing their service, as they can be absorbed or excreted by 
the body. In this way, the tissue surrounding can return to its original state, and a follow-
up surgery is avoided. Consequently, the combination of a biodegradable polymer with 
an antifouling coating will be a great advance in materials for making medical devices 
that prevent infections. 
Poly(-caprolactone) (PCL) is a semicrystalline polyester widely used in biomedical 
applications due to its biodegradability, biocompatibility, and good mechanical 
properties. Its degradation can last from several months to years, making it suitable for 
long-term biomedical applications [5]. In turn, the antifouling compound under study 
consists on a low-molecular weight tripeptide, which design allows its spontaneous 
adsorption onto any kind of substrate, as well as the creation of surfaces with anti-
adhesive properties [6]. Due to the insertion of the amino acid 3,4-dihydroxyl-L-
phenylalanine (DOPA), a key compound in the formation of mussel adhesive proteins, 
the peptide has the ability to attach to different surfaces [7]. In addition, the fluorine atom 
on each of the benzene rings provides the antifouling character to the peptide (see 
Fig.4.1). 
 
 
 
 
Figure 4.1. Chemical structures of PCL and Peptide. 
Poly(-caprolactone) (PCL) Antifouling peptide (P) 
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Taking everything into consideration, the coating of PCL with a new rationally designed 
antifouling peptide would lead to the development of innovative antifouling materials for 
medical applications. 
4.2. Results and discussion 
4.2.1. Coating of PCL films with antifouling peptide 
PCL films with a thickness of 100 m were obtained by casting from tetrahydrofuran 
(THF) solutions at room temperature. Then, square samples of PCL (1 cm2) were dipped 
into peptide aqueous alkaline solutions at different concentrations (0.1 mg/mL, 0.2 
mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, and 4 mg/mL) for 2 hours (see Fig.4.2). It 
should be noted that when the solution reached a pH around 8.5, the initially transparent 
solution changes to a suspension composed by floating white aggregates. Afterwards, the 
coated films were rinsed extensively with distilled water and dried into a vacuum oven. 
Catechol group of the peptide enables its immobilization on PCL surface by a simple 
dipping process under alkaline conditions [8]. 
 
 
 
 
 
 
 
Figure 4.2. Schematic illustration of the dip coating process of 
PCL films in the peptide solution. 
Tris 
pH = 8 - 8.5 
PCL 
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4.2.2. Surface characterization 
Transmission Electron Microscopy (TEM) images were recorded to analyze the coverage 
of the peptide onto the polymeric surface. As it can be seen, the peptide has a tendency 
to form aggregates rather than a homogeneous coating on the substrate (see Fig. 4.3). 
  
  
Figure 4.3. TEM images of the peptide on PCL films: (a) PCL 
coated with a peptide solution of 0.1 mg/mL, and (b) with a 
peptide concentration of 0.2 mg/mL. 
100 nm 
100 nm 
50 nm
50 nm
a 
b 
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In order to assess the coating, different samples were analyzed using X-ray photoelectron 
spectroscopy (XPS). This technique revealed the presence of nitrogen and fluorine atoms 
of the peptide on PCL surfaces (see Fig. 4.4 and Table 4.1). 
 
 
 
 
 
 
 
 
Figure 4.4. XPS spectra of bare PCL (black), PCL coated with a 
peptide solution of 0.1 mg/mL (red), 0.5 mg/mL (blue), and 1 
mg/mL (pink). 
Table 4.1. Surface elemental composition of PCL films coated 
with different concentrations of the peptide determined by XPS, 
and the nitrogen/fluorine atomic ratio (N/F). 
 
 
 
 
 
PCL+Pep 0 mg/mL 0.1 mg/mL 0.5 mg/mL 1 mg/mL 
% C 81.894 77.088 73.843 71.492 
% O 14.421 17.547 17.857 16.954 
% N - 2.951 4.101 6.299 
% F - 1.662 2.580 4.228 
N/F - 1.776 1.589 1.490 
800 700 600 500 400 300 200
F1s
C1s
N1s
Binding energy (eV)
 PCL
 PCL+Pep 0.1 mg/ml
 PCL+Pep 0.5 mg/ml
 PCL+Pep 1 mg/ml
O1s
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The atomic percentage of N and F became higher as the concentration of peptide 
increased. Moreover, N/F ratio was very close to the theoretical value according to the 
structure of the peptide (3N/2F = 1.5). 
In addition, samples were analyzed using Attenuated Total Reflectance Fourier 
Transform Infrared (ATR-FTIR) spectroscopy. For the purpose of studying the peptide 
deposition on polymeric films, the analysis of the spectra was focused in regions between 
3200-3400 cm-1 and 1500-1700 cm-1 where PCL does not show any band [9]. 
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Figure 4.5. ATR-FTIR spectra of bare peptide, PCL coated with 
a peptide solution of 0.5 mg/mL, 1 mg/mL, 2 mg/mL, and 4 
mg/mL. (a) N-H stretching region, and (b) amide I and aromatic 
rings zone. 
After coating, new bands appeared at 3361 and 3308 cm-1 (see Fig. 4.5a) that can be 
assigned to the N-H stretching vibrations of the peptide, indicative of the presence of 
itself on the polymer. In the 1500-1700 cm-1 region, the bands at 1653 and 1618 cm-1 
indicates-helix and -sheet structures of the amide I in the peptide, whereas the bands 
at 1548 and 1512 cm-1 represent the aromatic rings (Fig. 4.5b) [10]. After the analysis of 
the bands obtained in Figure 4, it was concluded that the optimal concentration of peptide 
solution for PCL coating was 2 mg/mL.  
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As mentioned above, the bacterial adhesion on a surface is a key factor in biofilm 
formation. Hence, hydrophobic surfaces can reduce the contact with bacteria, limiting the 
bacterial attachment which forms the biofilm [11]. A surface is considered hydrophobic 
with a contact angle greater than 90º, whereas below 90º a surface is hydrophilic. With 
the aim of studying the hydrophobicity in the samples, contact angle measurements were 
performed onto surfaces of bare PCL and PCL coated into different peptide solutions (0.5 
mg/mL, 1 mg/mL and 2 mg/mL), using a Drop Shape Analyzer. It was concluded that 
modified substrates exhibited a slight increase in the contact angle, and therefore, a slight 
increase in hydrophobicity as the peptide concentration increased (see Fig. 4.6). The 
addition of fluorine atoms contained in the antifouling coating restricted the contact 
between the surface and water. Thus, the less contact results in a lower chance of bacteria 
to attach to the polymer [11]. 
 
 
 
 
Figure 4.6. Contact angle measurements of PCL, and 
superficially modified PCL surfaces after dip coating in different 
peptide solutions: (a) PCL, (b) PCL coated with a peptide 
solution of 0.5 mg/mL, (c) 1 mg/mL, and (d) 2 mg/mL. 
Finally, in order to study the stability of the coating within a biological media, samples 
of PCL coated with the peptide at a concentration of 2 mg/mL were immersed into 100 
mL of 0.1 M PBS medium (pH 7.4) at 37 ºC for 24 h. ATR-FTIR spectra were compared 
before and after the experiment. As long as the characteristic bands (1512, 1548, 1618, 
1653, 3308 and 3361 cm-1) remained the same after one day under physiological 
conditions, it was proven that the coating is stable (see Fig. 4.7).  
PCL film 
84º 88º 91º 97º 
1 mg/mL peptide solution 2 mg/mL peptide solution 0.5 mg/mL peptide solution
a b c d 
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Figure 4.7. ATR-FTIR spectra of PCL film coated with a peptide 
solution of 2 mg/mL before immersing the film into 100 mL of 
PBS buffer at 37 ºC (red), and after 24 h into the buffer solution 
and dried into a vacuum oven (black). (a) N-H stretching region, 
and (b) amide I and aromatic rings zone. 
4.2.3 Biofilm Formation on PCL Surfaces Coated with Antifouling Peptide 
Considering 2 mg/mL the optimal peptide concentration for coating PCL surfaces, bare 
and peptide-coated PCL films (PCL+P) were incubated overnight at 37 ºC in inoculums 
of Escherichia coli, in order to assess the bacterial attachment. Then, bacteria formed 
during the incubation were removed from the surfaces, diluted and cultured on LB agar 
plates. After the incubation of the plates, the number of colonies formed was counted 
(Fig. 4.8). Data were analyzed using the one-way ANOVA method (p < 0.05), and it was 
concluded that the means among samples of PCL and PCL+P are significantly different. 
That being said, it was observed a reduction of 23 % in the amount of colonies formed on 
the surface when compared with bare PCL.  
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Figure 4.8. Number of E. coli colonies grown on bare and 
peptide-coated PCL surfaces. 
4.3. Conclusions 
Bacterial adhesion to surfaces and subsequent biofilm formation are a leading cause of 
chronic infections. In this work, films of PCL were superficially modified with a synthetic 
tripeptide that interferes with the first step of biofilm formation. The coating occurs 
spontaneously, since the antifouling peptide contains an amino acid group DOPA that 
acts as glue. This is a much simpler strategy compared to other surface coupling methods, 
which require extensive surface modifications and complex reaction steps. In this context, 
peptide-coated surfaces were characterized by means of TEM, XPS, ATR-FTIR and 
Contact Angle, and it was found that the coating is not homogenous, that the maximum 
values of coating were obtained when the PCL films were immersed in 2 mg/mL peptide 
aqueous alkaline dispersion, as well as that it can be obtained hydrophobic surfaces. 
Furthermore, it was concluded that the coating remain stable in human body conditions. 
Eventually, it was determined that the PCL coated with the peptide achieve a reduction 
of 23 % in the amount of E. coli colonies formed. Taking everything into consideration, 
with this work we would be able to provide an additional advantage to a biomaterial such 
as the PCL.  
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In the current PhD thesis an exhaustive study of the phase behavior, miscibility, 
interactions, drug release kinetics, as well as antibacterial activity of systems composed 
of poly(ɛ-caprolactone) with a bioactive molecule has been carried out. These properties 
of a material must be elucidated in order to design a drug eluting device for a specific 
application. The main conclusions derived from the research work are highlighted below:  
 
 The miscibility in a polymer-drug system can be established through the analysis 
of the glass transition temperature. In cases where the analysis is not conclusive 
(for example when the Tgs of the polymer and the drug are very close), the analysis 
can be complemented by studying the depression of the melting points of the pure 
species. In addition, this analysis gives information about the strength of the 
interactions through the interaction parameter χ, present in the Flory-Huggings 
theory. 
 
 FTIR spectroscopy is a valuable tool to support the miscibility behavior of the 
polymer/drug systems and to analyze the specific interactions responsible for 
miscibility. In the systems investigates in this thesis, hydrogen bonding 
interactions have been confirmed between the carbonyl groups (-C=O) of PCL 
and the hydroxyl groups (-OH) present in the different drugs investigated: thymol, 
chloramphenicol, and quercetin. 
 
 Miscibility affects strongly the spherulitic morphology of PCL. AFM can be used 
to evaluate the changes in morphology upon blending, which usually result in less 
compact spherulites in which the amorphous material is pushed to the 
interspherulitic regions. 
 
 Drug eluting devices provide greater therapeutic efficacy than conventional ones, 
reducing the side effects associated with excessive dosages. In vitro drug release 
analyses performed during the study indicate that the bioactive agent is released 
by diffusion through the swelled polymeric matrix once it is in amorphous form. 
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Likewise, the results revealed that the release is determined by the composition, 
as well as by the interactions established in the blends. The release behavior of the 
systems studied is presented below: 
 
o PCL/THY – THY presents a slow release, since only the 23 % is 
released in a week, hence, it can be used to build antimicrobial devices 
for long lasting action. 
o PCL/CAM – The release of the antibiotic depends on the composition. 
When there is less than 10 wt.% of CAM in the blend, it is in amorphous 
forms and, after an initial burst, the drug is released at a constant rate. 
Therefore, it can be a good choice in applications where it is necessary 
to attain rapidly the effective therapeutic concentration and to maintain 
it for some hours. 
o PCL/Q – The release kinetics have been investigated for samples of 
different thicknesses. Quercetin is released by diffusion from the 
surface of the films upon PBS penetration, thus, in nanometric films the 
whole drug is released, since the distance to reach the drug is small. 
Conversely, part of the quercetin remains inside the polymeric matrix 
in the micrometric films, due to the inability of PBS to reach the inner 
flavonoid. When comparing films and scaffolds with the same 
composition (PCL/Q 90/10), the larger pores of mats composed by 
micro and nanofibers, enable a faster release, since the surface area to 
volume ratio is bigger. 
 
 The agar diffusion test against E. coli shows that the chloramphenicol can be 
released in a controlled way without losing antibacterial activity. 
 
 Finally, with the aim of preventing the formation of bacterial colonies on implants, 
the PCL was successfully coated with a synthetic tripeptide that interferes with 
the first step of biofouling, due to a DOPA linker.
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A3. Symbols and Abbreviations 
ΔG free energy 
ΔHm melting enthalpy 
ΔT supercooling 
ΔS entropy 
Δν frequency shift 
ε0 permittivity in vacuum 
εr relative permittivity 
 volume fraction 
ρ density 
 interaction parameter 
 dipole moment 
A absorbance 
B interaction energy density 
C alpha carbon 
Ct cumulative drug released at time t 
C∞ starting amount of drug 
k Boltzmann constant 
lc lamellar thickness 
m degree of polymerization 
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Mn number average molecular weight 
Mw weight average molecular weight 
NA Avogadro number 
R universal gas constant 
Tc crystallization temperature 
Tg glass transition temperature 
Tm melting temperature 
Tm0 equilibrium melting temperature 
V volume 
wt..% weight percent  
ACN acetonitrile 
AFM atomic force microscopy 
ANOVA analysis of variance 
ASD amorphous solid dispersion 
ATR attenuated total reflectance 
CAM chloramphenicol 
CNF carbon nanofibers 
CNT carbon nanotubes 
DES drug eluting stent 
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DNA deoxyribonucleic acid 
DOPA 3,4-dihydroxyl-L-phenylalanine 
DSC differential scanning calorimetry 
E.coli Escherichia coli 
EML list of essential medicines 
FA formic acid 
FTIR Fourier transform infrared spectroscopy  
HB hydrogen bonding 
LB Luria Bertani 
NMR  nuclear magnetic resonance 
NP nanoparticles 
PBS phosphate buffered saline 
PES  potential energy surfaces 
PCL poly(ε-caprolactone) 
PDLLA poly(D,L-lactide) 
PLLA poly(L-lactide) 
QCM-D quartz crystal microbalance-dissipation 
QM quantum mechanical 
SCRF self-consistent reaction field 
SEM scanning electron microscope 
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TEM transmission electron microscopy 
TFE 2,2,2-trifluoroethanol 
THF tetrahydrofuran 
THY  thymol 
TNT tunneling nanotubes 
UV ultraviolet 
WHO world health organization 
XPS X-ray photoelectron spectroscopy 
XRD X-ray diffraction 
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